

International Society for Heart and Lung Transplantation  
26th Annual Meeting and Scientific Sessions  
April 5-8, 2006  
Auditorium Hotel  
Madrid  
Final Program

## **BOARD OF DIRECTORS**

### **President**

Mark L. Barr, MD, Los Angeles, CA

### **Past President**

Alec Patterson, MD, St. Louis, MO

### **President-Elect**

Robert C. Robbins, MD, Stanford, CA

### **Secretary-Treasurer**

Robert C. Bourge, MD, Birmingham, AL

### **Directors**

Katherine J. Hoercher, RN, Cleveland, OH  
Keith McNeil, FRACP, Brisbane, Australia  
Mandeep Mehra, MD, Baltimore, Maryland  
Bruce R Rosengard, MD, Cambridge, United Kingdom  
Ronald H. Kerman, PhD, Houston TX  
Walter Klepetko, MD, Vienna, Austria  
Stephen R. Large, FRCS, Cambridge, United Kingdom  
Steven A. Webber, MBChB, Pittsburgh PA  
Nicholas R. Banner, FRCP, Harefield, United Kingdom  
Mariell Jessup, MD, Philadelphia, PA  
Bruno M. Meiser, MD, Munich, Germany

### **JHLT Editor**

James K. Kirklin, MD, Birmingham AL

### **Transplant Registry Medical Director**

Marshall I. Hertz, MD, Minneapolis, MN

### **Scientific Program Chair**

John Dark, MB, FRCS, Newcastle Upon Tyne, United Kingdom

### **Development Committee Co-Chair**

Leslie W. Miller, MD, Minneapolis, MN

### **Staff**

Amanda W. Rowe, Executive Director  
Phyllis Glenn, Director of Membership Services  
Lisa Edwards, Director of Meetings  
LeeAnn Mills, Director of Operations

International Society for Heart and Lung Transplantation  
14673 Midway Road, Suite 200  
Addison, TX 75001  
Phone: 972-490-9495  
Fax: 972-490-9499  
[www.ishlt.org](http://www.ishlt.org)  
[ishlt@ishlt.org](mailto:ishlt@ishlt.org)

## **SCIENTIFIC PROGRAM COMMITTEE**

Mark L. Barr, MD, President  
John H. Dark, MD, Program Chair  
Robert C. Bourge, MD, Birmingham, AL  
Michael Burch, MD, London, United Kingdom  
Jason D. Christie, MD, Philadelphia, PA  
R. Duane Davis, MD, Durham, NC  
Nicolaas DeJonge, MD, Utrecht, The Netherlands  
Mark Estenne, MD, Brussels, Belgium  
Roger E. Evans, PhD, Rochester, MN  
Martin J. Goddard, FRCS, FRCPath, Cambridge, United Kingdom  
Bartley P. Griffith, MD, Baltimore, MD  
Axel Haverich, MD, Hannover, Germany  
Shahid Husain, MD, Pittsburgh, PA  
Maryl R. Johnson, MD, Madison, WI  
Shaf Keshavjee, MD, Toronto, Canada  
James K. Kirklin, MD, Birmingham, AL  
Christianne Kugler, MScN, PhD(c), Hannover, Germany  
Joren C. Madsen, MD, DPhil, Boston, MA  
Kenneth R. McCurry, Pittsburgh, PA  
Mandeep R. Mehra, Baltimore, MD  
Folke Nilsson, MD, PhD, Goteburg, Sweden  
Michael Petty, MS, RN, CCNS, Minneapolis, MN  
Branislav Radovancevic, MD, Houston, TX  
Stuart C. Sweet, MD, PhD, St. Louis, MO  
Andres Varela, MD, Madrid, Spain  
Thomas K. Waddell, MD, PhD, Toronto, Canada

## **ABSTRACT REVIEWERS**

Barbara Alexander, MD, Durham, NC  
James S. Allan, MD, Marblehead, MA  
Allen S. Anderson, MD, Chicago, IL  
Juan M. Aranda, MD, Alachua, FL  
Abbas Ardehali, MD, Los Angeles, CA  
Paul Aurora, MRCP, London, United Kingdom  
Aggie H. Balk, MD, Rotterdam, The Netherlands  
Nicholas R. Banner, FRCP, Harefield, United Kingdom  
Claes-Hakan Bergh, MD, PhD, Vastra Fronlunda, Sweden  
Gerald J. Berry, MD, Stanford, CA  
Sangeeta M. Bhorade, MD, Chicago, IL  
Emma Birks, MRCP, Harefield, United Kingdom  
Elizabeth Blume, MD, Boston, MA  
Annette Boehler, MD, Zurich, Switzerland  
Roberta C. Bogaev, MD, FACC, FACP, San Antonio, TX  
Susan C. Brozena, MD, North Wales, PA  
Susan M. Chernenko, MN, Toronto, ON, Canada  
Stephen C. Clark, MD, Newcastle Upon Tyne, United Kingdom  
Paul A. Corris, MB, FRCP, Newcastle Upon Tyne, United Kingdom  
Sandra A. Cupples, DNSc, RN, Potomac, MD  
Hiroshi Date, MD, Okayama, Japan  
Sabina M. De Geest, RN, PhD, Basel, Switzerland  
Marc De Perrot, MD, Toronto, ON, Canada  
Thomas J. Dengler, MD, Heidelberg, Germany

Fabienne Dobbels, MSc, Leuven, Belgium  
Debi H. Dumas-Hicks, RN, Metairie, LA  
Jim J. Egan, MD, Dublin, Ireland  
Howard J. Eisen, MD, Philadelphia, PA  
Stefan Fischer, MD, Toronto, ON, Canada  
Michael C. Fishbein, MD, Los Angeles, CA  
Andrew J. Fisher, MRCP, PhD, Newcastle Upon Tyne, United Kingdom  
Miguel A. Gomez-Sanchez, MD, Madrid, Spain  
Kate Gould, FRcPath, Newcastle Upon Tyne, United Kingdom  
Kathleen L. Grady, PhD, RN, Chicago, IL  
Todd J. Grazia, MD, Denver, CO  
Elizabeth Hammond, MD, Salt Lake City, UT  
Ari L.J. Harjula, MD, Helsinki, Finland  
Asif Hasan, MD, Newcastle Upon Tyne, United Kingdom  
Ray E. Hersherberger, MD, Portland, OR  
Robert Higgins, MD, Chicago, IL  
Debra L. Isaac, MD, Calgary, AB, Canada  
Annemarie Kaan, MCN, RN, Vancouver, BC, Canada  
Steven M. Kawut, MD, New York, NY  
Anne Keogh, MBBS, MD, Sydney, Australia  
Jon Kobashigawa, MD, Los Angeles, CA  
Theo Kofidis, MD, Hannover, Germany  
Robert L. Kormos, MD, Pittsburgh, PA  
Robert M. Kotloff, MD, Philadelphia, PA  
Carlo A. Labarrere, MD, Indianapolis, IN  
Stephen R. Large, MS, MRFP, FRCS, Cambridge, United Kingdom  
Kark B. Lemstrom, MD, PhD, Helsinki, Finland  
Matthias Loebe, MD, PhD, Houston, TX  
George B. Mallory, Jr, MD, Houston, TX  
Paul J. Mather, MD, Philadelphia, PA  
Hikaru Matsuda, MD, Hyogo, Japan  
Bruce McManus, MD, Vancouver, BC, Canada  
Alan H. Menkis, MD, Winnipeg, MB, Canada  
Bryan F. Meyers, MD, St. Louis, MO  
Thalachallour Mohanakumar, PhD, St. Louis, MO  
Michael S. Mulligan, MD, Seattle, WA  
Catherine M. Murks, RN, MS, NP, Chicago, IL  
John B. O'Connell, MD, Chicago, IL  
Linda Ohler, RN, MSN, Arlington, VA  
Jonathan B. Orens, MD, Baltimore, MD  
Francis D. Pagani, MD, PhD, Ann Arbor, MI  
Elfriede Pahl Schuette, MD, Chicago, IL  
Wayne D. Paris, MSW, PhD, Carbondale, IL  
Gareth Parry, MD, Newcastle Upon Tyne, United Kingdom  
Alec Patterson, MD, St. Louis, MO  
Si M. Pham, MD, Miami, FL  
Richard N. Pierson, MD, Baltimore, MD  
Laura J. Pinderski-Oslund, MD, San Diego, CA  
Doris Rassi, MBBS, MRCPPath, Cambridge, United Kingdom  
Bruno Reichart, MD, Munich, Germany  
Dale G. Renlund, MD, Salt Lake City, UT  
Robert C. Robbins, MD, Stanford, CA  
Richard J. Rodeheffer, MD, Rochester, MN  
Antonio B. Roman, PhD, Barcelona, Spain  
Eric A. Rose, MD, New York, NY  
Marlene Rose, PhD, Harefield, Middlesex, United Kingdom

Bruce R. Rosengard, MD, Cambridge, United Kingdom  
Ralph A. Schmid, MD, Berne, Switzerland  
Michael Schmoeckel, MD, Munich, Germany  
Stephan Schueler, , Newcastle Upon Tyne, United Kingdom  
Lianne G. Singer, MD, FRCPC, Toronto, ON, Canada  
Andrew L. Smith, MD, Atlanta, GA  
Gregory I. Snell, FRACP, Prahran, Australia  
Keld Sorensen, MD, Aarhus, Denmark  
Susan Stewart, FRCPath, Cambridge, United Kingdom  
Nicole Suciufoca, PhD, New York, NY  
Doris A. Taylor, PhD, Minneapolis, MN  
George Tellides, MD, New Haven, CT  
Patricia A. Uber, Pharm.D, Baltimore, MD  
Adrian B. Van Bakel, MD, PhD, Charleston, SC  
Dirk Van Raemdonck, MD, PhD, Leuven, Belgium  
Johan Vanhaecke, MD, Leuven, Belgium  
David Vega, MD, Atlanta, GA  
Geert M. Verleden, MD, PhD, Leuven, Belgium  
John Wallwork, MBChb, FRCS, Cambridge, United Kingdom  
Maarten Walravens, Aalst, Belgium  
Willem Weimar, MD, Rotterdam, The Netherlands  
Robert G. Weintraub, MBBS, FRACP, Parkville, Australia  
Richard D. Weisel, MD, Toronto, ON, Canada  
Lori J. West, MD, D.Phil, Toronto, ON, Canada  
Glen Westall, FRACP, Melbourne, Australia  
Connie White-Williams, MSN, Birmingham, AL  
George M. Wieselthaler, MD, Vienna, Austria  
David S. Wilkes, MD, Indianapolis IN  
Gayle L. Winters, MD, Boston, MA  
James B. Young, MD, Cleveland, OH  
Martin R. Zamora, MD, Denver, CO  
Adriana Zeevi, PhD, Pittsburgh, PA  
Andreas O. Zuckermann, MD, Vienna, Austria

## **DEVELOPMENT COMMITTEE**

Mandeep R. Mehra, MD, Co-Chair  
Leslie W. Miller, MD, Co-Chair  
Alec Patterson, MD  
Robert Robbins, MD  
Mark L. Barr, MD

## **EDUCATION COMMITTEE**

Mandeep R. Mehra, MD, Chair  
Mark L. Barr, MD  
Robert Robbins, MD  
Duane Davis, MD  
John Dark, MD, FRCS  
Shaf Keshavjee, MD

## **FINANCE COMMITTEE**

Robert C. Bourge, MD, Treasurer and Chair  
Mark L. Barr, MD  
Robert Robbins, MD  
James K. Kirklin, MD  
Leslie W. Miller, MD

## **GRANTS AND AWARDS COMMITTEE**

Duane David, MD, Co-Chair  
Susan Stewart, FRCPath, Co-Chair  
Mark L. Barr, MD, Immediate Past Co-Chair

## **HISTORY AND ARCHIVES COMMITTEE**

Hector Ventura, MD, Chair  
Stephan Schueler, MD  
David KC Cooper, MD, PhD  
Sir Terence English, FRCS  
Sharon Hunt, MD  
James K. Kirklin, MD  
Jon Kobashigawa, MD  
Mandeep Mehra, MD  
Alec Patterson, MD

## **NOMINATING COMMITTEE**

Alec Patterson, MD, Chair  
Stephan Schueler, MD  
James Young, MD  
Jon Kobashigawa, MD  
Mark L. Barr, MD

## **REGISTRY EXECUTIVE COMMITTEE**

Marshall I. Hertz, MD, Medical Director  
Mark M. Boucek, MD, Associate Director for Pediatric Heart Transplantation  
David Waltz, MD, Associate Director for Pediatric Lung Transplantation

Leah B. Edwards, PhD, Associate Director for Data Analysis  
Berkeley M. Keck, RN, MPH, Associate Director for Database Management  
David O. Taylor, MD, Associate Director for Heart Transplantation  
Elbert P. Trulock, MD, Associate Director for Lung Transplantation

## **SCIENTIFIC COUNCIL CHAIRS**

### **Cell Transplantation/Tissue Engineering**

TBD, Chair  
Bruce Rosengard, MD, Board Liaison

### **Heart Failure and Transplant Medicine**

Maria Rosa Costanzo, MD, Co-Chair  
Edoardo Gronda, MD, Co-Chair  
Mariell Jessup, MD, Board Liaison

### **Infectious Diseases**

F. Kate Gould, MBBS, Chair  
Mariell Jessup, MD, Board Liaison

### **Mechanical Circulatory Support Devices**

TBD, Co-Chair  
James K. Kirklin, MD, Board Liaison

### **Nursing and Social Sciences**

Jane Maclver, RN, MSN, Co-Chair  
Michael G. Petty, MS, RN, CCNS, Co-Chair  
Katherine Hoercher, RN, Board Liaison

### **Pathology and Basic Science**

Susan Stewart, FRCPath, Co-Chair  
James George, PhD, Co-Chair  
Ron Kerman, PhD, Board Liaison

### **Pediatric Transplantation**

Michael Burch, MD, Co-Chair  
MaryAnne Chrisant, MD, Co-Chair  
Francesco Parisi, MD, Co-Chair  
Stuart Sweet, MD, PhD, Co-Chair  
Lori West, MD, DPhil, Co-Chair  
Steven Webber, MB, ChB, Board Liaison

### **Pulmonary Arterial Hypertension**

Raymond Benza, MD, Co-Chair  
Reda Girgis, MB BCh, Co-Chair  
John Scott, MD, Co-Chair  
Keith McNeil, MD, Board Liaison

### **Pulmonary Transplantation**

Allan Glanville, MD, FRACP, Co-Chair  
Marc Estenne, MD, Co-Chair  
Martin Zamora, MD, Secretary  
Keith McNeil, MD, Board Liaison

## **ISHLT PAST PRESIDENTS**

1981-1982	Michael Hess, MD
1982-1984	Jack Copeland, MD
1984-1986	Terence English, FRCS
1986-1988	Stuart Jamieson, MD
1988-1990	Bruno Reichart, MD
1990-1991	Margaret Billingham, MD
1991-1992	Christian Cabrol, MD
1992-1993	John O'Connell, MD
1993-1994	Eric Rose, MD
1994-1995	John Wallwork, FRCS
1995-1996	Sharon Hunt, MD
1996-1997	William Baumgartner, MD
1997-1998	Leslie Miller, MD
1998-1999	Alan Menkis, MD, FRCS(C)
1999-2000	Robert L. Kormos, MD
2000-2001	Anne Keogh, MBBS, MD
2001-2002	James B. Young, MD
2002-2003	Stephan Schuler, MD
2003-2004	Jon Kobashigawa, MD
2004-2005	Alec Patterson, MD



## **PAST PROGRAM CHAIRS**

1988 Los Angeles, CA  
John C. Baldwin, MD

1990 San Diego, CA  
D. Glenn Pennington, MD

1991 Paris, France  
John B. O'Connell, MD

1992 San Diego, CA  
Eric A. Rose, MD

1993 Boca Raton, FL  
Maria Rosa Costanzo, MD

1994 Venice, Italy  
John Wallwork, MBChB, FRCS

1995 San Francisco, CA  
Leslie W. Miller, MD

1996 New York, NY  
William A. Baumgartner, MD

1997 London, England  
Stephan Schueler, MD

1998 Chicago, IL  
James B. Young, MD

1999 San Francisco, CA  
Mark L. Barr, MD

2000 Osaka, Japan  
Jon Kobashigawa, MD

2001 Vancouver, Canada  
David O. Taylor, MD

2002 Washington, DC  
Robert C. Robbins, MD

2003 Vienna, Austria  
Bruce R. Rosengard, MD

2004 San Francisco, CA  
Mandeep Mehra, MD

2005 Philadelphia, PA  
Shaf Keshavjee, MD

## **ISHLT AWARD RECIPIENTS**

### **Lifetime Achievement Award**

2004 Sir Magdi Yacoub, MD  
1999 Keith Reemtsma, MD  
1996 Norman Shumway, MD

### **Lifetime Service Award**

1997 Jacques Losman  
1996 Michael Kaye

### **ISHLT/Roche Transplant Career Development Award**

2002 Anthony Azakie, MD  
2000 Gordon D. Wu, MD

### **ISHLT/Novartis Transplant Career Development Award**

2004 Allan M. Ramirez, MD

### **ISHLT/Roche Transplant Research Fellowship Grant**

2005 Ahmad Saad, MD  
2004 Kendra N. Taylor, PhD  
2003 Felix Fernandez, MD  
2002 Ruediger Hoebelt, MD  
2001 Matteo Vatta, PhD  
2001 Arnar Geirsson, MD  
2000 Christopher H. Wigfield, FRCS  
1999 Donald Wong, PhD  
Sivasai Krovvidi, PhD  
1998 Kelly S.A. Blair, MD  
A.M. El Gamel, MD  
1997 Jonathen Chen, MD  
Anne K. Raisanen-Sokolowski, MD  
1996 Tuija S. Ikonen, MD

### **ISHLT/Novartis Transplant Research Fellowship Grant**

2000 Richard S. Lee, MD  
1999 George Juang, MD  
Satoshi Saito, MD  
1998 Margaret L. Schwarze, MD

### **ISHLT/Fujisawa Transplant Research Fellowship Grant**

2005 Arne Neyrinck, MD  
2004 Christian A. Gleissner, MD  
2003 Ewout J. van den Bos, MD  
1997 Alyssa M. Krasinskas, MD

### **ISHLT/Actelion Transplant Research Development Award**

2004 Tsuyoshi Shoji, MD, PhD

### **ISHLT/XDx Transplant Research Development Award**

2004 Monica Zwierzchoniewska, MD

### **ISHLT/Chiron Transplant Research Development Award**

2005 Ryan C. Fields, MD

### **ISHLT/Wyeth-Ayerst Transplant Research Fellowship Grant**

1998 Christine L. Lau, MD

### **ISHLT/Ortho Biotech Transplant Research Fellowship Grant**

1997 Owen T. Lawrence, MD  
1996 Andrew F. Pierre, MD  
1995 Frances L. Johnson, MD

### **ISHLT Transplant Research Fellowship Grant**

1998 Scott D. Ross, MD

### **ISHLT Nursing Research Grant**

2005 Annemarie F. Kaan, MCN  
2004 Deidre E. Logan, PhD  
2003 Diane H. Leloudis, RN, MSN  
2003 Janet E. Madill, PhD  
2002 Annette J. De Vito Dabbs, RN, MN, PhD  
2001 Lynn Doering, RN, DNSc  
2000 Nancy M. Albert, MSN, RN  
1999 Jeanne Salyer, PhD  
1998 Katherine St. Clair, RN, MSN  
1997 Eileen Collins, RN, PhD

### **Caves Award**

2005 Sigrid Sandner, MD  
Frank D'Ovidio, MD  
2004 M.D. Peterson, MD  
2003 Sigrid Sandner, MD  
2002 Peter Blaha, MD  
2001 Alexander S. Krupnick, MD  
2000 Michael P. Fischbein, MD  
1999 Joerg Koglin, MD  
1998 Carla C. Baan, MD  
1997 Simon D. Eiref, MD  
1996 Moninder S. Bhabra, MD  
1995 Elizabeth A. Davis, MD  
1994 Jobst Winter, MD  
1994 Alain Chapelier, MD  
1993 David Marshman, MD  
1992 David P. Kapelanski, MD  
1991 A. Jiminez, MD  
1990 Andres J. Duncan, MD

1989 A.M. Wood, MD  
1988 Charles D. Fraser, Jr., MD  
1987 Wim Van Der Bij, MD  
1986 Stuart J. Knechtle, MD  
1985 Michael A. Breda, MD  
1984 Hermann Reichenspurner, MD  
1983 Robbin G. Cohen, MD

### **Nursing Excellence Research Award**

2005 Mary Amanda Dew, PhD

## **CONTINUING MEDICAL EDUCATION INFORMATION**

### **Accreditation**

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 30 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

### **Disclosure**

Current guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker's presentation. Each speaker has been requested to complete a disclosure statement. Such disclosures will be printed in the Final Program. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

### **Educational Objectives**

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

### **Goals**

To enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease: and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

### **Target Audience**

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

### **Learning Objectives**

At the conclusion of this meeting, participants should be able to:

\* identify, prevent, and treat post-transplant complications of immunosuppression including infection, renal dysfunction, and post-transplant malignancy

- \* compare and evaluate the relative advantages and disadvantages of various pharmacologic, non-pharmacologic, and biologic immunosuppression techniques
- \* understand current and developing organ preservation/reperfusion techniques and the impact of these on the transplanted organ, and use that knowledge to optimize donor selection and extend the donor pool
- \* compare and evaluate the advantages and disadvantages of various mechanical circulatory support systems and their associated patient selection criteria
- \* describe the state of the art in clinical heart and lung failure treatment and the criteria for the selection of patients for transplant therapy
- \* understand current animal models of basic science immunology and their application to the transplant setting
- \* evaluate issues of controversy, such as age, prior transplantation, and systemic diseases, in the selection of candidates for heart and lung transplantation
- \* understand the pathology of acute and chronic rejection and its application in the formulation of a definitive diagnosis of rejection
- \* identify the issues unique to pediatric transplantation, and apply to pediatric transplantation the relevant practices and therapies of adult transplantation
- \* evaluate the current and developing alternatives to orthotopic transplantation, including mechanical circulatory support, xenotransplantation, and a variety of surgical alternatives: assess the future of these therapies: and compare the value of these therapies as alternatives and/or bridges to transplantation
- \* evaluate and implement the use of alternative methods of monitoring and treating rejection
- \* identify, prevent, and treat donor-transmitted diseases

## Disclosure

Current guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker's presentation. Each speaker has been requested to complete a disclosure statement. The names of the speakers that have indicated a relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest (e.g. ownership of stock, significant honoraria/consulting fees, or direct research support from a commercial organization.) are listed below. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

FACULTY/PRESENTATION	COMPANY AFFILIATION	RELATIONSHIP
Barbara Alexander	Bio-Rad	Research Support for Clinical Study
David Baran	Astellas	Grant Support
Sangeeta Borhade	Astellas Pharma	Research Grant funds
Robert C. Bourge	Encysive, Actelion, United Therapeutics, Pfizer	Grant Support
Marcelo Cantarovich	Novartis, Roche	Consultant
Jacqueline Conelissen	Novartis UK	Unrestricted educational grant
John Conte	Chase Medical Corporation	Research Funding
Paul Corris	Pfizer, Actelion	Consultant/Research Support
Maria Crespo-Leiro	XDx	Cargo II Investigator
Carols Del Rio	Genvec	Research Grant, Genvec
Thomas Dengler	Wyeth	Research Support
Ramona Doyle	Pfizer, Encysive, Cotherix	Consultant
Thomas Egan	Cincinnati Sub-Zero, Cryolife, Ethicon, Medtronic, Olympus, Pilling Surgical, Portex, Terumo, US Surgical and Vitrolife	Research Support by Donations in Kind
Howard Eisen	Novartis, XDx	Research Support, Scientific Advisory Committee
Maria Frigerio	Novartis	Member of Steering Committee on Ongoing Trials
James F. George	Therakos	Consultant
Reda Girgis	Encysive	Consultant, Research Support
Kate Gould	Pfizer, Zengus	
Bartley Griffith	Abiomed, Circulite	Advisory Board
Ramsey Hachem	Astellas	Funding
Nicole Hiemann	German Government	Research Study Support
Shahid Husain	Pfizer, Enzon, Astellas	Speaker panel, Grants
Valluvan Jeevanandam	TransMedics	Scientific Advisor
Steven Kawut	Actelion, Pfizer, Cotherix	Research Funding & Speaking
Anne Keogh	Scios, Glaxo Smith Kline, Novartis, Roche, Actelion, Myogen	Consultant, Advisor & Clinical Trial Investigator
Shaf Keshavjee	XDx	Consultant, Scientific Advisor
Michelle Kittleson	Novartis	Direct Research Support
Jon Kobashigawa	Astellas, Novartis, Roche	Research Grants, Advisory Boards, Speaking Honoraria
Robert Kormos	Thoratec	Supported Fellowship
Bernard Kubak	Pfizer, Enzon	Speaker honorarium, Speaker's
Sudhir Kushwaha	Wyeth-Ayerst	Recipient of Research Grant for Part of the study

Wayne Levy	Pfizer, Novartis, Scios, Amgen	Consulting, Speakers Bureau, Grants
James Long	WorldHeart, Thoratec	Consultant, Speaker
Jean Luc Vachieri	Pfizer, Actelion, Astra Zeneca, Medtronic	Scientific Advisory Board Member, Lecturer
Charles Marboe	XDx	Consultant
Franke Mattner	Pfizer	Research Support
Patrick McConnell	GenVec, Inc., Transoma Medical	Research Support and Materials, Consultant
Kenneth McCurry	Astellas, Pfizer	Speaker, Grant-Support
Bruce McManus	Novartis	Research Contract
Keith McNeil	Actelion, Glaxo Smith Kline	Scientific Advisory Committee
Mandeep Mehra	Roche, Novartis, XDx, Astellas	Consultant, Research Grant Recipient
Bart Meyns	Circulite	Scientific Advisory Board
Paul Mohacci	Wyeth, Roche	Scientific Advisory Board Member, Research Support
Robert Naeije	Encysive	Funding of Participations to Meetings
Karl Nelson	WorldHeart	Employee(cant read it)
Gareth Parry	Roche	Research Support
Jignesh Patel	Novartis, Astellas, Roche	Research Grants, Advisory Boards
Jignesh Patel	Astellas, Novartis, Roche	Advisory Board, Research Grants
Si Pham	Astellas	Research Support
Richard Pierson, III	Merck	Direct Research Support
Gregorio Rabago	Roche	Advisory Board Member of Clinical Study
W. Robert Morrow	Roche	Research Grant
Bruce Rosengard	TransMedics	Medical Advisory Boar, PI (UK) Protect Trial
Heather Ross	Astellas, Novartis, Wyeth	Consultant, Research Support
Markus Rothenburger	Novartis	Financial Support of Study
Stuart Russell	Thoratec	Research Support, Consultant
Randall Starling	XDx	Scientific Advisory Committee Member
Stig Steen	Vitrolife AB, Sweden	Royalties for Preservation solutions (Perfadex)
Frank Strobl	Therakos	Employee
Terry Strom	Roche	Patents licensed to Roche
Seiichiro Sugimoto	The Ministry of Health, Labor and Welfare, Japan	Research Grant
Hioyuki Tsukui	Thoratec	Fellowship
Dirk Van Raemdonck	Vitrolife, Gotheburg, Sween	Steem Solution
Thomas Waddell	Novartis	Research Support
Lori West	Astellas	Research project Support/Consultant
John Woodard	Ventracor Ltd	Employee
Edward Zavala	TransMedics	Consulting Advisor
Andreas Zuckermann	XDx, Novartis, Wyeth, Genzyme	Cargo II Steering Committee, Advisory Board Member, Lecturer

The International Society for Heart and Lung Transplantation is most grateful for the educational grants and the support of

Platinum Partner  
ASTELLAS

Gold Partner  
NOVARTIS  
ROCHE

Silver Partner  
ENCYSIVE  
TRANSMEDICS  
XDX

toward this

Twenty Sixth Annual Meeting and Scientific Sessions



MAPS

## PROGRAM TEMPLATE

## SCIENTIFIC PROGRAM

All meetings and activities will take place at the Auditorium Hotel unless otherwise specified. All papers will be presented in English.

### TUESDAY, APRIL 4, 2006

#### **8:00 AM - 7:00 PM**

Exhibit Hall Set-Up (England and Spain Rooms)

#### **10:00 AM – 5:00 PM**

Lung Transplant Biopsy Re-Grading Taskforce Meeting (Alcudia)

#### **5:00 PM - 9:00 PM**

ISHLT Board of Directors Meeting (Zarauz)

### WEDNESDAY, APRIL 5, 2006

#### **7:00 AM - NOON**

Exhibit Hall Set-Up (England and France Rooms)

#### **8:00 AM - 6:00 PM**

Registration Desk Open (Congress Entrance)

#### **8:00 AM - 6:00 PM**

Speaker Ready Room Open (Bonn)

#### **9:00 AM - 11:00 AM**

ISHLT Board of Directors Meeting (Zarauz)

#### **11:00 AM - 1:30 PM**

#### **XDX LUNCHEON SYMPOSIUM**

#### **Clinical Integration of Molecular and Pathological Information in Thoracic Transplantation**

(Venezia/Milan)

*Supported by an Educational Grant from XDX*

**Chairs: Martin J. Goddard, FRCS, FRCPath and Maria G. Crespo-Leiro, MD**

Panel: Randall C. Starling, MD; Bruce McManus, MD, PhD; Susan Stewart, FRCPath; Andreas O. Zuckermann, MD

Case Presenters: Bruce McManus, MD, PhD and Susan Stewart, FRCPath

**11:00 AM** *Pathological Classification of Acute Rejection in Thoracic Transplantation*, Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom

**11:15 AM** *Interactive Case Discussions: Diagnosis and Treatment of Cellular Rejection*

**11:45 AM** *Molecular Immunology of the Alloimmune Response in Thoracic Transplantation*, Adriana Zeevi, PhD, University of Pittsburgh, Pittsburgh, PA

**12:05 PM** *Interactive Case Discussions: Diagnosis and Treatment of Antibody Mediated Rejection*

**12:35 PM** *Clinical Perspectives in Molecular Testing in Thoracic Transplantation*, Andreas O.

Zuckermann, MD, University of Vienna, Vienna, Austria

**12:50 PM** *Discussion*

**1:00 PM** *Luncheon*

#### **NOON - 6:00 PM**

Exhibitor Move-In (England and France Rooms)

#### **NOON - 8 PM**

Poster Session 1 Mounting (Germany FMDC Rooms)

**12:30 PM - 1:30 PM**

Lunch Buffet (Madrid Café)

**1:30 PM - 3:30 PM**

**SATELLITE SYMPOSIUM 1**

**Do We Need a Bridge to Transplant Indication for Mechanical Support?**

**(Auditorio)**

**Chairs: Robert Kormos, MD and Markus Wilhelm, MD**

**1:30 PM** *European Reality*, George Wieselthaler, MD, University of Vienna, Vienna, Austria

**1:55 PM** *US Reality*, Branislav Radovacevic, MD, Texas Heart Institute, Houston, TX

**2:20 PM** *Industry Reality*, John Woodard, Ventracor Limited, Chatsworth, Australia

**2:45 PM** *Device Reliability*, O. H. Frazier, MD, Texas Heart Institute, Houston, TX

**3:05 PM** *Panel Discussion*

**1:30 PM - 2:45 PM**

**SATELLITE SYMPOSIUM 2**

**Fungal Diseases in Thoracic Organ Transplantation**

**(Venezia/Milan)**

**Chairs: F. Kate Gould, MBBS and Vincent G. Valentine, MD**

**1:30 PM** *Overview of Fungal Infections in Thoracic Transplantation*, Patricia Munoz, MD, Hospital General Universitario Gregorio Marañón, Madrid, Spain

**1:45 PM** *Fungal Diagnostics: Are We There Yet?* Barbara D. Alexander, MD, Duke University Medical School, Durham, NC

**2:00 PM** *Risk Factors and Prophylaxis Strategies for Invasive Fungal Infections in Thoracic Organ Transplant Recipients*, Shahid Husain, MD, MS, University of Pittsburgh Medical Center, Pittsburgh, PA

**2:15 PM** *Fungal Infections of Ventricular Assist Devices: Prevention and Treatment*, Bernard Kubak, MD, PhD, University of California at Los Angeles, Los Angeles, CA

**2:30 PM** *Discussion*

**1:30 PM - 3:30 PM**

**SATELLITE SYMPOSIUM 3: Non-Heart-Beating Donors (Donation After Cardiac Death - DCD) in Lung Transplantation**

**(Roma)**

**Chairs: Alec Patterson, MD and Stig Steen, MD, PhD**

**1:30 PM** *Experimental Rationale for Use of NHBD*, Thomas Egan, MD, University of North Carolina, Chapel Hill, NC

**1:50 PM** *Definition and Categories/ Ethics and Legal Logistics of NHBD*, John Dark, MB, FRCS, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom

**2:10 PM** *Ex-Vivo Evaluation of NHBD Lungs*, Dirk Van Raemdonck, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

**2:30 PM** *Clinical Application and Practical Tips on Controlled NHBD Transplantation*, Robert B. Love, MD, University of Wisconsin, Madison, WI

**2:50 PM** *Clinical Update on Uncontrolled NHBD Transplantation*, Andres Varela, MD, Hospital University Puerta de Hierro, Madrid, Spain

**3:10 PM** *Discussion*

**1:30 PM - 3:30 PM**

**SATELLITE SYMPOSIUM 4: Contraindications and Controversies in Pediatric Thoracic Transplantation**

**(Germany SDBP)**

**Chairs: Marlyn S. Woo, MD and Asif Hasan, MD**

**1:30 PM** *The Plumbing is Still Important: A Surgeon's Perspective on Pediatric Thoracic Transplantation*, Martin Elliott, MD, FRCS, Great Ormond Street Hospital, London, United Kingdom

**2:00 PM** *Infectious Contraindications and Complications in Pediatric Thoracic Transplant*, Lara Danziger-Isakov, MD, MPH, Cleveland Clinic, Cleveland, OH

**2:30 PM** *Choosing the Optimal Immunosuppressive Strategy for Pediatric Thoracic Transplantation*, Albert Faro, MD, Washington University, St. Louis, MO

**3:00 PM** *Are There Ethical Contraindications to Pediatric Thoracic Transplantation?*

Debate: *Children with Cystic Fibrosis Should be Offered Lung Transplantation*

*Pro*: Paul Aurora, MRCP, Great Ormond Street Hospital, London, United Kingdom

*Con*: Theodore G. Liou, MD, University of Utah, Salt Lake City, UT

**3:30 PM - 4:00 PM**

Coffee Break in Auditorio Foyer

**4:00 PM - 6:00 PM**

**SATELLITE SYMPOSIUM 5: The Future: Low Flow Micro-Devices for Advanced Heart Failure (Auditorio)**

**Chairs: Stephen R. Large, FRCS and Michael Dandel, MD**

**4:00 PM** *How Little do we Need and of What?* Bartley P. Griffith, MD, University of Maryland Medical School, Baltimore, MD

**4:20 PM** *Low Flow Right Heart Support for a Short Time*, Igor Gregoric, MD, Texas Heart Institute, Houston, TX

**4:40 PM** *VADs as a Platform for Spontaneous Recovery*, Michael J. Jurmann, MD, German Heart Institute Berlin, Berlin, Germany

**5:00 PM** *VADs as a Platform for Cellular Therapy*, Francis D. Pagani, MD, PhD, University of Michigan

**5:20 PM** *VADs as a Platform for Drug Therapies*, Emma Birks, MRCP, Harefield Hospital, Harefield, United Kingdom

**5:40 PM** *Panel Discussion*

**4:00 PM - 6:00 PM**

**ROCHE SYMPOSIUM: Looking Beyond Cellular Rejection in Cardiac Transplantation (Venezia/Milan)**

**Supported by an Educational Grant from Roche**

**Chairs: Mandeep R. Mehra, MD and Gregorio Rabago, MD**

**4:00 PM** *Chair's Introduction*, Gregorio Rabago, MD, Clinica Universitaria, Pamplona, Spain

**4:10 PM** *The Role of Antibody Mediated Mechanisms of Acute and Chronic Rejection*, Michael C. Fishbein, MD, University of California at Los Angeles, Los Angeles, CA

**4:30 PM** *Non-HLA Antibodies and Cardiac Allograft Vasculopathy*, Richard N. Pierson, III, MD, University of Maryland, Baltimore, MD

**4:50 PM** *Clinical Trials in Cardiac Transplantation: Endpoints Beyond Acute Rejection*, Jon Kobashigawa, MD, University of California at Los Angeles, Los Angeles, CA

**5:10 PM** *Potential of New Immunosuppressive Strategies*, Nicholas R. Banner, FRCP, Harefield Hospital, Harefield, United Kingdom

**5:30 PM** *Interactive Case Discussion*

**5:55 PM** *Conclusion*

**4:00 PM - 5:15 PM**

**SATELLITE SYMPOSIUM 6: Immunobiology of Graft Vascular Disease (Roma)**

**Chairs: Carla C. Baan, MD and James F. George, PhD**

**4:00 PM** *Mechanisms of Chronic Rejection - The Role of Early Injury*, Terry B. Strom, Harvard University Medical School, Boston, MD

**4:20 PM** *The Origin of the Hyperplastic Intima: Stem Cells and Vascular Disease*, Jan Luuk Hillebrands, PhD, University Medical Center Groningen, Groningen, The Netherlands

**4:40 PM** *Non-immune Mechanisms of Post-transplant Vascular Disease: HO-1 and its Products*, Miguel Che Parreira Soares, PhD, Instituto Gulbenkian de Ciencia, Oeiras, Portugal

**5:00 PM** *Discussion*

**4:00 PM - 6:00 PM**

**SATELLITE SYMPOSIUM 7: Predictors of Long-Term Outcomes in Thoracic Transplantation (Germany SDBP)**

**Chairs: Christianne Kugler, MS, RN and Michael Petty, MS, RN**

**4:00 PM** *Inter-professional Team Approaches to Improve Physical and Psychosocial Functioning for Thoracic Transplant Candidates*, Sandra Martin, RN, CNS, University Hospital Leuven, Leuven, Belgium

**4:20 PM** *Continuing Patient Education Before and After Transplantation: New Approaches to an Older Problem*, Linda Ohler, MS, RN, CCTC, FAAN, Marymount University, Arlington, VA

**4:40 PM** *Evaluation of Pre-transplant Compliance as a Predictor for Long-term Outcomes: Do we Have Measurement Instruments?* Fabienne Dobbels, MSc, PhD(c), University Hospital Leuven, Leuven, Belgium

**5:00 PM** *Health-Related Quality of Life: Is it a Reliable Predictor for Long-term Outcomes After Transplantation?* Elisabeth ten Vergert, PhD, University Medical Center Groningen, Groningen, The Netherlands

**5:20 PM** *Non-adherence as a Proxy for Suicide*, Mary Freeman, LICSW, University of Florida, Gainesville, FL

**5:40 PM** *Dealing with Long-Term Complications of Thoracic Transplantation: Diabetes, Gout and Osteoporosis*, Connie White Williams, MSN, University of Alabama, Birmingham, AL

**6:00 PM - 7:00 PM**

Exhibit Hall Opening/Tapas Reception (England and Spain Rooms)

**7:00 PM - 8:00 PM**

Registry Executive Committee Meeting (Zarauz)

**Thursday, April 6, 2006**

**8:00 AM - 6:00 PM**

Registration Desk Open (Congress Entrance)

**8:00 AM - 6:00 PM**

Speaker Ready Room Open (Bonn)

**8:00 AM - 7:00 PM**

Poster Session 1 Viewing (Germany FMDC)

**8:15 AM - 9:15 AM**

**Joint Heart Failure and Transplant Medicine/MCSD Scientific Council Meeting** (Venezia/Milan)

**Pathology and Basic Science Scientific Council Meeting** (Roma)

**Pulmonary Transplantation Scientific Council Meeting** (Germany SDBP)

**Cell Transplantation/Tissue Engineering Scientific Council Meeting** (Alcudia)

**9:00 AM – 1:00 PM**

Exhibit Halls Open (England and France Rooms)

**9:30 AM - 11:30 AM**

**OPENING PLENARY SESSION (Auditorio)**

**Chairs: Mark L. Barr, MD and John Dark, MB, FRCS**

**9:30 AM** *Welcome*, Mark L. Barr, MD, ISHLT President, University of Southern California, Los Angeles, CA

**9:40 AM** *Scientific Program Report*, John Dark, MB, FRCS, Scientific Program Chair, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom

**9:50 AM** *Registry Report*, Marshall I. Hertz, MD, Medical Director, ISHLT International Heart and Lung Transplant Registry, University of Minnesota, Minneapolis, MN

**10:20 AM** *Mechanical Circulatory Support Device Registry Report*, James K. Kirklin, MD, University of Alabama, Birmingham, AL

**10:35 AM** *Organ Donation – The Spanish Model*, Rafael Matesanz, MD, Organizacion Nacional de Transplantes, Madrid, Spain

**10:55 AM** *Pioneers in Transplantation Lecture Series: 20 Years of Neonatal Heart Transplantation*, Leonard L. Bailey, MD, Loma Linda University Medical Center, Loma Linda, CA

**11:30 AM - NOON**

Coffee Break in Exhibit Halls (England and France Rooms)

Poster Viewing (Germany FMDC)

**NOON - 2:00 PM**

**CONCURRENT SESSION 1**

**Clinical Heart Transplantation: Late Outcomes After Heart Transplantation: Can We Go on Forever? (Auditorio)**

**Chairs: Robert C. Bourge, MD and Maria G. Crespo-Leiro, MD**

**NOON (1)** *Is Prograf the Panacea for Calcineurin Blockade? A Word of Caution for Lower Risk Rejectors*; J. Stehlik,<sup>1</sup> J.K. Kirklin,<sup>2</sup> D.C. Naftel,<sup>2</sup> B.S. Clemson,<sup>3</sup> B. Czerska,<sup>4</sup> S. Russell,<sup>5</sup> T. Stevens,<sup>6</sup> J. Folsom,<sup>1</sup> M.R. Pritzker,<sup>7</sup> <sup>1</sup>Department of Veteran Affairs Medical Center, Salt Lake City, UT; <sup>2</sup>The University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Downstate Heart Transplant Center, Peoria, IL; <sup>4</sup>Henry Ford

Hospital, Detroit, MI; <sup>5</sup>Johns Hopkins Hospital, Baltimore, MD; <sup>6</sup>Mid America Heart Institute of St. Luke's Hospital, Kansas City, MO; <sup>7</sup>Abbott Northwestern Hospital, Minneapolis, MN

**12:15 PM (2)** *The Natural History of Cardiac Allograft Systolic Function and Determinant of Functional Capacity in the U.S. Population of Heart Transplant Recipients*; K. Lietz,<sup>1</sup> J.M. Herre,<sup>2</sup> R. John,<sup>3</sup> L.W. Miller,<sup>1</sup> <sup>1</sup>Cardiovascular Division, University of Minnesota, Minneapolis, MN; <sup>2</sup>Cardiovascular Division, Eastern Virginia Medical School, Norfolk, VA; <sup>3</sup>Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

**12:30 PM (3)** *UNOS Status at the Time of Heart Transplantation Predicts Long-Term Survival*; F.H. Cheema,<sup>1</sup> S. Aggarwal,<sup>1</sup> C.S. Forster,<sup>1</sup> T.P. Martens,<sup>1</sup> V.K. Topkara,<sup>1</sup> I. George,<sup>1</sup> M. Russo,<sup>1</sup> S.H. Bailey,<sup>1</sup> F. Paultre,<sup>1</sup> B.C. Esrig,<sup>1</sup> M.C. Oz,<sup>1</sup> D.M. Mancini,<sup>2</sup> M.C. Deng,<sup>2</sup> Y. Naka,<sup>1</sup> <sup>1</sup>Surgery, Columbia University College of Physicians and Surgeons - New York Presbyterian Hospital, New York, NY; <sup>2</sup>Medicine, Columbia University College of Physicians and Surgeons - New York Presbyterian Hospital, New York, NY

**12:45 PM (4)** *Smoking after Heart Transplantation Significantly Shortens Survival*; P. Botha,<sup>1</sup> K. White,<sup>1</sup> R. Peaston,<sup>2</sup> J. Forty,<sup>1</sup> J.H. Dark,<sup>1</sup> G. Parry,<sup>1</sup> <sup>1</sup>Department of Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; <sup>2</sup>Department of Biochemistry, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom

**1:00 PM (5)** *Influence of Tobacco Addition in the Outcome of Heart Transplant Recipients*; J. Segovia,<sup>1</sup> L. Alonso-Pulpón,<sup>1</sup> J. Jiménez-Mazuecos,<sup>1</sup> M. Gómez-Bueno,<sup>1</sup> J.M. Escudier,<sup>1</sup> A. Blasco,<sup>1</sup> E. Castedo,<sup>1</sup> A. Briceño,<sup>1</sup> R. Burgos,<sup>1</sup> J. Ugarte,<sup>1</sup> <sup>1</sup>Unidad de Trasplante Cardiaco, Hospital Universitario Puerta de Hierro, Madrid, Spain

**1:15 PM (6)** *Are All Expanded Donors Created Equal?*; B.A. Pisani,<sup>1</sup> J.C. Mendez,<sup>1</sup> A.J. Anderson,<sup>1</sup> A.J. Tector,<sup>1</sup> <sup>1</sup>Heart Transplant Program, St. Luke's Medical Center, Milwaukee, WI

**1:30 PM (7)** *Severe Left Ventricular Hypertrophy Predicts Mortality in Heart Transplant Recipients*; R. Goodroe,<sup>1</sup> S. Padgett,<sup>1</sup> P. Anderson,<sup>1</sup> B. Ryan-Baille,<sup>1</sup> W. Uber,<sup>1</sup> J. Ikonomidis,<sup>1</sup> A.J. Crumbley,<sup>1</sup> A. VanBakel,<sup>1</sup> M. Zile,<sup>1</sup> N.L. Pereira,<sup>1</sup> <sup>1</sup>Departments of Medicine, Surgery and Pharmacy, Medical University of South Carolina, Charleston, SC

**1:45 PM (8)** *Pre-Transplant Interferon Gamma AA Genotype Predicts Lower Long-Term Survival in African and Caucasian-American Heart Transplant Recipients*; B.L. Coleman,<sup>1</sup> L.S. Czer,<sup>2</sup> S.C. Jordan,<sup>3</sup> J. Mirocha,<sup>4</sup> S. Goland,<sup>5</sup> S. Raissi,<sup>1</sup> W. Chen,<sup>1</sup> G. Fontana,<sup>1</sup> R.M. Kass,<sup>1</sup> A. Trento,<sup>1</sup> D.B. Tyan,<sup>11</sup> <sup>1</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>2</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>3</sup>Kidney Transplantation and Transplant Immunology, Cedars Sinai Medical Center, Los Angeles, CA; <sup>4</sup>Biostatistics, Cedars Sinai Medical Center, Los Angeles, CA; <sup>5</sup>Cardiology, Cedars Sinai Medical Center, Los Angeles, CA; <sup>6</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>7</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>8</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>9</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>10</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>11</sup>HLA and Immunogenetics, Cedars Sinai Medical Center, Los Angeles, CA

**NOON - 2:00 PM**

**CONCURRENT SESSION 2**

**Lung Heart/Lung Transplantation: Pulmonary Primary Graft Dysfunction - Trends, Markers, and Mediators ( Venezia/Milan)**

**Chairs: Jason D. Christie, MD and Dirk Van Raemdonck, MD, PhD**

**NOON (9)** *Elevated Pulmonary Artery Pressure Predicts Development of Severe Primary Graft Dysfunction in Paired Single Lung Transplant Recipients*; V.V. Sullivan,<sup>1</sup> B.A. Whitson,<sup>1</sup> D.M. Radosevich,<sup>1</sup> T.P.M. Whelan,<sup>1</sup> R.F. Kelly,<sup>1</sup> C.S. Herrington,<sup>1</sup> P.S. Dahlberg,<sup>1</sup> <sup>1</sup>Division of Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN



**12:15 PM (10)** *Changes in Incidence and Thirty Day Mortality of Primary Graft Dysfunction*; C.L. Kuntz,<sup>1,2</sup> D. Hadjiliadis,<sup>2</sup> J.S. Sager,<sup>2</sup> V.N. Ahya,<sup>2</sup> A. Pochettino,<sup>3</sup> R.M. Kotloff,<sup>2</sup> J.D. Christie,<sup>1,2</sup> <sup>1</sup>Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA; <sup>2</sup>Department of Pulmonary and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; <sup>3</sup>Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA

**12:30 PM (11)** *Primary Graft Dysfunction and Long-Term Pulmonary Function Following Lung Transplantation*; M.E. Prekker,<sup>1</sup> C.S. Herrington,<sup>1</sup> T.P.M. Whelan,<sup>1</sup> M.I. Hertz,<sup>1</sup> P.S. Dahlberg,<sup>1</sup> B. Whitson,<sup>1</sup> <sup>1</sup>Thoracic Transplantation, University of Minnesota, Minneapolis, MN

**12:45 PM (12)** *Early ECMO (Extracorporeal Membrane Oxygenation) Improves Survival after Severe Primary Graft Dysfunction (PGD) in Lung Transplantation*; C.H. Wigfield,<sup>1,2</sup> J.D. Lindsey,<sup>1,2</sup> T.G. Steffens,<sup>1</sup> N.M. Edwards,<sup>1</sup> R.B. Love,<sup>1,2</sup> <sup>1</sup>Cardiothoracic Surgery, University of Wisconsin Hospitals, Madison, WI; <sup>2</sup>Lung Injury Research Group, University of Wisconsin Hospitals, Madison, WI

**1:00 PM (13)** *Early Trend Analysis after Severe Primary Graft Dysfunction Following Lung Transplantation*; M.E. Prekker,<sup>1</sup> C.S. Herrington,<sup>1</sup> P.S. Dahlberg,<sup>1</sup> <sup>1</sup>Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN

**1:15 PM (14)** *Dynamic Changes in Plasma ICAM and VWF Levels in Primary Graft Dysfunction after Lung Transplantation*; J.D. Christie,<sup>1</sup> S. Kawut,<sup>3</sup> J. DeAndrade,<sup>2</sup> A. Milstone,<sup>4</sup> A. Weinacker,<sup>5</sup> J. Orens,<sup>6</sup> V. Lama,<sup>7</sup> E. Demissie,<sup>1</sup> S. Bellamy,<sup>1</sup> L. Ware,<sup>4</sup> the Lung Transplant Outcomes Group, <sup>1</sup>University of Pennsylvania School of Medicine, Philadelphia, PA; <sup>2</sup>University of Alabama, Birmingham, AL; <sup>3</sup>Columbia University, New York, NY; <sup>4</sup>Vanderbilt University, Nashville, TN; <sup>5</sup>Stanford University, Stanford, CA; <sup>6</sup>Johns Hopkins University, Baltimore, MD; <sup>7</sup>University of Michigan, Ann Arbor, MI

**1:30 PM (15)** *Serum VEGF Levels in Lung Transplant Recipients Predict Primary Graft Dysfunction*; S. Aharinejad,<sup>1,2</sup> K. Krenn,<sup>2</sup> S. Taghavi,<sup>1</sup> W. Klepetko,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria

**1:45 PM (16)** *The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot Study*; A. Amital,<sup>1</sup> D. Shitrit,<sup>1</sup> Y. Raviv,<sup>1</sup> D. Bendayan,<sup>1</sup> A. Kogan,<sup>2</sup> G. Sahar,<sup>2</sup> M. Saute,<sup>2</sup> I. Bakal,<sup>1</sup> M.R. Kramer,<sup>1</sup> <sup>1</sup>Pulmonary Institute, Rabin Medical Center-Belinson Campus, Petach Tikva, Israel; <sup>2</sup>Cardiothoracic Department, Rabin Medical Center-Belinson Campus, Petach Tikva, Israel

**NOON - 2:00 PM**

### **CONCURRENT SESSION 3**

#### **Pediatrics: Outcomes and Retransplantation in Pediatric Thoracic Transplantation (Roma)**

*Chairs: Stuart C. Sweet, MD, PhD and*

**NOON (17)** *Heart Transplantation in Children with Markedly Elevated Pulmonary Vascular Resistance*; G. Ofori-Amanfo,<sup>1</sup> D. Hsu,<sup>1</sup> J.M. Lamour,<sup>1</sup> S. Mital,<sup>1</sup> M.L. O'Byrne,<sup>1</sup> A.J. Smerling,<sup>1</sup> J.M. Chen,<sup>1</sup> R. Mosca,<sup>1</sup> L.J. Addonizio,<sup>1</sup> <sup>1</sup>Pediatrics, Columbia University Medical Center, New York, NY

**12:15 PM (18)** *Survival in Allosensitized Children after Listing for Heart Transplantation*; B. Feingold,<sup>1</sup> A. Girnita,<sup>2</sup> P. Olesnevich,<sup>1</sup> A. Zeevi,<sup>2</sup> E.S. Quivers,<sup>1</sup> S.A. Miller,<sup>1</sup> S.A. Webber,<sup>1</sup> <sup>1</sup>Pediatric Cardiology and Cardiothoracic Transplantation, Children's Hospital of Pittsburgh, Pittsburgh, PA; <sup>2</sup>Tissue Typing and Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA

**12:30 PM (19)** *Flow-Based Screening for Preformed Alloantibody Prior to Pediatric Heart Transplantation*; C.S. Almond,<sup>1</sup> I. Wood,<sup>2</sup> E.L. Milford,<sup>2</sup> L. Smoot,<sup>1</sup> J.M. Elder,<sup>1</sup> H.J. Bastardi,<sup>1</sup> R. Thiagarajan,<sup>1</sup> E.D. Blume,<sup>1</sup> <sup>1</sup>Cardiology, Children's Hospital Boston, Boston, MA; <sup>2</sup>Tissue Typing Laboratory, Brigham and Women's Hospital, Boston, MA

**12:45 PM (20)** *The Role of Surveillance Bronchoscopy in Pediatric Lung Transplant Recipients*; C. Benden,<sup>1</sup> A.S. Ranasinghe,<sup>1</sup> O. Harpur-Sinclair,<sup>1</sup> P. Aurora,<sup>1</sup> <sup>1</sup>Cardiothoracic Transplant Unit, Great Ormond Street Hospital for Children, London, United Kingdom

**1:00 PM (12)** *Cognitive and Emotional Development in Infant Heart Transplant Recipients*; V. Krishnamurthy,<sup>1</sup> J.P. Jones,<sup>1</sup> J.G. Nichols,<sup>1</sup> T. Naramor,<sup>1</sup> M.C. Freier,<sup>1,2</sup> <sup>1</sup>Psychology, Loma Linda University, Loma Linda, CA; <sup>2</sup>Pediatrics, Loma Linda Childrens Hospital, Loma Linda, CA

**1:15 PM (22)** *Infant Heart Transplant Recipients as Children and Adolescents: A Study of Long-Term Medical Morbidities*; A. Kulikowska,<sup>1</sup> C.B. Huddleston,<sup>2</sup> S.K. Gandhi,<sup>2</sup> C.E. Canter,<sup>1</sup> <sup>1</sup>Pediatrics, Washington University, St. Louis, MO; <sup>2</sup>Surgery, Washington University, St. Louis, MO

**1:30 PM (23)** *Risk Factors for Mortality Following Pediatric Heart Retransplantation: Analysis from the International Society of Heart and Lung Transplantation Registry*; C.S. Almond,<sup>1</sup> E.D. Blume,<sup>1</sup> L.B. Edwards,<sup>2</sup> M.M. Boucek,<sup>3</sup> <sup>1</sup>Department of Cardiology, Children's Hospital Boston, Boston, MA; <sup>2</sup>UNOS and The International Society for Heart and Lung Transplantation, Richmond, VA; <sup>3</sup>Department of Cardiology, Joe DiMaggio Children's Hospital, Hollywood, FL

**1:45 PM (24)** *Cardiac Retransplantation in Pediatrics: A Multi-Institutional Study*; C. Chin,<sup>1</sup> D. Naftel,<sup>2</sup> E. Pahl,<sup>3</sup> T. Shankel,<sup>4</sup> M.L. Clark,<sup>2</sup> P. Gamberg,<sup>1</sup> J. Kirklín,<sup>2</sup> S. Webber,<sup>5</sup> the PHTS, <sup>1</sup>Stanford University Medical Center, Palo Alto, CA; <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Children's Memorial Hospital, Chicago, IL; <sup>4</sup>Loma Linda University Medical Center, Loma Linda, CA; <sup>5</sup>Children's Hospital of Pittsburgh, Pittsburgh, PA

**NOON - 2:00 PM**

**CONCURRENT SESSION 4**

**Cutting Edge in Organ Dysfunction and Support (Germany SDBP)**

**Chairs: Axel Haverich, MD and Abbas Ardehalli, MD**

**NOON (25)** *A Novel Population of Flk1+/CD31- Adult Derived Cardiac Progenitor Cells Is Capable of Functional Myocardial Repair*; H.C. Ott,<sup>1</sup> T.S. Matthiessen,<sup>1</sup> J. Brechtken,<sup>1</sup> X. Xin,<sup>1</sup> W. Nelson,<sup>1</sup> S. Goh,<sup>1</sup> D.A. Taylor,<sup>1</sup> <sup>1</sup>Center for Cardiovascular Repair, University of Minnesota, Minneapolis, MN

**12:15 PM (26)** *Remote Myocardial Function Contributes to Improved Left Ventricular Performance and Remodeling after Autologous Skeletal Myoblast Transplantation in Ischemic Heart Failure*; P.I. McConnell,<sup>1</sup> C.L. DelRio,<sup>1</sup> P. Kwiatkowski,<sup>1</sup> D.B. Jacoby,<sup>2</sup> A. Zawadzka,<sup>2</sup> B.C. Sun,<sup>1</sup> R.E. Michler,<sup>3</sup> <sup>1</sup>Cardiothoracic Surgery, The Ohio State University, Columbus, OH; <sup>2</sup>GenVec, Inc., Charlestown, MA; <sup>3</sup>Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY

**12:30 PM (27)** *In Vitro and In Vivo Immune Responses to Intracardiac Allogeneic Porcine Mesenchymal Stem Cell (MSC) Transplantation: Are Tolerogenic Regimen Required?*; A.J. Poncelet,<sup>1</sup> J. Vercruysse,<sup>1</sup> A. Saliez,<sup>1</sup> P. Gianello,<sup>1</sup> <sup>1</sup>Experimental Surgery Laboratory, Catholic University of Louvain, Brussels, Belgium

**12:45 PM (28)** *Regulation of Antibody Responses Leads to Prolonged Heterotopic and Orthotopic Cardiac Xenograft Survival*; G.W. Byrne,<sup>1</sup> W.R. Davies,<sup>1</sup> K. Oi,<sup>1</sup> H.D. Tazelaar,<sup>1</sup> D.N. Fass,<sup>1</sup> W.K. Kremers,<sup>1</sup> J.S. Logan,<sup>1</sup> C.G.A. McGregor,<sup>1</sup> <sup>1</sup>William J von Liebig Transplant Center; Department of Surgery, Mayo Clinic, Rochester, MN

**1:00 PM (29)** *Induction of Neonatal B Cell Tolerance to Human Blood Group A Antigen in a Murine Model of ABO-Incompatible Infant Heart Transplantation*; X. Fan,<sup>1</sup> H. Lang,<sup>1</sup> A. Ang,<sup>1</sup> K. Tao,<sup>1</sup> L. West,<sup>1</sup> <sup>1</sup>Heart Transplant Program, The Hospital for Sick Children, Toronto, ON, Canada

**1:15 PM (30)** *Critical Role of Toll-Like Receptor (TLR) 4 in Lung Ischemia-Reperfusion Injury (IRI)*; G. Zanotti,<sup>2</sup> S. Randell,<sup>3</sup> W. Funkhouser,<sup>4</sup> M. Sevala,<sup>1</sup> T. Egan,<sup>1</sup> <sup>1</sup>Surgery, University of North Carolina,

Chapel Hill, NC; <sup>2</sup>Cardiac Surgery, Hopital San Matteo, Pavia, Italy; <sup>3</sup>Medicine, University of North Carolina, Chapel Hill, NC; <sup>4</sup>Pathology, University of North Carolina, Chapel Hill, NC

**1:30 PM (31)** *Sphingosine 1-Phosphate Ameliorates Ischemia Reperfusion Injury after Experimental Lung Transplantation*; M. Okazaki,<sup>1</sup> S. Dharmarajan,<sup>1</sup> T. Ishiyama,<sup>1</sup> N.A. Das,<sup>1</sup> A.S. Krupnick,<sup>1</sup> D. Kreisel,<sup>1</sup> G.A. Ptterson,<sup>1</sup> <sup>1</sup>Department of Surgery, Washington University School of Medicine, St. Louis, MO

**1:45 PM (32)** *Low Dose Carbon Monoxide Protects Rat Lung Grafts from Ischemia-Reperfusion*; J. Kohmoto,<sup>1</sup> A. Nakao,<sup>1</sup> T. Kaizu,<sup>1</sup> A. Tsung,<sup>1</sup> A. Ikeda,<sup>1</sup> H. Toyokawa,<sup>1</sup> S.A. Yousem,<sup>1</sup> T.R. Billiar,<sup>1</sup> A.M. Choi,<sup>1</sup> N. Murase,<sup>1</sup> K.R. McCurry,<sup>1</sup> <sup>1</sup>University of Pittsburgh, Pittsburgh, PA

**2:00 PM - 4:00 PM**

ISHLT Editorial Board Meeting (Zarauz)

**2:00 PM - 4:00 PM**

Thoracic Transplant Registry Meeting (Alcudia)

**2:00 PM - 4:00 PM**

**ASTELLAS LUNCHEON SYMPOSIUM: New Directions in Calcineurin Inhibition (Auditorio)**  
**Supported by an Educational Grant from Astellas**

**Chairs: Bruno Meiser, MD and Lori J. West, MD, DPhil**

**2:15 PM** *Current Clinical Trials of Calcineurin Inhibition in Heart Transplantation*, David O. Taylor, MD, Cleveland Clinic, Cleveland, OH

**2:35 PM** *Calcineurin-based Therapy in Heart Transplantation*, Mauro Rinaldi, MD, IRCCS Policlinico San Mateo, Pavia, Italy

**2:55 PM** *Alternative Routes of CNI Administration*, Patricia A. Uber, PharmD, University of Maryland, Baltimore, MD

**3:15 PM** *Genetic Variation and CNI Effect*, Steven A. Webber, MDChB, University of Pittsburgh, Pittsburgh, PA

**3:30 PM** *Do Calcineurin Inhibitors Affect Tolerance Induction?*, Joren C. Madsen, MD, DPhil, Harvard University, Boston, MA

**3:50 PM** *Discussion, Summary and Conclusions*

**2:00 PM – 3:30 PM**

Lunch Buffet (Madrid Café)

**2:25 PM - 3:55 PM**

**MINI ORAL POSTER PRESENTATIONS SESSION 1 (Roma)**

**Chairs: Leslie W. Miller, MD and Stephan Schueler, MD**

**2:25 PM (33)** *Seattle Heart Failure Model – An Individualized Prediction of Mortality*; W.C. Levy,<sup>1</sup> D. Mozaffarian,<sup>2</sup> D.T. Linker,<sup>1</sup> <sup>1</sup>Cardiology, University of Washington, Seattle, WA; <sup>2</sup>School of Public Health, Harvard, Boston, MA

**2:30 PM (34)** *Impact of Peak VO<sub>2</sub> and VE/VCO<sub>2</sub> Slope as Prognostic Factor in Beta Blockers Era, in Candidates to Heart Transplant*; G.V. Guimaraes,<sup>1</sup> M.S. Silva,<sup>1</sup> V.M. d'Avila,<sup>1</sup> V. Issa,<sup>1</sup> G. Souza,<sup>1</sup> E. Ciolac,<sup>1</sup> C. Pereira,<sup>1</sup> A. Ferras,<sup>1</sup> E.A. Bocchi,<sup>1</sup> <sup>1</sup>Medical School, University of Sao Paulo, Heart Institute, Sao Paulo, Brazil

**2:35 PM (35)** *Surgical Ventricular Restoration Versus Cardiac Transplantation: Hospital Charges, Outcomes, and Survival Analyses of Two Surgical Options for Ischemic Cardiomyopathy*; J.A. Williams,<sup>1</sup> N.D. Patel,<sup>1</sup> L.U. Nwakanma,<sup>1</sup> J.V. Conte,<sup>1</sup> <sup>1</sup>Cardiac Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD

**2:40 PM (36)** *Combined Heart-Kidney Transplantation Reduces Costs and Improves Survival Compared to LVAD Destination Therapy for Patients with Concomitant Heart and Kidney Failure*; K.K. Khush,<sup>1</sup> V. Bhalla,<sup>1</sup> C. Rifkin,<sup>1</sup> K. Rago,<sup>1</sup> D. McGlothlin,<sup>1</sup> F. Vincenti,<sup>1</sup> D. Hill,<sup>1</sup> C. Hoopes,<sup>1</sup> T. De Marco,<sup>1</sup>  
<sup>1</sup>Medicine/Cardiology, University of California, San Francisco, CA

**2:45 PM (37)** *Combined Heart and Kidney Transplantation in Patients with End-Stage Heart and Kidney Failure*; K.K. Khush,<sup>1</sup> V. Bhalla,<sup>1</sup> C. Rifkin,<sup>1</sup> D. McGlothlin,<sup>1</sup> F. Vincenti,<sup>1</sup> C. Hoopes,<sup>1</sup> T. De Marco,<sup>1</sup>  
<sup>1</sup>Medicine/Cardiology, University of California, San Francisco, CA

**2:50 PM (38)** *Increased Mortality with Post-Operative Renal Failure after Cardiac Transplant*; S.K. Moualla,<sup>1</sup> J.M. Boyle,<sup>2</sup> S. Arrigain,<sup>1</sup> S. Worely,<sup>1</sup> M. Bakri,<sup>1</sup> J.P. Yared,<sup>1</sup> R. Heyka,<sup>1</sup> R. Starling,<sup>1</sup> C.V. Thakar,<sup>2</sup>  
<sup>1</sup>Cardiovascular Medicine, Nephrology, Cardiothoracic Anesthesia, Biostatistics, Cleveland Clinic Foundation, Cleveland, OH; <sup>2</sup>Nephrology, University of Cincinnati, Cincinnati, OH

**2:55 PM (39)** *Is Pre-Transplant Vascular Disease a Risk Factor for Mortality and Morbidity after Heart Transplant?*; H. Takayama,<sup>1</sup> A.B. Nathens,<sup>2</sup> G.S. Aldea,<sup>1</sup> D.P. Fishbein,<sup>3</sup> E.D. Verrier,<sup>1</sup> C.T. Salerno,<sup>1</sup>  
<sup>1</sup>Cardiothoracic Surgery, University of Washington, Seattle, WA; <sup>2</sup>Surgery, University of Washington, Seattle, WA; <sup>3</sup>Cardiology, University of Washington, Seattle, WA

**3:00 PM (40)** *Pre-Existing Pulmonary Hypertension in Patients with End-Stage Heart Failure: Impact on Clinic Outcome and Hemodynamic Follow-Up after Orthotopic Heart Transplantation*; S. Goland,<sup>1</sup> L.S.C. Czer,<sup>2</sup> R. Kass,<sup>3</sup> J. Mirocha,<sup>4</sup> C. Chapelli,<sup>5</sup> B. Coleman,<sup>6</sup> M. De Robertis,<sup>7</sup> S. Raissi,<sup>8</sup> W. Cheng,<sup>9</sup> G. Fontana,<sup>10</sup> A. Trento,<sup>11</sup>  
<sup>1</sup>Cardiology, Cedars Sinai Medical Center, Los Angeles, CA; <sup>2</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>3</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>4</sup>Biostatistics, Cedars Sinai Medical Center, Los Angeles, CA; <sup>5</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>6</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>7</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>8</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>9</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>10</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; <sup>11</sup>Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA

**3:05 PM (41)** WITHDRAWN

**3:10 PM (42)** *Ethnic Differences in the Perception of Quality of Life in Females with Congestive Heart Failure: A Comparison of Hispanic, African American, and Caucasian Patients (ACC)*; G. Spezziani,<sup>1</sup> C. Arrieta,<sup>1</sup> J. Chirinos,<sup>1</sup> J. Jimenez,<sup>1</sup>  
<sup>1</sup>Cardiology, University of Miami, Jackson Memorial Medical Center, Miami, FL

**3:15 PM (43)** *Center Specific Outcome Experience with Extended Cardiac Donors in Primary and Re-Do Heart Transplantation*; J.C. Mendez,<sup>1</sup> B.A. Pisani,<sup>1</sup> M. Fischer,<sup>1</sup> A.J. Anderson,<sup>1</sup> C. Bartoszewski,<sup>1</sup> F.X. Downey,<sup>1</sup> A.J. Tector,<sup>1</sup>  
<sup>1</sup>Heart Transplant Program, St Luke's Medical Center., Milwaukee, WI

**3:20 PM (44)** *Influence of Donor and Recipient Characteristics on Recipient Survival: An Analysis of Data in the Spanish Heart Transplantation Registry*; L. Almenar,<sup>1</sup> L.A. Alonso-Pulpon,<sup>1</sup> M.G. Crespo-Leiro,<sup>1</sup> J.M. Arizon,<sup>1</sup> F. Glez-Vilchez,<sup>1</sup> J. Palomo,<sup>1</sup> V. Brossa,<sup>1</sup> J. Delgado,<sup>1</sup> N. Manito,<sup>1</sup> G. Rabago,<sup>1</sup> E. Lage,<sup>1</sup> J.L. Rodriguez-Lambert,<sup>1</sup> E. Roig,<sup>1</sup> D. Pascual,<sup>1</sup> L. Sanz,<sup>1</sup> L. De-la-Fuente,<sup>1</sup>  
<sup>1</sup>Spanish Registry of Heart Transplantation, Sociedad Espanola Cardiologia, Valencia, Spain

**3:25 PM (45)** *The Association between Body Mass Index and Long Term Survival in Patients Undergoing Heart Transplantation*; F.H. Cheema,<sup>1</sup> M. Noel,<sup>1</sup> C.S. Forster,<sup>1</sup> S. Aggarwal,<sup>1</sup> P.K. Khanna,<sup>1</sup> T.P. Martens,<sup>1</sup> S.H. Bailey,<sup>1</sup> F. Paultre,<sup>1</sup> M.C. Oz,<sup>1</sup> D.M. Mancini,<sup>2</sup> Y. Naka,<sup>1</sup>  
<sup>1</sup>Surgery, Columbia University College of Physicians and Surgeons - New York Presbyterian Hospital, New York, NY; <sup>2</sup>Medicine, Columbia University College of Physicians and Surgeons - New York Presbyterian Hospital, New York, NY

**3:30 PM (46)** *4-Year Incidence of MACE and Economic Burden in De Novo Heart Transplant Patients: A Comparison of Everolimus and Azathioprine (AZA)*; H. Eisen,<sup>1</sup> R. Starling,<sup>2</sup> J. Kobashigawa,<sup>3</sup> <sup>1</sup>College of Medicine, Drexel University, Philadelphia, PA; <sup>2</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>3</sup>UCLA Medical Center, Los Angeles, CA

**3:35 PM (47)** *Can Cardiac Allograft Rejection Be Diagnosed Noninvasively?*; C.T. Aguiar,<sup>1</sup> M.J. Rebocho,<sup>1</sup> M. Abecasis,<sup>1</sup> M. Marques,<sup>1</sup> R. Hernandez,<sup>1</sup> R. Gouveia,<sup>2</sup> J.M. Figueira,<sup>3</sup> J.Q. Melo,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, Hospital Santa Cruz, Carnaxide, Portugal; <sup>2</sup>Pathology, Hospital Santa Cruz, Carnaxide, Portugal; <sup>3</sup>Clinical Chemistry, Hospital Santa Cruz, Carnaxide, Portugal

**3:40 PM (48)** *Long-Term Results of Tacrolimus Monotherapy in Cardiac Transplant Recipients*; S.A. Lubitz,<sup>1</sup> D.A. Baran,<sup>2</sup> S. Pinney,<sup>1</sup> S. Kaplan,<sup>3</sup> M. Chan,<sup>1</sup> M. Courtney,<sup>1</sup> S. Lansman,<sup>3</sup> D. Spielvogel,<sup>3</sup> A. Gass,<sup>1</sup> <sup>1</sup>Mount Sinai Medical Center, New York, NY; <sup>2</sup>Newark Beth Israel Medical Center, Newark, NJ; <sup>3</sup>Westchester Medical Center, Valhalla, NY

**3:45 PM (49)** *Mycophenolic Acid (MPA) Area-Under-the-Curve (AUC) Measurements in Stable Patients after Heart Transplantation (HTX)*; A.O. Doesch,<sup>1</sup> Ph. Ehlermann,<sup>1</sup> A. Koch,<sup>2</sup> T.J. Dengler,<sup>2</sup> <sup>1</sup>Department of Cardiology, University of Heidelberg, Heidelberg, Germany; <sup>2</sup>Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany

**3:50 PM (50)** *The Combination of Sirolimus and Tacrolimus for Primary Immunosuppression after Heart Transplantation – 3-Year Results*; I. Kaczmarek,<sup>1</sup> S. Sadoni,<sup>1</sup> M. Mueller,<sup>1</sup> D. Bengel,<sup>1</sup> B. Meiser,<sup>1</sup> B. Reichart,<sup>1</sup> <sup>1</sup>Department of Cardiac Surgery, Grosshadern University Hospital, Ludwig-Maximilians University, Munich, Germany

**2:25 PM - 3:55 PM**

**MINI ORAL POSTER PRESENTATIONS SESSION 2 (Germany SDBP)**

**Chairs: Marshall Hertz, MD and Geert M. Verleden, MD, PhD**

**2:25 PM (51)** *Long Term Results Post Conventional Lung Volume Reduction Surgery Exceeds Outcome of Lung Transplantation for Emphysema*; P.M. Hopkins,<sup>1</sup> H. Seale,<sup>1</sup> J. Walsh,<sup>1</sup> R. Tam,<sup>1</sup> F. Kermeen,<sup>1</sup> S. Bell,<sup>1</sup> K. McNeil,<sup>1</sup> <sup>1</sup>Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia

**2:30 PM (52)** *Six Minute Walk Distance (6MWD) Predicts Waiting List Survival in Idiopathic Pulmonary Fibrosis (IPF)*; D.J. Lederer,<sup>1</sup> S.M. Arcasoy,<sup>1</sup> J.S. Wilt,<sup>1</sup> H.A. Yegen,<sup>1</sup> F. D'Ovidio,<sup>2</sup> J.R. Sonett,<sup>2</sup> S.M. Kawut,<sup>1,3</sup> <sup>1</sup>Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY; <sup>2</sup>Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY; <sup>3</sup>Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY

**2:35 PM (53)** *Blood Pressure Levels and Nocturnal Decline in Lung Transplant Candidates Awaiting Donor Organs: A Longitudinal Study*; D.M. Lanuza,<sup>1</sup> C.A. Lefaiver,<sup>2</sup> R. Brown,<sup>1</sup> S. Bhorade,<sup>3</sup> <sup>1</sup>School of Nursing, University of Wisconsin-Madison, Madison, WI; <sup>2</sup>School of Nursing, Loyola University of Chicago, Chicago, IL; <sup>3</sup>Pulmonary-Lung Transplant Program, Loyola University Medical Center, Maywood, IL

**2:40 PM (54)** *Effects of PDE-5 Inhibitor on Pulmonary Macro- and Microcirculation*; V. Milekhin,<sup>1</sup> N. Pizanis,<sup>1</sup> R. Maykan,<sup>1</sup> G. Butrous,<sup>2</sup> H. Jakob,<sup>1</sup> M. Kamler,<sup>1</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, West German Heart Center Essen, University Hospital Essen, Essen, Germany; <sup>2</sup>Pfizer Laboratories, Sandwich, United Kingdom

**2:45 PM (55)** *Incidence of Abnormal Liver Function Tests in Patients with Pulmonary Arterial Hypertension (PAH) Treated for One Year with Sitaxsentan or Bosentan*; R.E. Girgis,<sup>1</sup> A.M. Keogh,<sup>2</sup> R.L. Benza,<sup>3</sup> R. Naeije,<sup>4</sup> <sup>1</sup>Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD; <sup>2</sup>Heart Transplant Unit, St Vincent's Hospital, Darlinghurst, NSW, Australia; <sup>3</sup>Pulmonary

Vascular Disease Program, University of Alabama at Birmingham, Birmingham, AL; <sup>4</sup>Department of Pathophysiology, University of Brussels, Brussels, Belgium

**2:50 PM (56) *Non-Heart-Beating Lung Donation in the Netherlands: The First Experience***; M.E. Erasmus,<sup>1</sup> W. van der Bij,<sup>2</sup> E.A.M. Verschuuren,<sup>2</sup> <sup>1</sup>Cardio-Thoracic Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; <sup>2</sup>Internal Medicine, Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

**2:55 PM (57) *Protective Effect of Nebulized Salmeterol Xinafoate in Pulmonary Warm Ischemia–Reperfusion Injury***; F. Chen,<sup>1</sup> T. Nakamura,<sup>2</sup> T. Fujinaga,<sup>1</sup> J. Zhang,<sup>1</sup> A. Aoyama,<sup>1</sup> H. Hamakawa,<sup>1</sup> H. Sakai,<sup>1</sup> N. Hanaoka,<sup>1</sup> T. Bando,<sup>1</sup> H. Wada,<sup>1</sup> T. Fukuse,<sup>1</sup> <sup>1</sup>Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; <sup>2</sup>Experimental Therapeutic, Translational Research Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan

**3:00 PM (58) *Donor Treatment with Nitric Oxide Does Not Improve Reperfusion Injury after Transplantation of Lungs Damaged by Brain Death***; V.S. Avlonitis, J.A. Kirby, J.H. Dark, Department of Surgery, Medical School, University of Newcastle, Newcastle, United Kingdom; Department of Surgery, Medical School, University of Newcastle, Newcastle, United Kingdom; Department of Surgery, Medical School, University of Newcastle, Newcastle, United Kingdom

**3:05 PM (59) *Different Prevalence and Variability of Oxygenation Ratio after Single and Bilateral Lung Transplantation***; T. Oto,<sup>1</sup> A. Griffiths,<sup>1</sup> D. Pilcher,<sup>1</sup> B. Levvey,<sup>1</sup> T. Williams,<sup>1</sup> G. Snell,<sup>1</sup> <sup>1</sup>Lung Transplant Unit, The Alfred Hospital, Melbourne, Victoria, Australia

**3:10 PM (60) *Pulmonary Capillaritis Is a Form of Humoral Rejection in Lung Transplant Recipients***; M.R. Zamora,<sup>1</sup> P. Rai,<sup>1</sup> D. Weill,<sup>1</sup> T. Grazia,<sup>1</sup> T. Astor,<sup>1</sup> D. Lyu,<sup>1</sup> M.N. Nicolls,<sup>1</sup> <sup>1</sup>Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO

**3:15 PM (61) *Immunocytochemical Detection of Pepsin in Alveolar Macrophages Can Serve as a Marker of Reflux Associated Aspiration in Lung Transplant Recipients***; O. Elidemir,<sup>1</sup> H. Zhang,<sup>1</sup> K.N. Van Hook,<sup>1</sup> M. Doan,<sup>1</sup> L.L. Fan,<sup>1</sup> G.B. Mallory,<sup>1</sup> <sup>1</sup>Pediatric Pulmonology, Baylor College of Medicine, Houston, TX

**3:20 PM (62) *Effect of Donor Glutathione-S-Transferase Genotype on the Development of Bronchiolitis Obliterans Syndrome after Lung Transplantation***; D. Hadjiliadis,<sup>1</sup> R. Lingaraju,<sup>1</sup> R.M. Kotloff,<sup>1</sup> V.N. Ahya,<sup>1</sup> D. Lipson,<sup>1</sup> J.S. Sager,<sup>1</sup> A. Pochettino,<sup>1</sup> J.D. Christie,<sup>1</sup> <sup>1</sup>Lung Transplant Program, University of Pennsylvania, Philadelphia, PA

**3:25 PM (63) *Exhaled Breath Condensate Biomarker Analysis: A Non-Invasive Diagnostic Tool after Lung Transplantation?***; A. Krishnan,<sup>1</sup> P.S. Thomas,<sup>2</sup> S. Chow,<sup>2</sup> A. Sandrini,<sup>1</sup> M. Plit,<sup>3</sup> M. Malouf,<sup>3</sup> A.R. Glanville,<sup>3</sup> D.H. Yates,<sup>1</sup> <sup>1</sup>Thoracic Medicine, St. Vincent's Hospital, Sydney, NSW, Australia; <sup>2</sup>University of NSW, Sydney, NSW, Australia; <sup>3</sup>The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia

**3:30 PM (64) *Impact of Co-Medication with a Potent P450 Inhibitor on the Shape of the Blood Concentration Curve of Cyclosporine A after Lung Transplantation***; S. Irani,<sup>1</sup> C. Mahler,<sup>1</sup> K. Fattinger,<sup>2</sup> E.W. Russi,<sup>1</sup> R. Speich,<sup>1</sup> A. Boehler,<sup>1</sup> <sup>1</sup>Clinic of Pulmonary Medicine, Zurich, Switzerland; <sup>2</sup>Clinical Pharmacology, University Hospital, Zurich, Switzerland

**3:35 PM (65) *Hypovitaminosis D Is Associated with Accelerated Bone Loss in Lung Transplant Recipients***; A.M. Ramirez,<sup>1,2</sup> A. Pelaez,<sup>1,2</sup> D. Vega,<sup>3</sup> S. Force,<sup>1,3</sup> E.C. Lawrence,<sup>1,2</sup> V. Tangpricha,<sup>2</sup> <sup>1</sup>McKelvey Lung Transplantation Center, Atlanta, GA; <sup>2</sup>Department of Medicine, Emory University, Atlanta; <sup>3</sup>Cardiothoracic Surgery, Emory University, Atlanta

**3:40 PM (66) *Risk of Pulmonary Aspergillosis after Bronchial Stent Placement in Lung Transplant (LTX) Recipients***; M.M. Crespo,<sup>1</sup> K. Raza,<sup>2</sup> B.A. Johnson,<sup>1</sup> K. McCurry,<sup>3</sup> J. Pilewski,<sup>1</sup> S. Husain,<sup>2</sup> <sup>1</sup>Pulmonary, Allergy and Critical Care, University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>2</sup>Transplant Infectious

Disease, University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>3</sup>Cardio-Thoracic Department, University of Pittsburgh Medical Center, Pittsburgh, PA

**3:45 PM (67)** *Unexplained Chronic Anaemia and Leucopaenia in Lung Transplant Recipients Secondary to Parvovirus B-19 Infection*; P.M. Hopkins,<sup>1</sup> F. Kermeen,<sup>1</sup> J. Dunning,<sup>1</sup> K. McNeil,<sup>1</sup> <sup>1</sup>Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia

**3:00 PM – 4:00 PM**

Afternoon Coffee in Exhibit Halls (England and France Rooms)

**3:00 PM - 7:00 PM**

Exhibit Halls Open (England and France Rooms)

**4:00 PM - 6:00 PM**

**CONCURRENT SESSION 5**

**Donor Management and Organ Distribution/Preservation: How Do You Mend a Broken Lung? (Auditorio)**

**Chairs: Andres Varela, MD and Marc De Perrot, MD**

**4:00 PM (68)** *Do We Need To Flush the Lung from the NHB Donor and How?*; C. Van De Wauwer,<sup>1</sup> A. Neyrinck,<sup>1</sup> N. Geudens,<sup>1</sup> F. Rega,<sup>1</sup> G.M. Verleden,<sup>3</sup> T. Lerut,<sup>2</sup> D.E.M. Van Raemdonck,<sup>1,2</sup> <sup>1</sup>Center for Experimental Surgery and Anaesthesiology, KU Leuven, Leuven, Belgium; <sup>2</sup>Department of Thoracic Surgery, UZ Leuven, Leuven, Belgium; <sup>3</sup>Laboratory for Pneumology, KU Leuven, Leuven, Belgium

**4:15 PM (69)** *Improved Lung Function by Postmortem Administration of Urokinase in Canine Lung Transplantation from Non-Heart-Beating Donors*; R. Sugimoto,<sup>1</sup> <sup>1</sup>Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Okayama, Japan

**4:30 PM (70)** *Lungs from HBD Have an Increased Inflammatory Status and Impaired Performance Compared to NHBD*; A.P. Neyrinck,<sup>1</sup> F.R. Rega,<sup>1</sup> C. Van De Wauwer,<sup>1</sup> N. Geudens,<sup>1</sup> G.M. Verleden,<sup>2</sup> P. Wouters,<sup>1</sup> T.E. Lerut,<sup>3</sup> D.E.M. Van Raemdonck,<sup>1,3</sup> <sup>1</sup>Center for Experimental Surgery and Anaesthesiology, KU Leuven, Leuven, Belgium; <sup>2</sup>Laboratory for Pneumology, KU Leuven, Leuven, Belgium; <sup>3</sup>Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium

**4:45 PM (71)** *The Donor Lung Improves with Time and Aprotinin Treatment after Brain Death*; V.S. Avlonitis, A.J. Rostron, J.A. Kirby, J.H. Dark, Department of Surgery, Medical School, University of Newcastle, Newcastle, United Kingdom; Department of Surgery, Medical School, University of Newcastle, Newcastle, United Kingdom; Department of Surgery, Medical School, University of Newcastle, Newcastle, United Kingdom

**5:00 PM (72)** *Grade 3 Primary Graft Dysfunction (PGD) Following Lung Transplantation (LTx) Is Significantly Associated with Donor Pulmonary Emboli (PE)*; T. Oto,<sup>1</sup> A.P. Griffiths,<sup>1</sup> B.J. Levvey,<sup>1</sup> T. Kotsimbos,<sup>1</sup> D.S. Esmore,<sup>1</sup> T.J. Williams,<sup>1</sup> M. Rabinov,<sup>1</sup> G.I. Snell,<sup>1</sup> <sup>1</sup>Heart & Lung Transplant Unit, The Alfred Hospital, Melbourne, Victoria, Australia

**5:15 PM (73)** *Influence of the Method of Lung Preservation on Outcomes in 681 Consecutive Lung Transplants in UK*; J.S. Ganesh,<sup>1</sup> C.A. Rogers,<sup>1</sup> N.R. Banner,<sup>1</sup> R.S. Bonser,<sup>1</sup> <sup>1</sup>On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

**5:30 PM (74)** *PDE-5 Inhibitor Modified Lung Perfusion Improves Graft Function and Microcirculation after 24h Ischemia*; N. Pizanis,<sup>1</sup> V. Milekhin,<sup>1</sup> P. Massoudy,<sup>1</sup> I. Aleksic,<sup>1</sup> G. Butrous,<sup>2</sup> H. Jakob,<sup>1</sup> M. Kamler,<sup>1</sup> <sup>1</sup>Thoracic- and Cardiovascular Surgery, West German Heart Center Essen, Essen, Germany; <sup>2</sup>Pfizer Laboratories, Sandwich, United Kingdom

**5:45 PM (75)** *Are Lungs from Uncontrolled NHBD Good Enough for Transplant Purposes? Preclinical Validation Method*; J.R. Nunez,<sup>1</sup> F. Del Rio,<sup>1</sup> J. Calatayud,<sup>2</sup> F. Hernando,<sup>2</sup> A. Gomez,<sup>2</sup> J.R. Jarabo,<sup>2</sup> A. Varela,<sup>3</sup> J.L. Balibrea,<sup>2</sup> <sup>1</sup>Transplant Coordination Unit, University Hospital San Carlos, Madrid, Spain; <sup>2</sup>Thoracic Surgery Unit, University Hospital San Carlos, Madrid, Spain; <sup>3</sup>Thoracic Surgery Unit, Clinica Puerta de Hierro, Madrid, Spain

**4:00 PM - 6:00 PM**

**CONCURRENT SESSION 6**

**Clinical Heart Failure: Novel Mechanisms and Therapy in Advanced Heart Failure (Venezia/Milan)**

**Chairs: Nicolaas De Jonge, MD and Patricia Uber, PharmD**

**4:00 PM (76)** *Congestive Heart Failure in Fabry Cardiomyopathy: Natural History Experience in an International Cohort of 1,448 Patients*; L.J. Pinderski,<sup>1</sup> J. Strotmann,<sup>2</sup> <sup>1</sup>Medicine, University of California, San Diego, San Diego, CA; <sup>2</sup>Medicine, University of Wurzburg, Wurzburg, Germany

**4:15 PM (77)** *Survival of Patients Referred for Heart Transplantation – Prospective, Registry Based Analysis*; T. Zeilinski,<sup>1</sup> J. Korewicki,<sup>1</sup> A. Browarek,<sup>1</sup> M. Zembala,<sup>2</sup> M. Zakliczynski,<sup>2</sup> J. Sadowski,<sup>3</sup> P. Przybylowski,<sup>3</sup> M. Garlicki,<sup>4</sup> on behalf of POLCARD HF Collaboration, <sup>1</sup>Heart Failure and Transplantation, Institute of Cardiology, Warsaw, Poland; <sup>2</sup>Cardiac Surgery and Transplantation, Silesian Center of Heart Diseases, Zabrze, Poland; <sup>3</sup>Vascular and Cardiac Surgery and Transplantation, Collegium Medicum Jagiellonian University, Krakow, Poland; <sup>4</sup>Cardiac Surgery, CSK MSWiA, Warsaw, Poland

**4:30 PM (78)** *Patterns and Clinical Correlates of Intramyocardial and Epicardial Fat Deposition in Advanced Heart Failure*; P.A. Uber, M.R. Mehra, Department of Medicine, University of Maryland, Baltimore, MD

**4:45 PM (79)** *High Incidence of Suboptimal Location of Left Ventricular Pacing Leads in Patients Who Failed Cardiac Resynchronization Therapy*; K.K. Liao,<sup>1</sup> J. D'Cunha,<sup>1</sup> R. John,<sup>1</sup> L. Joyce,<sup>1</sup> A. Boyle,<sup>2</sup> E. Missov,<sup>2</sup> M. Colvin-Adams,<sup>2</sup> R.M. Bolman III,<sup>1</sup> L. Miller,<sup>2</sup> <sup>1</sup>Cardiovascular Surgery, University of Minnesota, Minneapolis, MN; <sup>2</sup>Cardiology, University of Minnesota, Minneapolis, MN

**5:00 PM (80)** *Does a Positive Vasodilator Response to Sildenafil Predict Survival after Heart Transplantation in Patients with Pulmonary Hypertension?*; C. Jimenez,<sup>1</sup> M.A. Gomez-Sanchez,<sup>1</sup> P. Escribano,<sup>1</sup> F. Hernandez,<sup>1</sup> J.F. Delgado,<sup>1</sup> <sup>1</sup>Heart Failure and Pulmonary Hypertension Unit. Department of Cardiology, Hospital 12 de Octubre, Madrid, Spain

**5:15 PM (81)** *In-Hospital Mortality of Patients Hospitalized with Acute Heart Failure Treated with Vasodilators with or without Diuretics: An Observational Propensity Matched Study*; R.S. Johannes,<sup>1</sup> M.R. Costanzo,<sup>2</sup> V. Gupta,<sup>1</sup> M. Saltzberg,<sup>2</sup> S. Suri,<sup>3</sup> T. Ashraf,<sup>3</sup> <sup>1</sup>Cardinal Health Clinical Knowledge Services, Marlborough, MA; <sup>2</sup>Midwest Heart Foundation, Downers Grove, IL; <sup>3</sup>Scios, Inc, Fremont, CA

**5:30 PM (82)** *Levosimendan Improves Renal Function in Patients with Advanced Chronic Heart Failure Awaiting Cardiac Transplantation*; B. Vrtovec,<sup>1</sup> G. Zemljic,<sup>1</sup> M. Bunc,<sup>1</sup> A.P. Yazdanbakhsh,<sup>2</sup> <sup>1</sup>Department of Cardiology, Ljubljana University Medical Center, Ljubljana, Slovenia; <sup>2</sup>Department of Cardiovascular Surgery, University of Amsterdam, Amsterdam, Netherlands

**5:45 PM (83)** *Incremental Survival Benefit with Better Adherence to JCAHO Heart Failure Core Performance Measures: A Study of 2144 Patients*; A.G. Kfoury, K.D. Rasmusson, J.A. Hall, T.K. French, H.L. Rimmasch, C.A. Roberts, R.S. Evans, D.L. Lappe, J.B. Muhlestein, J.L. Anderson, D.G. Renlund, Heart Failure Prevention and Treatment Program, LDS Hospital, Salt Lake City, UT

**4:00 PM - 6:00 PM**

**CONCURRENT SESSION 7**

**Basic Science and Immunobiology: Chemokines/Regulatory Cells (Roma)**

**Chairs: Joren C. Madsen, MD, DPhil and Thomas Dengler, MD**



**4:00 PM (84)** *Chemokine Receptor Blockade with a Synthetic Non-Peptide Compound Attenuates Cardiac Allograft Vasculopathy*; G.R. Hsieh,<sup>1</sup> G.T. Schnickel,<sup>1</sup> C. Garcia,<sup>1</sup> A. Shefizadeh,<sup>2</sup> M.C. Fishbein,<sup>1</sup> A. Ardehali,<sup>1</sup> <sup>1</sup>Division of Cardiac Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA

**4:15 PM (85)** *CCR7 Expression by Recipient T-Cells and Dendritic Cells Attenuates the Development of Transplant Arteriosclerosis*; S.M. Ensminger,<sup>1</sup> S.N. Helm,<sup>1</sup> L. Ohl,<sup>2</sup> M. Wollin,<sup>3</sup> T. Fischlein,<sup>1</sup> M. Weyand,<sup>1</sup> R. Forster,<sup>2</sup> <sup>1</sup>Department of Cardiac Surgery, University of Erlangen Nuernberg, Erlangen, Bavaria, Germany; <sup>2</sup>Institute for Immunology, Medizinische Hochschule Hannover, Hannover, Lower Saxony, Germany; <sup>3</sup>Department of Medicine III, University of Erlangen Nuernberg, Erlangen, Bavaria, Germany

**4:30 PM (86)** *Myocardial CCL19 Expression Affects CCR7-Dependent Circulating CD8 T-Cell Homing in Heart Allograft Recipients with Acute Rejection*; P. Athanassopoulos,<sup>1</sup> A. Peeters,<sup>2</sup> L.M.B. Vaessen,<sup>2</sup> J. Velthuis,<sup>2</sup> P.E. Zondervan,<sup>4</sup> A.H.M.M. Balk,<sup>3</sup> A.P.W.M. Maat,<sup>1</sup> C.C. Baan,<sup>2</sup> A.J.J.C. Bogers,<sup>1</sup> W. Weimar,<sup>2</sup> <sup>1</sup>Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands; <sup>2</sup>Internal Medicine, Erasmus MC, Rotterdam, Netherlands; <sup>3</sup>Cardiology, Erasmus MC, Rotterdam, Netherlands; <sup>4</sup>Pathology, Erasmus MC, Rotterdam, Netherlands

**4:45 PM (87)** *Combined CXCR3 and CCR5 Blockade Attenuates Acute and Chronic Rejection*; G.T. Schnickel,<sup>1</sup> G.R. Hsieh,<sup>1</sup> C. Garcia,<sup>1</sup> A. Shefizadeh,<sup>1</sup> M.C. Fishbein,<sup>2</sup> A. Ardehali,<sup>1</sup> <sup>1</sup>Division of Cardiac Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA

**5:00 PM (88)** *LFA-1 Induced Cardiac Allograft Survival: Tolerance Induction Requires Host MHC Class I Expression*; R.J. Plenter,<sup>1</sup> J.N. Beilke,<sup>2</sup> R.G. Gill,<sup>2</sup> B.A. Pietra,<sup>1</sup> <sup>1</sup>Division of Cardiology, The Childrens Hospital, Denver, CO; <sup>2</sup>Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO

**5:15 PM (89)** *Relationship between Cardiac Allograft Vasculopathy and Expression of ILT3, ILT4 and FOXP3 in Endomyocardial Biopsies*; N. Suciu-Foca,<sup>1</sup> E. Ho,<sup>1</sup> L. Scotto,<sup>1</sup> H. Lin,<sup>1</sup> M. Deng,<sup>2</sup> M. Cadeiras,<sup>2</sup> C. Marboe,<sup>1</sup> R. Cortesini,<sup>1</sup> D. Mancini,<sup>2</sup> <sup>1</sup>Pathology, Columbia University, New York, NY; <sup>2</sup>Medicine, Columbia University, New York, NY

**5:30 PM (90)** *Photopheresis Stimulates the Generation of Regulatory T Cells*; F. Strobl,<sup>1</sup> J. Huber,<sup>1</sup> A. Krutsick,<sup>1</sup> K. Campbell,<sup>1</sup> D. Peritt,<sup>1</sup> <sup>1</sup>Research and Clinical Development, THERAKOS, Inc., Exton, PA

**5:45 PM (91)** *FOXP3+ T-Cells Regulate Anti-Donor Responses in the Graft after Heart Transplantation*; C.C. Baan,<sup>1</sup> I.E. Dijke,<sup>1</sup> A.H. Balk,<sup>2</sup> S.S. Korevaar,<sup>1</sup> P.E. Zondervan,<sup>3</sup> A.P. Maat,<sup>2</sup> W. Weimar,<sup>1</sup> <sup>1</sup>Internal Medicine, Erasmus MC, Rotterdam, Netherlands; <sup>2</sup>Thorax Center, Erasmus MC, Rotterdam, Netherlands; <sup>3</sup>Pathology, Erasmus MC, Rotterdam, Netherlands

**4:00 PM - 6:00 PM**

#### **CONCURRENT SESSION 8**

**Pulmonary Hypertension: Newer Therapies for Primary Pulmonary Hypertension (Germany SDBP)**  
**Chairs: Steven M. Kawut, MD and Jean Luc Vachiery, MD**

**4:00 PM (92)** *Sitaxsentan Improves Time to Clinical Worsening (TCW) in Patients with Pulmonary Arterial Hypertension (PAH)*; R.J. Oudiz,<sup>1</sup> A.E. Frost,<sup>2</sup> E.C. Lawrence,<sup>3</sup> N. Galie,<sup>4</sup> R.J. Barst,<sup>5</sup> <sup>1</sup>Liu Center for Pulmonary Hypertension, UCLA Medical Center, Los Angeles, CA; <sup>2</sup>Baylor College of Medicine, Houston, TX; <sup>3</sup>McKelvey Lung Transplantation Center, Emory University School of Medicine, Atlanta, GA; <sup>4</sup>University of Bologna, Bologna, Italy; <sup>5</sup>Columbia University College of Physicians & Surgeons, New York, NY

**4:15 PM (93)** *Combination of Bosentan with Prostanoids or Sildenafil in Pulmonary Arterial Hypertension Was Well Tolerated: Results from the TRAX Database*; J. Carlsen,<sup>1</sup> D.G. Kiely,<sup>2</sup> M.M. Hoepfer,<sup>3</sup> E. Segal,<sup>4</sup> M. Humbert,<sup>5</sup> <sup>1</sup>Medical Department., Rigshospitalet, Copenhagen, Denmark; <sup>2</sup>Department of Respiratory

Medicine, Royal Hallamshire Hospital, Sheffield, United Kingdom; <sup>3</sup>Department of Respiratory Medicine, Medical School, Hannover, Germany; <sup>4</sup>Global Drug Safety Department., Actelion Pharmaceuticals, Allschwil, Switzerland; <sup>5</sup>Service de Pneumologie, Hospital Antoine Beclere, Clamart, France

**4:30 PM (94)** *Sitaxsentan Improves Six Minute Walk Distance in Patients with Pulmonary Arterial Hypertension Related to Congenital Heart Defects*; R.L. Benza,<sup>1</sup> A.M. Keogh,<sup>2</sup> D.D. Ivy,<sup>3</sup> J. Sandoval,<sup>4</sup> R.J. Barst,<sup>5</sup> <sup>1</sup>Pulmonary Vascular Disease Program, University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>Heart Transplant Unit, St Vincent's Hospital, Darlinghouse, NSW, Australia; <sup>3</sup>Department of Cardiology, The Children's Hospital, Denver, CO; <sup>4</sup>Cardiopulmonary Department, National Institute of Cardiology of Mexico, Mexico City, Mexico; <sup>5</sup>Columbia U. College of Physicians & Surgeons, New York, NY

**4:45 PM (95)** *Treprostinil as First-Line Treatment in Severe Pulmonary Arterial Hypertension: Effects on Clinical Outcome and Survival*; C. Jimenez,<sup>1</sup> P. Escribano,<sup>1</sup> M.D. Martin,<sup>2</sup> J.F. Delgado,<sup>1</sup> M.T. Velazquez,<sup>1</sup> <sup>1</sup>Heart Failure and Pulmonary Hypertension Unit. Department of Cardiology, Hospital 12 de Octubre, Madrid, Spain; <sup>2</sup>Unidad Medicina Preventiva, Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain

**5:00 PM (96)** *Bosentan Improves WHO Functional Class, Exercise Capacity and RV Size in Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)*; M. Musk,<sup>1</sup> D. Chambers,<sup>1</sup> S. Lawrence,<sup>1</sup> C. Jarey,<sup>1</sup> R. Fowler,<sup>1</sup> W. Chin,<sup>1</sup> E. Gabbay,<sup>1</sup> <sup>1</sup>Western Australian Pulmonary Hypertension Service, Royal Perth Hospital, Perth, Western Australia, Australia

**5:15 PM (97)** *Novel Doppler Echocardiographic Approach for Assessment of Pulmonary Vascular Resistance in Patients with Pulmonary Arterial Hypertension*; N. Selimovic,<sup>1</sup> B. Rundqvist,<sup>1</sup> C.-H. Bergh,<sup>1</sup> B. Andersson,<sup>1</sup> S. Pettersson,<sup>2</sup> O. Bech-Hanssen,<sup>2</sup> <sup>1</sup>Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; <sup>2</sup>Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden

**5:30 PM (98)** *Determinants of Survival in Pulmonary Hypertension Associated with Scleroderma*; R.E. Girgis,<sup>1</sup> S.C. Mathai,<sup>1</sup> H.C. Champion,<sup>2</sup> A. Zaiman,<sup>1</sup> L. Hummers,<sup>3</sup> F.M. Wigley,<sup>3</sup> P.M. Hassoun,<sup>1</sup> <sup>1</sup>Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD; <sup>2</sup>Cardiology, Johns Hopkins University, Baltimore, MD; <sup>3</sup>Johns Hopkins University, Baltimore, MD

**5:45 PM (99)** *N-Terminal Pro-B-Type Natriuretic Peptide as an Indicator of Disease Severity in a Heterogeneous Group of Patients with Pulmonary Arterial Hypertension*; A.K. Andreassen, R. Wergeland, S. Simonsen, O. Geiran, C. Guevara, T. Ueland, Cardiology, Rikshospitalet University Hospital, Oslo, Norway; Medical Biochemistry, Rikshospitalet University Hospital, Oslo, Norway; Cardiology, Rikshospitalet University Hospital, Oslo, Norway; Thoracic Surgery, Rikshospitalet University Hospital, Oslo, Norway; Cardiology, Rikshospitalet University Hospital, Oslo, Norway; Research Institute for Internal Medicine, Rikshospitalet University Hospital, Oslo, Norway

**6:00 PM - 7:00 PM**

**GENERAL POSTER SESSION 1 (Germany FMDC)**

**Abstracts #253-330**

**6:00 PM - 7:00 PM**

**Tapas Reception in Exhibit Halls (England and France Rooms)**

**7:00 PM - 9:00 PM**

Poster Session 1 Tear-Down (Germany FMDC)

**8:30 PM - 10:30 PM**

**PRESIDENT'S GALA RECEPTION (Casino de Madrid)**

(coat and tie required)

**FRIDAY, APRIL 7, 2006**

**8:00 AM - 6:00 PM**

Registration Desk Open (Congress Entrance)

**8:00 AM - 6:00 PM**

Speaker Ready Room Open (Bonn)

**8:00 AM - 11:00 AM**

Poster Session 2 Mounting (Germany FMDC)

**8:00 AM - 9:00 AM**

**Pediatric Transplantation Scientific Council Meeting** (Venezia/Milan)

**Pulmonary Hypertension Scientific Council Meeting** (Roma)

**Nursing and Social Sciences Scientific Council Meeting** (Germany SDBP)

**Infectious Diseases Scientific Council Meeting** (Alcudia)

**9:00 AM - 9:30 AM**

**ANNUAL BUSINESS MEETING (Members only)** (Auditorio)

**9:00 AM – 1:00 PM**

Exhibit Halls Open (England and France Rooms)

**9:30 AM - 11:30 AM**

**PLENARY SESSION (Auditorio)**

*Chairs: Joren C. Madsen, MD, DPhil and James K. Kirklin, MD*

**9:30 AM (100) Featured Abstract: Immunoregulatory Influences on Peripheral Blood Gene Expression in Lung Transplant Patients: The Lung Allograft Rejection Gene Expression Observational (LARGO) Study;** S. Keshavjee,<sup>1</sup> E.P. Trulock,<sup>2</sup> R.L. Doyle,<sup>3</sup> R.D. Davis,<sup>4</sup> J.G. Golden,<sup>5</sup> K.R. McCurry,<sup>6</sup> J.S. Wilt,<sup>7</sup> M. Strueber,<sup>8</sup> S.M. Arcasoy,<sup>7</sup> G.H. Caughey,<sup>5</sup> S. Sweet,<sup>2</sup> P. Jaksch,<sup>9</sup> P.A. Corris,<sup>10</sup> A.C. Mehta,<sup>11</sup> M.S. Mulligan,<sup>12</sup> O.E. Pajaro,<sup>13</sup> R. Woodward,<sup>15</sup> T.M. Klingler,<sup>15</sup> J.G. Wohlgenuth,<sup>15</sup> S. Rosenberg,<sup>15</sup> P. Lal,<sup>15</sup> J. Phillips,<sup>15</sup> K.C. Fang,<sup>15</sup> M.R. Zamora,<sup>14</sup> <sup>1</sup>University of Toronto, Toronto; <sup>2</sup>Washington University, St. Louis, MO; <sup>3</sup>Stanford University, Stanford, CA; <sup>4</sup>Duke University, Durham, NC; <sup>5</sup>University of California, San Francisco, San Francisco, CA; <sup>6</sup>University of Pittsburgh, Pittsburgh, PA; <sup>7</sup>Columbia University, New York, NY; <sup>8</sup>Hannover Medical School, Hannover, Germany; <sup>9</sup>University Hospital, Vienna, Austria; <sup>10</sup>University of Newcastle, Newcastle Upon Tyne, United Kingdom; <sup>11</sup>The Cleveland Clinic Foundation, Cleveland, OH; <sup>12</sup>University of Washington, Seattle, WA; <sup>13</sup>Mayo Clinic Jacksonville, Jacksonville, FL; <sup>14</sup>University of Colorado, Denver, CO; <sup>15</sup>XDx, South San Francisco, CA

**9:45 AM (101) Featured Abstract: CCR5 Blockade Prolongs Survival and Delays Cardiac Allograft Vasculopathy (CAV) in Non-Human Primates Treated with Cyclosporine A (CsA);** B.N.H. Nguyen,<sup>1</sup> A.M. Azimzadeh,<sup>1</sup> T. Zhang,<sup>1</sup> G. Wu,<sup>1</sup> S. Fresnay,<sup>1</sup> C. Schroeder,<sup>1</sup> K. Lyons,<sup>2</sup> I. Singer,<sup>2</sup> L. Peterson,<sup>2</sup> J. DeMartino,<sup>2</sup> R.N. Pierson III,<sup>2</sup> <sup>1</sup>Surgery, University of Maryland, Baltimore, MD; <sup>2</sup>Merck Research Laboratories, Rahway, NJ

**10:00 AM Invited Lecture: Danger Signals,** Polly Matzinger, PhD, National Institutes of Health, Bethesda, MD

**10:30 AM Invited Lecture: T-Regulatory Cells,** Kathryn J. Wood, PhD, MD, Oxford University, Oxford, United Kingdom

**11:00 AM Invited Lecture: Power Mix,** Terry B. Strom, MD, Harvard Medical School, Boston, MD

**11:30 AM - 7:00 PM**

Poster Session 2 Viewing (Germany FMDC)

**11:30 AM - NOON**

Coffee Break in Exhibit Halls (England and France Rooms)  
Poster Viewing (Germany FMDC)

**NOON - 2 :00 PM**

**CONCURRENT SESSION 9**

**Mechanical Circulatory Support: Clinical Outcomes (Auditorio)**

**Chairs: Bartley P. Griffith, MD and Edoardo Gronda, MD**

**NOON (102) *Predictors of Long-Term Survival in Destination Therapy Left Ventricular Assist Device Patients***; A.H. Healy,<sup>1</sup> A.G. Kfoury,<sup>1</sup> D.M. Nelson,<sup>1</sup> B.D. Horne,<sup>1</sup> H.K. Smith,<sup>1</sup> B.A. Kerwin,<sup>1</sup> C.R. Wecker,<sup>1</sup> K.M. Nelson,<sup>1</sup> D.G. Renlund,<sup>1</sup> J.W. Long,<sup>1</sup> <sup>1</sup>Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT

**12:15 PM (103) *Current Outcomes and Risk Factors for Ventricular Assist Device (VAD) Bridge Therapy: A Multi-Institutional Analysis***; B. Radovancevic,<sup>1</sup> R.N. Brown,<sup>2</sup> J.K. Kirklin,<sup>2</sup> F.D. Pagani,<sup>3</sup> G. Torre,<sup>4</sup> J.M. Herre,<sup>5</sup> P. Juarez,<sup>1</sup> <sup>1</sup>St. Luke's Episcopal Hospital, Houston, TX; <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>University of Michigan Hospital, Ann Arbor, MI; <sup>4</sup>Baylor College of Medicine, Houston, TX; <sup>5</sup>Sentara Norfolk General Hospital, Norfolk, VA

**12:30 PM (104) *Long-Term Out-of-Hospital Experience in Mechanical Circulatory Support Patients***; A. El-Banayosy,<sup>1</sup> L. Arusoglu,<sup>1</sup> L. Kizner,<sup>1</sup> M. Morshuis,<sup>1</sup> P. Sarnowski,<sup>1</sup> D. Cobaugh,<sup>1</sup> R. Koerfer,<sup>1</sup> <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

**12:45 PM (105) *Tight Perioperative Glucose Control Is Associated with Fewer LVAD Related Infections and Better Post-VAD Survival***; T.P. Martens,<sup>1</sup> M.J. Russo,<sup>1</sup> F.H. Cheema,<sup>1</sup> I. George,<sup>1</sup> M.Y. Tabksblat,<sup>1</sup> S. Alison-Mayne,<sup>1</sup> J.B. Goldberg,<sup>1</sup> R. Wang,<sup>1</sup> S.H. Bailey,<sup>1</sup> M. Argenziano,<sup>1</sup> A.S. Stewart,<sup>1</sup> M.C. Oz,<sup>1</sup> D.M. Mancini,<sup>2</sup> Y. Naka,<sup>1</sup> <sup>1</sup>Surgery, Columbia University College of Physicians and Surgeons - New York Presbyterian Hospital, New York, NY; <sup>2</sup>Medicine, Columbia University College of Physicians and Surgeons - New York Presbyterian Hospital, New York, NY

**1:00 PM (106) *Heparin-Induced Thrombocytopenia Adversely Affects Clinical Outcomes in Patients on Mechanical Circulatory Support***; S. Schenk,<sup>1</sup> A. El-Banayosy,<sup>1</sup> M. Morshuis,<sup>1</sup> W. Prohaska,<sup>1</sup> L. Arusoglu,<sup>1</sup> R. Koerfer,<sup>1</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, Heart Center NRW, Bad Oeynhausen, Germany

**1:15 PM (107) *Antibody Sensitisation Following LVAD Implantation Is Not Due to HLA Antibodies***; H. Newell,<sup>1</sup> J.D. Smith,<sup>1</sup> A.J. Danskin,<sup>1</sup> R.E. Fawson,<sup>1</sup> E. Birks,<sup>1</sup> M.L. Rose,<sup>1</sup> <sup>1</sup>Heart Science Centre, Royal Brompton & Harefield NHS Trust, Harefield, Middlesex, United Kingdom

**1:30 PM (108) *Evaluation of the Ventricular Assist Device Programme in the United Kingdom***; L.D. Sharples,<sup>1</sup> M.J. Buxton,<sup>2</sup> N. Caine,<sup>3</sup> for the EVAD UK Research Group,<sup>4</sup> <sup>1</sup>R&D Unit, Papworth Hospital NHS Trust, Papworth Everard, Cambridge, United Kingdom; <sup>2</sup>Health Economics Research Group, Brunel University, Uxbridge, Middlesex, United Kingdom; <sup>3</sup>R&D Unit, HM Government Department of Health, London, United Kingdom

**1:45 PM (109) *Preoperative Renal Failure Does Not Affect Outcome in Bridge-to-Transplantation with a Ventricular Assist Device Implantation***; H. Tsukui,<sup>1</sup> J.J. Teuteberg,<sup>2</sup> S. Winowich,<sup>1</sup> E. Stanford,<sup>1</sup> S. Weaver,<sup>1</sup> S. Murali,<sup>2</sup> M.A. Mathier,<sup>2</sup> D.M. McNamara,<sup>2</sup> L.M. Cadaret,<sup>2</sup> M.A. Simon,<sup>2</sup> Y. Toyoda,<sup>1</sup> R.L. Kormos,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>2</sup>Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA

**NOON - 2 :00 PM**

**CONCURRENT SESSION 10**

**Lung/Heart-Lung Transplantation: Bronchiolitis Obliterans Syndrome: Risk Factors and Mediators (Venezia/Milan)**

**Chairs: Marc Estenne, MD and Allan R. Glanville, MD, FRACP**

**NOON (110)** *Surfactant Protein A Gene Polymorphism Predicts BOS*; F. D'Ovidio,<sup>1</sup> H. Kaneda,<sup>1</sup> C. Andrade,<sup>1</sup> L.G. Singer,<sup>1</sup> C. Chaparro,<sup>1</sup> C. Gutierrez,<sup>1</sup> M. Hutcheon,<sup>1</sup> A. Pierre,<sup>1</sup> M. Liu,<sup>1</sup> T.K. Waddell,<sup>1</sup> J. Floros,<sup>2</sup> S. Keshavjee,<sup>1</sup> <sup>1</sup>Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada; <sup>2</sup>Department of Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, PA

**12:15 PM (111)** *Colonization of Lung Transplant Recipients with Pseudomonas Aeruginosa and the Development of Bronchiolitis Obliterans Syndrome*; P. Botha,<sup>1</sup> L. Archer,<sup>1</sup> R.L. Anderson,<sup>1</sup> J. Lordan,<sup>2</sup> J.H. Dark,<sup>1</sup> P.A. Corris,<sup>2</sup> F.K. Gould,<sup>1</sup> A. Fisher,<sup>2</sup> <sup>1</sup>Department of Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; <sup>2</sup>Immunobiology and Transplantation Research Group, University of Newcastle upon Tyne, Newcastle upon Tyne, Tyne and Wear, United Kingdom

**12:30 PM (112)** *Which Factors Predict the Beneficial Effect of Azithromycin in Patients with Bronchiolitis Obliterans Syndrome after Lung Transplantation?*; G.M. Verleden,<sup>1,2</sup> L.J. Dupont,<sup>1,2</sup> B.M. Vanaudenaerde,<sup>1,2</sup> D.E. Van Raemdonck,<sup>2,3</sup> <sup>1</sup>Department Pulmonary Dis, University Hospital Gasthuisberg, Leuven, Belgium; <sup>2</sup>Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium; <sup>3</sup>Department Thor Surg, University Hospital Gasthuisberg, Leuven, Belgium

**12:45 PM (113)** *Comparison of Exhaled Nitric Oxide (eNO) and Helium Slope (SHe) for the Early Detection of Graft Dysfunction after Heart-Lung (HLT) and Bilateral Lung (BLT) Transplantation*; A. Van Muylem,<sup>1</sup> C. Knoop,<sup>1</sup> M. Estenne,<sup>1</sup> <sup>1</sup>Chest Service, Erasme University Hospital, Brussels, Belgium

**1:00 PM (114)** *A Novel Diagnostic Marker for Bronchiolitis Obliterans in Lung Transplant Recipients: Serum KL-6 Level*; J.N. Walter,<sup>1</sup> M. Doan,<sup>2</sup> H. Zhang,<sup>2</sup> L.L. Fan,<sup>2</sup> G.B. Mallory,<sup>2</sup> R. Bag,<sup>3</sup> O. Elidemir,<sup>2</sup> <sup>1</sup>Pediatrics, Driscoll Children's Hospital, Corpus Christi, TX; <sup>2</sup>Pediatric Pulmonology, Baylor College of Medicine, Houston, TX; <sup>3</sup>Medicine, Baylor College of Medicine, Houston, TX

**1:15 PM (115)** *Role of Profibrotic Cytokines IL-17 and IL-11 in Chronic Rejection Following Lung Transplantation*; C. Bergeron,<sup>1,2</sup> M. Alkerithy,<sup>2</sup> T.C. Kotsimbos,<sup>3</sup> Q. Hamid,<sup>2</sup> <sup>1</sup>Medecine, Hotel-Dieu du CHUM, University of Montreal, Montreal, QC, Canada; <sup>2</sup>Meakins-Christie Laboratories, McGill University, Montreal, QC, Canada; <sup>3</sup>Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Melbourne, Australia

**1:30 PM (116)** *Soluble CD30 Is a Predictor of Bronchiolitis Obliterans Syndrome after Lung Transplantation*; E.A. Van de Graaf,<sup>1</sup> A.A. Bauwens,<sup>1</sup> D.A. Van Kessel,<sup>3</sup> W.G.J. Van Ginkel,<sup>2</sup> H.G. Otten,<sup>2</sup> <sup>1</sup>Heart Lung Center Utrecht, Academic Medical Center, Utrecht, Netherlands; <sup>2</sup>Department of Immunology, Academic Medical Center, Utrecht, Netherlands; <sup>3</sup>Heart Lung Center Utrecht, St Antonius Ziekenhuis, Nieuwegein, Netherlands

**1:45 PM (117)** *Is Gastro-Oesophageal Reflux More Frequent in Lung Transplant Patients with Chronic Rejection?*; L.J. Dupont,<sup>1</sup> K. Blondeau,<sup>2</sup> D. Sifrim,<sup>2</sup> D.M. Van Raemdonck,<sup>1</sup> G.M. Verleden,<sup>1</sup> <sup>1</sup>Lung Transplant Unit, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium; <sup>2</sup>Center for Gastroenterological Research, KU Leuven, Leuven, Belgium

**NOON - 2 :00 PM**

**CONCURRENT SESSION 11**

**Pediatrics: Complications and Solutions in Pediatric Thoracic Transplantation (Roma)**

*Chairs: Michael Burch, MD and Okan Elidemir, MD*

**NOON (118)** *Pre-Transplant Cytomegalovirus Serology Is a Risk Factor for Cardiac Allograft Vasculopathy in Children*; T. Hussain,<sup>1</sup> M.J. Fenton,<sup>1</sup> M. Burch,<sup>1</sup> P.M. Whitmore,<sup>1</sup> P. Rees,<sup>1</sup> M.J. Elliott,<sup>1</sup> P. Aurora,<sup>1</sup> <sup>1</sup>Paediatric Cardiology, Great Ormond Street Hospital, London, United Kingdom

**12:15 PM (119)** *Assessing the Effect of Sirolimus on Transplant Coronary Artery Disease in Children Using Intravascular Ultrasound*; M.A. Kuhn,<sup>1</sup> D.D. Deming,<sup>1</sup> R.L. Larsen,<sup>1</sup> A.V. De Amaya,<sup>1</sup> A.J. Razzouk,<sup>2</sup> R.E. Chinnock,<sup>1</sup> <sup>1</sup>Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA; <sup>2</sup>Cardiothoracic Surgery, Loma Linda University Children's Hospital, Loma Linda, CA

**12:30 PM (120)** *Improved Rejection Free Survival with Adjunctive Mycophenolate vs Azathioprine in Pediatric Heart Transplant Recipients*; W.R. Morrow,<sup>1</sup> D.C. Naftel,<sup>2</sup> E.E. Edens,<sup>1</sup> J.M. Lamour,<sup>3</sup> C. Canter,<sup>4</sup> J. Parker,<sup>1</sup> K. Ainley,<sup>1</sup> I. Kajevska,<sup>1</sup> S. Myers,<sup>2</sup> J.K. Kirklin,<sup>2</sup> <sup>1</sup>Department of Pediatrics, UAMS College of Medicine, Little Rock, AR; <sup>2</sup>Department of Surgery, University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Department of Pediatrics, Columbia University, New York, NY; <sup>4</sup>Department of Pediatrics, Washington University, St. Louis, MO

**12:45 PM (121)** *Determination of C2 Trough Levels of Cyclosporine Is Superior to C0 Measurement for Rejection Monitoring in Pediatric Heart Transplant Patients*; S. Schubert,<sup>1</sup> H. Lehmkuhl,<sup>1</sup> H. Abdul-Khaliq,<sup>1</sup> O. Miera,<sup>1</sup> N. Hiemann,<sup>1</sup> M. Huebler,<sup>1</sup> Y. Weng,<sup>1</sup> C. Knosalla,<sup>1</sup> F. Berger,<sup>1</sup> R. Hetzer,<sup>1</sup> <sup>1</sup>Deutsches Herzzentrum Berlin, Berlin, Germany

**1:00 PM (122)** *The Profile of Renal Function over Time in a Cohort of Pediatric Heart Transplant Recipients*; A.I. Dipchand,<sup>1</sup> W. Bharat,<sup>1</sup> S. Pollock-Barziv,<sup>1</sup> L.J. West,<sup>1</sup> B.W. McCrindle,<sup>1</sup> <sup>1</sup>Cardiology, Hospital for Sick Children, Toronto, ON, Canada

**1:15 PM (123)** *De Novo Calcineurin-Inhibitor-Free/Sirolimus-Based Immunosuppression in Pediatric Heart Transplant Recipients with Renal Failure*; M.J. Fenton,<sup>1</sup> M. Burch,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Transplant, Great Ormond Street Hospital for Children, London, United Kingdom

**1:30 PM (124)** *Fungal Infections after Pediatric Lung Transplantation*; L.A. Danziger-Isakov,<sup>1</sup> S. Worley,<sup>1</sup> P. Aurora,<sup>2</sup> D.M. Boyer,<sup>3</sup> C.K. Conrad,<sup>4</sup> O. Elidemir,<sup>5</sup> G.B. Mallory, Jr.,<sup>5</sup> P. Michelson,<sup>6</sup> P.J. Mogayzel, Jr.,<sup>7</sup> D. Parakininkas,<sup>8</sup> G.A. Visner,<sup>9</sup> S. Sweet,<sup>10</sup> A. Faro,<sup>10</sup> <sup>1</sup>Pediatrics, Cleveland Clinic Foundation, Cleveland, OH; <sup>2</sup>Pediatrics, Great Ormond Street Hospital & Institute for Child Health, London, United Kingdom; <sup>3</sup>Pediatrics, Harvard University & Boston Children's Hospital, Boston, MA; <sup>4</sup>Pediatrics, Stanford University, Palo Alto, CA; <sup>5</sup>Pediatrics, Baylor College of Medicine & Texas Children's Hospital, Houston, TX, United Kingdom; <sup>6</sup>Pediatrics, University of Pittsburgh, Pittsburgh, PA; <sup>7</sup>Pediatrics, The Johns Hopkins University Hospital, Baltimore, MD; <sup>8</sup>Pediatrics, Medical College of Wisconsin & Children's Hospital of Wisconsin, Milwaukee, WI; <sup>9</sup>Pediatrics, University of Florida, Gainesville, FL; <sup>10</sup>Pediatrics, Washington University School of Medicine & St. Louis Children's Hospital, St. Louis, MO

**1:45 PM (125)** *Epidemiology, Risk Factors, and Outcomes of Fungal Infections in Pediatric Heart Transplant Recipients*; T. Zaoutis,<sup>1</sup> D. Naftel,<sup>2</sup> M. Chrisant,<sup>1</sup> B. Kaufman,<sup>1</sup> B. Pearce,<sup>2</sup> R. Spicer,<sup>3</sup> T. Harris,<sup>1</sup> S. Webber,<sup>4</sup> the PHTS, <sup>1</sup>Children's Hospital of Philadelphia, Philadelphia, PA; <sup>2</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Children's Hospital Medical Center, Cincinnati, OH; <sup>4</sup>Children's Hospital of Pittsburgh, Pittsburgh, PA

**NOON - 2 :00 PM**

**CONCURRENT SESSION 12**

**Basic Science and Immunobiology: Mechanisms of Rejection (Germany SDBP)**

**Chairs: Carla C. Baan, MD and George Tellides, MD**

**NOON (126)** *Perforin and Fas, Taken Together, Represent Obligate and Parallel Pathways of CD4 T-Cell Mediated Cardiac Rejection*; T.J. Grazia, R.J. Plenter, A.N. Doan, R.G. Gill, B.A. Pietra, Department of Medicine, Division. of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO; Department of Pediatrics, University of Colorado Health Sciences Center, The Childrens Hospital, Denver, CO; Department of Medicine and Immunology, University of Colorado, Barbara Davis Center for Childhood Diabetes, Aurora, CO

**12:15 PM (127) Genetic Control of CD44 Expression by Intragraft Fibroblasts;** G.D. Wu,<sup>1</sup> M.L. Barr,<sup>2</sup> H. Zhu,<sup>1</sup> J.-I. Woo,<sup>1</sup> Y. He,<sup>1</sup> A.S. Klein,<sup>1</sup> <sup>1</sup>Comprehensive Transplant Center at Cedars-Sinai Medical Center; <sup>2</sup>Department of Cardiothoracic Surgery, University of Southern California, Los Angeles, CA

**12:30 PM (128) IL-21: The Primary Player in Rejection Processes;** C.C. Baan,<sup>1</sup> A.H.M.M. Balk,<sup>2</sup> S.S. Korevaar,<sup>1</sup> A.M.A. Peeters,<sup>1</sup> W. Weimar,<sup>1</sup> <sup>1</sup>Internal Medicine, Erasmus MC, Rotterdam, Netherlands; <sup>2</sup>Cardiology, Erasmus MC, University Medical Center, Rotterdam, Netherlands

**12:45 PM (129) Anti-Vimentin Antibodies Cause Accelerated Rejection of Major Histocompatibility Complex (MHC) Identical Murine Cardiac Allografts;** B. Mahesh,<sup>1</sup> P. Sarathchandra,<sup>1</sup> A.M. McCormack,<sup>1</sup> A.L. Holder,<sup>1</sup> M. Jacovides,<sup>1</sup> J.D. Smith,<sup>1</sup> M.L. Rose,<sup>1</sup> <sup>1</sup>Transplant Immunology, Harefield Hospital, Harefield, Middlesex, United Kingdom

**1:00 PM (130) Graft Endothelial Repopulation by Recipient Cells in the Absence of an Adaptive Immune Response Is IFN-gamma-Dependent and May Protect from Alloinjury;** G. Warnecke,<sup>1</sup> K.J. Wood,<sup>1</sup> <sup>1</sup>Nuffield Department. of Surgery, University of Oxford, Oxford, United Kingdom

**1:15 PM (131) Gene Transfer of Programmed Death Ligand-1 (PDL-1) Prolongs Allograft Survival in a Rat Model of Heart Transplantation;** J. Li, G. Vassalli, Transplantation Research, NIBR, Basel, Switzerland; <sup>1</sup>Services de Cardiologie, Chirurgie Expérimentale, Chirurgie Cardio-vasculaire, et Centre de Transplantation d'Organes, CHUV, Lausanne, Switzerland

**1:30 PM (132) Interplay between Inflammation and Angiogenesis in Cardiac Allografts – Therapeutic Applications for VEGFR-1 and -2 Inhibition;** A.I. Nykänen,<sup>1</sup> O. Raisky,<sup>2</sup> M. Hollmén,<sup>1</sup> R. Krebs,<sup>1</sup> J.M. Tikkanen,<sup>1</sup> Y. Wu,<sup>3</sup> D.J. Hicklin,<sup>3</sup> P.K. Koskinen,<sup>1</sup> K.B. Lemström,<sup>1</sup> <sup>1</sup>Transplantation Laboratory, University of Helsinki, Helsinki, Finland; <sup>2</sup>Hôpital Cardiologique Louis Pradel, Lyon, France; <sup>3</sup>ImClone Systems Incorporated, New York, NY

**1:45 PM (133) Focus on Inflammation and Oxidation: A New Approach to Management of Cardiac Allograft Vasculopathy;** G.T. Schnickel,<sup>1</sup> G.R. Hsieh,<sup>1</sup> C. Garcia,<sup>1</sup> A. Shefizadeh,<sup>1</sup> M.C. Fishbein,<sup>2</sup> A. Ardehali,<sup>1</sup> <sup>1</sup>Division of Cardiac Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA

**2:00 PM - 4:00 PM**

**NOVARTIS LUNCHEON SYMPOSIUM: Targeting the World-Wide Burden of Cardiac Allograft Vasculopathy (Auditorio)**

**Supported by an Educational Grant From Novartis**

**Chairs: Anne Keogh, MD and Paul J. Mohacs, MD**

**2:15 PM Identification of Health Care Resources Utilization due to Cardiac Allograft Vasculopathy,** Maria Frigerio, MD, Niguarda Ca Granda Hospital, Milan, Italy

**2:35 PM Translating Health Care Resource Utilization for Cardiac Allograft Vasculopathy Into Health Care Costs,** Howard J. Eisen, MD, Drexel University College of Medicine, Philadelphia, PA

**2:55 PM Practical Strategies to Address the Health Care Burden of Cardiac Allograft Vasculopathy- A Case-Based Approach,** Hans Lehmkuhl, MD, Deutsches Herzzentrum Berlin, Berlin, Germany

**3:15 PM Discussion**

**2:00 PM - 4:00 PM**

**ENCYSIVE LUNCHEON SYMPOSIUM: Pulmonary Arterial Hypertension: Evolving Therapeutic Concepts (Venezia/Milan)**

**Supported by an Educational Grant from Encysive**

**Chairs: Reda E. Girgis, MB BCh and Keith McNeil, FRACP**

**2:15 PM Prognostic Factors on PAH and Timing of Transplantation,** Reda E. Girgis, MB BCh, Johns Hopkins University, Baltimore, MD

**2:30 PM** *Managing PAH: The Physiologic Basis of Pharmacotherapy*, Robert C. Bourge, MD, University of Alabama, Birmingham, AL

**2:45 PM** *Emerging Therapeutic Options: Early Intervention and Combination Therapy*, Steven M. Kawut, MD, Columbia University, New York, NY

**3:00 PM** *What is on the Horizon for the Medical Treatment of PAH*, Professor Robert Naeije, Erasme Hospital, Brussels, Belgium

**3:15 PM** Debate: *PAH is no Longer an Indication for Lung Transplantation*

*Pro:* Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

*Con:* Paul A. Corris, MB, FRCP, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom

**3:45 PM** *Discussion*

**2:00 PM - 3:30 PM**

Lunch Buffet (Madrid Café)

**2:45 PM - 3:45 PM**

**MINI ORAL POSTER PRESENTATIONS SESSION 3 (Roma)**

**Chairs: James F. George, PhD and Thomas J. Dengler, MD**

**2:45 PM (134)** *Recovery of Heart Failure by Normalization of the Cardiac Extracellular Matrix after Microcurrent Application*; J. Mueller,<sup>1</sup> B. Kapeller,<sup>2</sup> K. Macfelda,<sup>2</sup> <sup>1</sup>Berlin Heart, Berlin, Germany; <sup>2</sup>Core Unit for Biomedical Research, Medical University Vienna, Vienna, Austria

**2:50 PM (135)** *Interruption of the Receptor for Advanced Glycation End Product Pathway Attenuates Pulmonary Reperfusion Injury*; D.I. Sternberg,<sup>1</sup> R. Gowda,<sup>1</sup> J. Sarkar,<sup>1</sup> S. Arcasoy,<sup>1</sup> J.M. D'Armiento,<sup>1</sup> A.M. Schmidt,<sup>1</sup> J.R. Sonett,<sup>1</sup> <sup>1</sup>Lung Transplant Program, Columbia University, New York, NY

**2:55 PM (136)** *Hepatocyte Growth Factor – A Link between Neutrophilic Inflammation and BOS?*; I.A. Forrest,<sup>1</sup> C. Ward,<sup>1</sup> D.M. Murphy,<sup>1</sup> G.E. Johnson,<sup>1</sup> D. Jones,<sup>2</sup> J.L. Lordan,<sup>1</sup> T.E. Cawston,<sup>2</sup> P.A. Corris,<sup>1</sup> <sup>1</sup>Applied Immunobiology and Transplantation Group, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; <sup>2</sup>Musculoskeletal Research Group, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom

**3:00 PM (137)** *Microarray Identifies Developmental Genes Expression in Small Airway Epithelial Cells Following TGF- $\beta$ 1 Stimulation*; M.R. Ahsan,<sup>1</sup> D.T. Keating,<sup>1</sup> R. Linehan,<sup>2</sup> D. Healy,<sup>1</sup> L. Nolke,<sup>1</sup> F. Wood,<sup>1</sup> J. McCarthy,<sup>1</sup> P. Doran,<sup>2</sup> J.J. Egan,<sup>1</sup> <sup>1</sup>Heart & Lung Transplant Programme, Mater Misericordiae Hospital, Dublin, Ireland; <sup>2</sup>Genome Resource Unit, Mater Misericordiae Hospital, Dublin, Ireland

**3:05 PM (138)** *Endothelin-1 Exacerbates Hypoxic Injury: Implication for Primary Allograft Dysfunction*; D. Ramzy,<sup>1</sup> L.C. Tumiaty,<sup>1</sup> N. Xu,<sup>1</sup> N. Khan,<sup>1</sup> S. Miriuka,<sup>2</sup> D.H. Delgado,<sup>2</sup> H.J. Ross,<sup>2</sup> V. Rao,<sup>1</sup> <sup>1</sup>Cardiac Surgery, Toronto General Hospital, Toronto, ON, Canada; <sup>2</sup>Cardiology, Toronto General Hospital, Toronto, ON, Canada

**3:10 PM (139)** *FK778: New Cellular and Molecular Mechanisms of Action*; S. Schrepfer,<sup>1,5</sup> T. Deuse,<sup>1</sup> F. Koch-Nolte,<sup>2</sup> H. Schaefer,<sup>3</sup> E. Schwedhelm,<sup>4</sup> R. Boeger,<sup>4</sup> H. Reichenspurner,<sup>1</sup> <sup>1</sup>Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; <sup>2</sup>Department of Immunology, University Hamburg, Hamburg, Germany; <sup>3</sup>Department of Pathology, University Hamburg, Hamburg, Germany; <sup>4</sup>Department of Pharmacology, University Hamburg, Hamburg, Germany; <sup>5</sup>Department of Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, CA

**3:15 PM (140)** *Polymorphisms of the MDR1 Gene and Freedom from Biopsy Proven Rejection in Heart Transplantation*; J.B. Barnard,<sup>1</sup> S. Sheldon,<sup>2</sup> S. Richardson,<sup>1</sup> J. Fildes,<sup>1</sup> N. Khasati,<sup>1</sup> V. Pravica,<sup>3</sup> I.V. Hutchinson,<sup>3</sup> C.T. Leonard,<sup>1</sup> N. Yonan,<sup>1</sup> <sup>1</sup>The Transplant Centre, South Manchester University Hospitals NHS Trust, Manchester, United Kingdom; <sup>2</sup>Tissue Typing Laboratory, Manchester Royal Infirmary, Manchester, United Kingdom; <sup>3</sup>Department of Immunology, Manchester University, Manchester, United Kingdom



**3:20 PM (141)** *Extracorporeal Photopheresis (ECP) Causes Intramyocardial Deletion of Graft-Specific T Cells in Murine Cardiac Transplants*; J.F. George,<sup>1</sup> L.L. Guo,<sup>1</sup> C. Gooden,<sup>1</sup> D.C. Naftel,<sup>1</sup> D. Peritt,<sup>2</sup> J.K. Kirklin,<sup>1</sup> <sup>1</sup>Department of Surgery, University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>THERAKOS Corporation, Exton, PA

**3:25 PM (142)** *Transplanted Human Cord Blood Derived Unrestricted Somatic Stem Cells (USSC) Improve Left-Ventricular Function and Prevent Left-Ventricular Dilation and Scar Formation after Acute Myocardial Infarction*; A. Ruhparwar,<sup>1</sup> A. Ghodsizad,<sup>2</sup> G. Koegler,<sup>3</sup> C. Bara,<sup>1</sup> H.M. Klein,<sup>2</sup> E. Gams,<sup>2</sup> M. Niehaus,<sup>4</sup> M. Karck,<sup>1</sup> A. Haverich,<sup>1</sup> <sup>1</sup>Division of Thoracic- and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; <sup>2</sup>Department of Thoracic and Cardiovascular Surgery, Heinrich-Heine-Universität Duesseldorf, Duesseldorf, Germany; <sup>3</sup>§ Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine-Universität, Duesseldorf, Germany; <sup>4</sup>Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany

**3:30 PM (143)** *On-Line Detection of Transplanted Autologous Skeletal Myoblast Survival in Infarcted Myocardium*; C.L. del Rio,<sup>1</sup> P.I. McConnell,<sup>1</sup> D.B. Jacoby,<sup>2</sup> B.D. Clymer,<sup>1</sup> R. Dzwonczyk,<sup>1</sup> M.B. Howie,<sup>1</sup> R.E. Michler,<sup>3</sup> <sup>1</sup>The Ohio State University, Columbus, OH; <sup>2</sup>GenVec, Inc, Charlestown, MA; <sup>3</sup>Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY

**3:35 PM (144)** *Monocytes Recognize Porcine Endothelial Alpha-Gal Via Galectin-3*; A. Greenwald,<sup>1</sup> R. Jin,<sup>1</sup> M.D. Peterson,<sup>2</sup> T.K. Waddell,<sup>1,2</sup> <sup>1</sup>Division of Thoracic Surgery, Toronto General Research Institute, Toronto, ON, Canada; <sup>2</sup>Division of Cardiac Surgery, Department of Surgery, Toronto, ON, Canada

**2:45 PM - 3:45 PM**

**MINI ORAL POSTER PRESENTATIONS SESSION 4 (Germany SDBP)**

**Chairs: Daniel Y. Loisance, MD and Francis L. Pagani, MD, PhD**

**2:45 PM (145)** *Protein Analysis of Changes in Sarcomeric and Non-Sarcomeric Proteins during Clinical Myocardial Recovery Following Left Ventricular Assist Device Support*; N. Latif,<sup>1</sup> M.H. Yacoub,<sup>1</sup> J.H. Hall,<sup>2</sup> S.M. Grindle,<sup>2</sup> E.J. Birks,<sup>1</sup> <sup>1</sup>Heart Science Centre, Imperial College, Harefield Hospital, Harefield, Middlesex, United Kingdom; <sup>2</sup>Cardiovascular Division, Department. of Medicine, University of Minnesota, Minneapolis

**2:50 PM (146)** *Gene Expression Profile and Regulation of MMPs and TIMPs in the Myocardium of Patients with Deteriorating Heart Failure Requiring LVAD Support Compared to Stable End-Stage Heart Failure*; L.E. Felkin,<sup>1</sup> E.J. Birks,<sup>2</sup> A. Khaghani,<sup>2</sup> M.H. Yacoub,<sup>1</sup> P.J.R. Barton,<sup>1</sup> <sup>1</sup>Heart Science Centre, Imperial College London, Harefield, Middlesex, United Kingdom; <sup>2</sup>Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

**2:55 PM (147)** *Changes in Connexin 43 Expression and the Incidence and Severity of Arrhythmias Following LVAD Recovery*; J. Hardy,<sup>2</sup> E.J. Birks,<sup>1,2</sup> N. Latif,<sup>2</sup> R. George,<sup>1,2</sup> A. Khaghani,<sup>1</sup> M.H. Yacoub,<sup>1</sup> <sup>1</sup>Transplant Unit, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; <sup>2</sup>Heart Science Centre, Harefield Hospital, Harefield, Middlesex, United Kingdom

**3:00 PM (148)** *Decorin Regulates TGF- $\beta$  Stimulated Fibrosis in Heart Failure and during LVAD Support*; M. Loebe,<sup>1</sup> D. Joyce,<sup>1</sup> R. Southard,<sup>1</sup> G. Noon,<sup>1</sup> K. Youker,<sup>1</sup> <sup>1</sup>Michael E DeBakey Department. of Surgery, Baylor College of Medicine, Houston, TX

**3:05 PM (149)** *Transcription Repression Factor NAB1 Downregulation in the Failing Heart after BIVAD Support*; J.C. Osorio,<sup>1</sup> A.M. Duque,<sup>1</sup> M. Mercado,<sup>2</sup> F. Cheema,<sup>2</sup> Y. Naka,<sup>2</sup> M. Oz,<sup>2</sup> R.S. Mosca,<sup>2</sup> J.M. Chen,<sup>2</sup> S. Mital,<sup>1</sup> <sup>1</sup>Pediatrics, Columbia University, New York, NY; <sup>2</sup>Cardiothoracic Surgery, Columbia University, New York, NY

**3:10 PM (150)** *Predictors of Survival in Patients on Mechanical Circulatory Support Awaiting Cardiac Transplantation*; A. El-Banayosy,<sup>1</sup> L. Arusoglu,<sup>1</sup> M. Morshuis,<sup>1</sup> L. Kizner,<sup>1</sup> P. Sarnowski,<sup>1</sup> D. Coughlin,<sup>1</sup> R.

Koerfer,<sup>1</sup> <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

**3:15 PM (151)** *The Impact of Obesity on Survival among Patients Requiring Left Ventricular Assist Device Implantation*; L. Semones,<sup>1</sup> G.P. Noon,<sup>2</sup> M.M. Loebe,<sup>2</sup> G. Torre,<sup>1</sup> V. Thohan,<sup>1</sup> <sup>1</sup>Cardiology, Methodist DeBakey Heart Center, Houston, TX; <sup>2</sup>Cardiothoracic Surgery, Baylor College of Medicine, Houston, TX

**3:20 PM (152)** *Decision Aid for Evaluation of Risk/Benefit of RVAD for Patients Receiving LVAD*; B.E. Uber,<sup>1</sup> J.J. Teuteberg,<sup>2</sup> R.L. Kormos,<sup>2</sup> J.F. Antaki,<sup>3</sup> H. Tsukui,<sup>2</sup> M.A. Simon,<sup>2</sup> S. Winowich,<sup>2</sup> E. Stanford,<sup>2</sup> S. Weaver,<sup>2</sup> Y. Toyoda,<sup>2</sup> S. Murali,<sup>2</sup> M.A. Mathier,<sup>2</sup> D.M. McNamara,<sup>2</sup> L.M. Cadaret,<sup>2</sup> K.R. McCurry,<sup>2</sup> <sup>1</sup>Bioengineering, University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>UMPC, Pittsburgh, PA; <sup>3</sup>Bioengineering, Carnegie Mellon University, Pittsburgh, PA

**3:25 PM (153)** *The Assessment of Preload-Dependent Cardiac Function during LVAD Support Using Telemetered Left Ventricular Pressure: A Comparison to Preload-Recruitable Stroke Work*; P.I. McConnell,<sup>1</sup> C.L. DelRio,<sup>1</sup> P. Kwiatkowski,<sup>1</sup> D. Farrar,<sup>2</sup> T. Shipkowitz,<sup>3</sup> R.E. Michler,<sup>1</sup> B.C. Sun,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, The Ohio State University, Columbus, OH; <sup>2</sup>Thoratec Corp., Pleasanton, CA; <sup>3</sup>Transoma Medical, St. Paul, MN

**3:30 PM (154)** *Home Inotropic Support in Children*; A.M. Berg, W.T. Mahle, L.K. Snell, *Transplant Services*, Children's Healthcare of Atlanta, Atlanta, GA; *Sibley Heart Center*, Children's Healthcare of Atlanta, Atlanta, GA; *Transplant and Cardiology Services*, Coram Healthcare, Denver, CO

**3:35 PM (155)** *To Vaccinate or Not To Vaccinate: Results of the Pediatric Heart Transplant Study (PHTS) Vaccination Survey*; C. White-Williams,<sup>1</sup> D. Naftel,<sup>1</sup> S. Webber,<sup>2</sup> M. Michaels,<sup>2</sup> A. Berg,<sup>3</sup> E. Bullock,<sup>4</sup> J. Dubois,<sup>5</sup> S. Rogers,<sup>6</sup> PHTS Transplant Coordinator Group, <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>University of Pittsburgh, Pittsburgh, PA; <sup>3</sup>Egleston Children's Hospital, Atlanta, GA; <sup>4</sup>Primary Children's Medical Center, Salt Lake City, UT; <sup>5</sup>Children's Hospital of Michigan, Detroit, MI; <sup>6</sup>Children's Memorial Hospital, Chicago, IL

**3:40 PM (156)** *The Utility of the Pre-Transplant Psychosocial Evaluation in Pediatric Populations: Benefits, Limitations, and Ethical Considerations*; D.S. Lefkowitz,<sup>1</sup> B.D. Hanna,<sup>1</sup> D. Antinoro,<sup>2</sup> M. McDonough,<sup>1</sup> L. Palacio,<sup>1</sup> <sup>1</sup>Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA; <sup>2</sup>Graduate School of Applied and Professional Psychology, Rutgers University, Piscataway, NJ

#### **3:00 PM - 4:00 PM**

Afternoon Coffee in Exhibit Halls (England and France Rooms)

#### **3:00 PM - 7:00 PM**

Exhibit Halls Open (England and France Rooms)

#### **4:00 PM - 6:00 PM**

##### **CONCURRENT SESSION 13**

**Clinical Heart Transplantation: Cardiac Allograft Vasculopathy: A Never-Ending Story (Auditorio)**  
**Chairs: Jon Kobashigawa, MD and Folke Nilsson, MD, PhD**

**4:00 PM (157)** *Early Detection of Cardiac Allograft Vasculopathy through Gene Expression Profiling – Insights of the CARGO Study*; M.C. Deng,<sup>1</sup> M. Cadeiras,<sup>1</sup> H.M. Baron,<sup>2</sup> H.M. Marboe,<sup>1</sup> R.C. Starling,<sup>3</sup> H. Eisen,<sup>4</sup> H. Valantine,<sup>5</sup> S.A. Hunt,<sup>5</sup> J. Kobashigawa,<sup>6</sup> M.R. Mehra,<sup>7</sup> D.F. Pauly, S. Murali,<sup>8</sup> S. Mital,<sup>1</sup> G. Berry,<sup>5</sup> M. Billingham,<sup>5</sup> J. Wohlgemuth,<sup>2</sup> R. Dedrick,<sup>2</sup> <sup>1</sup>Medicine, Columbia University, New York, NY; <sup>2</sup>Research & Development, XDx, Inc., San Francisco, CA; <sup>3</sup>Medicine, Cleveland Clinic Foundation, Cleveland, OH; <sup>4</sup>Medicine, Drexel University College of Medicine, Philadelphia, PA; <sup>5</sup>Medicine, Stanford University, Palo Alto, CA; <sup>6</sup>Medicine, University of California, Los Angeles, CA; <sup>7</sup>Medicine, University of Maryland Medical Center, Maryland, MD; <sup>8</sup>Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>9</sup>Medicine, University of Florida, Gainesville, FL

**4:15 PM (158)** *Reliability of Left Ventricular Systolic Wall Motion Reduction for Non-Invasive Prediction of Transplant Coronary Artery Disease*; M. Dandel,<sup>1</sup> Y. Lai,<sup>1</sup> E. Wellnhofer,<sup>2</sup> H.B. Lehmkuhl,<sup>1</sup> C. Knosalla,<sup>1</sup> O. Grauhan,<sup>1</sup> R. Hetzer,<sup>1</sup> <sup>1</sup>Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

**4:30 PM (159)** *Validation of the Prognostic Value of a New Intravascular Ultrasound Score for the Evaluation of Graft Vessel Disease*; M. Gómez-Bueno,<sup>1</sup> J. Segovia,<sup>1</sup> L. Alonso-Pulpón,<sup>1</sup> J. Jiménez-Mazuecos,<sup>1</sup> F. Alfonso,<sup>2</sup> J. Goicolea,<sup>1</sup> R. Hernández Antolín,<sup>2</sup> J.M. Escudier,<sup>1</sup> A. Blasco,<sup>2</sup> C. Macaya,<sup>2</sup> <sup>1</sup>Unidad de Trasplante Cardíaco, Hospital Universitario Puerta de Hierro, Madrid, Spain; <sup>2</sup>Unidad de Cardiología Intervencionista, Hospital Universitario San Carlos, Madrid, Spain

**4:45 PM (160)** *Can Multislice CT Scan Replace Systematic Coronarography in Heart Transplant Recipients?*; E. Vermes,<sup>1</sup> P. Dupouy,<sup>2</sup> M. Kirsch,<sup>1</sup> Jm. Pernes,<sup>2</sup> D. Loisançe,<sup>1</sup> <sup>1</sup>Cardiac Surgery, Henri Mondor Hospital, Creteil, France; <sup>2</sup>Cardiology, Hopital Prive d'anthony, Anthony, France

**5:00 PM (161)** *Angiographic and Clinical Course of Cardiac Allograft Vasculopathy: Implications for Studies of Interventions To Slow Disease Progression*; M. Rockx,<sup>1</sup> P.W. Pflugfelder,<sup>1</sup> W.J. Kostuk,<sup>1</sup> <sup>1</sup>Division of Cardiology, LHSC University Hospital, London, ON, Canada

**5:15 PM (162)** *Inhibition of Cardiac Allograft Vasculopathy by Sirolimus and Mycophenolate: Asymmetric Dimethyl Arginine as a Potential Therapeutic Target*; L. Potena,<sup>1,3</sup> W. Fearon,<sup>1</sup> K. Sydow,<sup>1</sup> C. Holweg,<sup>1</sup> H. Luikart,<sup>1</sup> E. MocarSKI,<sup>2</sup> H. Valantine,<sup>1</sup> J. Cooke,<sup>1</sup> <sup>1</sup>Cardiovascular Medicine, Stanford University, Stanford, CA; <sup>2</sup>Microbiology and Immunology, Stanford University, Stanford, CA; <sup>3</sup>Cardiovascular Diseases, University of Bologna, Bologna, Italy

**5:30 PM (163)** *Why Do Some Heart Transplantation Recipients Not Develop Graft Vessel Disease on the Long Term?*; J. Segovia,<sup>1</sup> L. Alonso-Pulpón,<sup>1</sup> M. Gómez-Bueno,<sup>1</sup> F. Alfonso,<sup>2</sup> R. Hernández-Antolín,<sup>2</sup> J.M. Escudier,<sup>1</sup> J. Goicolea,<sup>1</sup> C. Macaya,<sup>2</sup> <sup>1</sup>Unidad de Trasplante Cardíaco, Hospital Universitario Puerta de Hierro, Madrid, Spain; <sup>2</sup>Interventional Cardiology Unit, Hospital Universitario San Carlos, Madrid, Spain

**5:45 PM (164)** *When To List for Re-Do Heart Transplant in Patients with Severe Cardiac Allograft Vasculopathy*; J.K. Patel,<sup>1</sup> A. Seid,<sup>1</sup> A. Mansukhani,<sup>1</sup> O.M. Thompson,<sup>1</sup> G.W. Wu,<sup>1</sup> H. Laks,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**4:00 PM - 6:00 PM**

#### **CONCURRENT SESSION 14**

#### **Phillip K. Caves Award Candidate Presentations (Venezia/Milan)**

Chairs: Shaf Keshavjee, MD and Bruce Rosengard, MD

**4:00 PM (165)** *CD4<sup>+</sup>CD25<sup>+</sup> T-Cell Mediated Regulation of Autoimmunity Following Human Lung Transplantation*; A. Bharat,<sup>1</sup> R.C. Fields,<sup>1</sup> A. Aloush,<sup>2</sup> E.P. Trulock,<sup>2</sup> G.A. Patterson,<sup>3</sup> T. Mohanakumar,<sup>1,4</sup> <sup>1</sup>Surgery/Transplant, Washington University School of Medicine, Saint Louis, MO; <sup>2</sup>Internal Medicine/Pulmonary, Washington University School of Medicine, Saint Louis; <sup>3</sup>Surgery/ Cardiothoracic, Washington University School of Medicine, Saint Louis, MO; <sup>4</sup>Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO

**4:15 PM (166)** *The Impact of Human Donor Lung Gene Expression Profiles on Survival after Lung Transplantation: A Case-Control Study*; M. Anraku, M.J. Cameron, T.K. Waddell, M. Liu, M. Sato, A.F. Pierre, M. dePerrot, D.J. Kelvin, S. Keshavjee, Thoracic Surgery Research Laboratory, Toronto Lung Transplant Program, Toronto General Research Institute, University of Toronto, Toronto, ON, Canada

**4:30 PM (167)** *Pulmonary Allograft Tolerance in Pigs Is Associated with Increased Frequency and Regulatory Function of CD4<sup>+</sup>CD25<sup>+</sup> T Cells*; G. Warnecke,<sup>1</sup> M. Avsar,<sup>1</sup> B. Kruse,<sup>1</sup> S. Thissen,<sup>1</sup> C. Peters,<sup>1</sup> R. Reinhard,<sup>1</sup> A.R. Simon,<sup>1</sup> J.H. Karstens,<sup>2</sup> A. Haverich,<sup>1</sup> M. Struber,<sup>1</sup> <sup>1</sup>Division Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; <sup>2</sup>Department. of Radiotherapy and Special Oncology, Hannover Medical School, Hannover, Germany

**4:45 PM (168)** *Cardiac Resynchronization Therapy Induces Cellular Reverse Remodelling in Failing Human Hearts*; G.H.M. Oliveira,<sup>1,2</sup> V. Thohan,<sup>1</sup> M.M. Koerner,<sup>2</sup> M. Loebe,<sup>1,3</sup> G.P. Noon,<sup>1,3</sup> N. Nasir,<sup>1</sup> G. Torre-Amione,<sup>1</sup> <sup>1</sup>Cardiovascular Medicine, Methodist DeBakey Heart Center, Houston, TX; <sup>2</sup>Internal Medicine and Cardiology, Baylor College of Medicine, Houston, TX; <sup>3</sup>Cardiovascular Surgery, Baylor College of Medicine, Houston, TX

**5:00 PM (169)** *Transferable CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T Cells Mediate Unrelated Cardiac Graft Acceptance in Neonatally-Tolerized Mice*; B. Hofmann,<sup>1</sup> L. Mai,<sup>2</sup> K. Tao,<sup>2</sup> A.M. Lamhonwah,<sup>2</sup> L.J. West,<sup>2</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Sachsen-Anhalt, Germany; <sup>2</sup>Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada

**5:15 PM (170)** *Ex Vivo Continuous Perfusion Allows for Evaluation of Hearts from Nonbeating Donor Hearts*; M.J. Collins,<sup>1</sup> T. Ozeki,<sup>1</sup> M. Kwon,<sup>1</sup> J. Gu,<sup>1</sup> R.N. Pierson,<sup>1</sup> R.S. Poston,<sup>1</sup> <sup>1</sup>Cardiac Surgery, University of Maryland Medical System, Baltimore, MD

**5:30 PM (171)** *Human Leukocyte Antigens Class II Expression in Heart Transplant Recipients Treated with Cyclosporine in Combination with Azathioprine, Mycophenolate Mofetil or Sirolimus*; R. Wojnicz,<sup>1</sup> M. Zakliczynski,<sup>2</sup> J. Nozynski,<sup>2</sup> A. Majkusiak,<sup>1</sup> R. Przybylski,<sup>2</sup> M. Zembala,<sup>2</sup> <sup>1</sup>Department of Cardiology, Silesian Center for Heart Diseases, Silesian Medical University, Zabrze, Poland; <sup>2</sup>Department of Cardiac Surgery and Transplantation, Silesian Center for Heart Diseases, Silesian Medical University, Zabrze, Poland

**5:45 PM (172)** *Mechanical Unloading of the Failing Heart Restores Strain Related Calcium Handling Protein Expression*; A. Kilic,<sup>1</sup> J.R. Nash,<sup>1</sup> T. Li,<sup>1</sup> D.J. Prastein,<sup>1</sup> G. Schwartzbauer,<sup>1</sup> T.D.C. Nolan,<sup>1</sup> Z. Wu,<sup>1</sup> B.P. Griffith,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, University of Maryland, Baltimore, MD

**4:00 PM - 6:00 PM**

**CONCURRENT SESSION 15**

**Infectious Diseases: Everything But Bubonic Plague (Roma)**

**Chairs: Tom Kotsimbos, MD and Barbara Alexander, MD**

**4:00 PM (173)** *Assessment of Pseudomonas aeruginosa Colonisation Post Lung Transplantation*; L. Archer,<sup>1</sup> A. Fisher,<sup>2</sup> P. Botha,<sup>3</sup> F.K. Gould,<sup>2</sup> <sup>1</sup>Department of Microbiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom; <sup>2</sup>Applied Immunology and Transplantation Research Group, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; <sup>3</sup>Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**4:15 PM (174)** *The Role of Cytomegalovirus in the Development and Progression of Pre-Transplant Ischaemic Heart Disease*; A.H. Walker,<sup>1</sup> J.E. Fildes,<sup>2</sup> C.T. Leonard,<sup>2</sup> N. Yonan,<sup>2</sup> <sup>1</sup>The Department of Cardiothoracic Surgery, Northern General Hospital, Sheffield, United Kingdom; <sup>2</sup>The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester, United Kingdom

**4:30 PM (175)** *Usefulness of Pre-Emptive Therapy for Cytomegalovirus Disease in the First Year after Heart Transplantation: A Study of 236 Patients*; M.J. Paniagua,<sup>1</sup> M.G. Crespo-Leiro,<sup>1</sup> J. Muniz,<sup>2</sup> R. Marzoa,<sup>1</sup> C. Naya,<sup>1</sup> A. Canizares,<sup>3</sup> P. Pazos,<sup>1</sup> A. Juffe,<sup>1</sup> A. Castro-Beiras,<sup>1</sup> <sup>1</sup>Heart Transplant Unit, CHU Juan Canalejo, A Coruna, Spain; <sup>2</sup>Instituto Ciencias de la Salud, Universidad de A Coruna, A Coruna, Spain; <sup>3</sup>Virology, CHU Juan Canalejo, A Coruna, Spain

**4:45 PM (176)** *Reactivation of T-CRUZI Infection after Heart Transplant*; L. Favaloro,<sup>1</sup> M. Diez,<sup>1</sup> A. Schijman,<sup>2</sup> C. Vigliano,<sup>1</sup> M. Peradejordi Lastra,<sup>1</sup> J. Burgos,<sup>2</sup> A. Bertolotti,<sup>1</sup> R. Favaloro,<sup>1</sup> <sup>1</sup>Intrathoracic Transplant, Favaloro Foundation, Buenos Aires, Argentina; <sup>2</sup>INGEBI, Buenos Aires, Argentina

**5:00 PM (177)** *Is Toxoplasmosis Prophylaxis Necessary? A 28 Year Follow-Up at 2 Transplant Centers*; D.A. Baran,<sup>1</sup> M.M. Alwarshetty,<sup>1</sup> S. Alvi,<sup>1</sup> L.H. Arroyo,<sup>1</sup> S.L. Lansman,<sup>2</sup> D. Spielvogel,<sup>2</sup> S. Pinney,<sup>2</sup> A.L.

Gass,<sup>2</sup> M.J. Zucker,<sup>1</sup> <sup>1</sup>Heart Failure and Transplant, Newark Beth Israel Medical Center, Newark, NJ; <sup>2</sup>Cardiovascular Institute, Mt. Sinai Medical Center, New York, NY

**5:15 PM (178)** *Effect of Antimycotic Prophylaxis with Itraconazol and Voriconazol in Patients Following Lung Transplantation*; F. Mattner,<sup>1</sup> S. Fischer,<sup>2</sup> H. Weissbrodt,<sup>1</sup> B. Haubitz,<sup>3</sup> J. Gottlieb,<sup>4</sup> I.F. Chaberny,<sup>1</sup> A. Simon,<sup>2</sup> P. Gastmeier,<sup>1</sup> M. Strueber,<sup>2</sup> <sup>1</sup>Hannover Thoracic Organ Transplant Program, Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany; <sup>2</sup>Division of Cardiothoracic Surgery, Medical School Hannover, Hannover, Germany; <sup>3</sup>Division of Neuroradiology, Medical School Hannover, Hannover, Germany; <sup>4</sup>Division of Pulmonary Medicine, Medical School Hannover, Hannover, Germany

**4:00 PM - 6:00 PM**

**CONCURRENT SESSION 16**

**Pathology: Real Findings in Real Tissue (Germany SDBP)**

**Chairs: Martin J. Goddard, FRCS, FRCPath and Bruce McManus, MD, PhD**

**4:00 PM (179)** *Increased Molecular Testing Scores Associated with Agreement among Cardiac Pathologists for the Diagnosis of ISHLT 3A and Higher Rejection*; C.C. Marboe,<sup>1</sup> M.C. Deng,<sup>1</sup> G. Berry,<sup>2</sup> M. Billingham,<sup>2</sup> H.J. Eisen,<sup>3</sup> D. Pauly,<sup>4</sup> H. Baron,<sup>5</sup> T. Klingler,<sup>5</sup> P. Lal,<sup>5</sup> I. Mahmood,<sup>5</sup> J. Wohlgemuth,<sup>5</sup> R. Starling,<sup>6</sup> <sup>1</sup>Pathology/Cardiology, Columbia University, New York, NY; <sup>2</sup>Pathology, Stanford University, Stanford, CA; <sup>3</sup>Cardiology, Drexel University, Philadelphia, PA; <sup>4</sup>Cardiology, University of Florida, Gainesville, FL; <sup>5</sup>Research and Development, XDx, South San Francisco, CA; <sup>6</sup>Cardiology, Cleveland Clinic Foundation, Cleveland, OH

**4:15 PM (180)** *Evidence of Microvasculopathy on Endomyocardial Biopsy Is Associated with Poor Survival after Heart Transplantation – An Analysis of 15,540 Tissue Sections*; N.E. Hiemann,<sup>1</sup> C. Knosalla,<sup>1</sup> H.B. Lehmkuhl,<sup>1</sup> R. Hetzer,<sup>1</sup> R. Meyer,<sup>1</sup> <sup>1</sup>Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

**4:30 PM (181)** *Myocardial Interleukin-6 Expression Is Associated with Elevated C-Reactive Protein and Cardiac Allograft Vasculopathy*; C.A. Labarrere,<sup>1</sup> M.A. Ortiz,<sup>1</sup> G. Campana,<sup>1</sup> M.J. Sosa,<sup>1</sup> C. Terry,<sup>1</sup> D.E. Pitts,<sup>2</sup> D.A. Hormuth,<sup>2</sup> M.C. Deng,<sup>3</sup> <sup>1</sup>Methodist Research Institute, Clarian Health Partners, Indianapolis, IN; <sup>2</sup>Clarian Health Transplant Center, Clarian Health Partners, Indianapolis, IN; <sup>3</sup>Heart Failure Center, Department of Medicine, Columbia University, New York, NY

**4:45 PM (182)** *Microvascular Prothrombogenicity and Cardiac Allograft Vasculopathy in a Rat Model of Heterotopic Heart Transplantation*; C.A. Labarrere,<sup>1</sup> M.A. Ortiz,<sup>1</sup> N. Ruzmetov,<sup>1</sup> M.J. Sosa,<sup>1</sup> G. Campana,<sup>1</sup> C. Terry,<sup>1</sup> L.A. Baldrige,<sup>2</sup> R. Antonopoulos,<sup>1</sup> H.L. DiCarlo,<sup>1</sup> <sup>1</sup>Methodist Research Institute, Clarian Health Partners, Indianapolis, IN; <sup>2</sup>Department of Pathology, Indiana University School of Medicine, Indianapolis, IN

**5:00 PM (183)** *Everolimus Reduces Intimal Proliferation in an Ex-Vivo Model of Vascular Injury*; J. Cornelissen,<sup>1</sup> A. Gandlau-White,<sup>1</sup> M. Southwood,<sup>1</sup> M. Goddard,<sup>1</sup> A. Vuylsteke,<sup>2</sup> J. Wallwork,<sup>2</sup> <sup>1</sup>Department of Pathology, Papworth Hospital NHS Trust, Cambridge, United Kingdom; <sup>2</sup>Surgical Unit, Papworth Hospital NHS Trust, Cambridge, United Kingdom

**5:15 PM (184)** *Characterization of T-Cells Located in Arterial Walls with Coronary Artery Vasculopathy*; E. de Koning,<sup>1</sup> M.C. Hagemeijer,<sup>1</sup> D.F. van Wichem,<sup>1</sup> J. van Kuik,<sup>1</sup> M.F.M. van Oosterhout,<sup>1</sup> N. de Jonge,<sup>2</sup> J. Lahpor,<sup>2</sup> F.H.J. Gmelig-Meyling,<sup>3</sup> R.A. de Weger,<sup>1</sup> <sup>1</sup>Pathology, University Medical Center, Utrecht, Netherlands; <sup>2</sup>Heart Lung Center, University Medical Center, Utrecht, Netherlands; <sup>3</sup>Immunology, University Medical Center, Utrecht, Netherlands

**6:00 PM - 7:00 PM**

**GENERAL POSTER SESSION 2 (Germany FMDC)**

**Abstracts #331-420**

**6:00 PM - 7:00 PM**

**Tapas Reception in Exhibit Halls** (England and France Rooms)

**7:00 PM - 10:00 PM**

Poster Teardown (Germany FMDC)

**7:00 PM - 10:00 PM**

Exhibitor Move-Out (England and France Rooms)

**Saturday April 8, 2006**

**7:00 AM – NOON**

Exhibit Hall Tear-Down (England and France Rooms)

**7:30 AM – 4:15 PM**

Speaker Ready Room Open (Bonn)

**8:00 AM - 2:00 PM**

Registration Desk Open (Congress Entrance)

**8:30 AM - 10:15 AM**

**PLENARY SESSION (Auditorio)**

*Chairs: Robert Kormos, MD and Alec Patterson, MD*

**8:30 AM Awards Presentations**

**8:45 AM (185) Featured Abstract: Hepatitis C Virus Antibody Positive Donors (DHCV+): Impact on Survival Depends on Recipient Age; L.B. Gasink,<sup>1</sup> E.A. Blumberg,<sup>1</sup> A.K. Israni,<sup>2</sup> S.S. Desai,<sup>1</sup> A.R. Localio,<sup>3</sup> E. Lautenbach,<sup>1,3</sup> <sup>1</sup>Department of Medicine, University of Pennsylvania, Philadelphia, PA; <sup>2</sup>Department of Medicine, University of Minnesota, Rochester, MN; <sup>3</sup>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA**

**9:00 AM (186) Featured Abstract: Mid-Term Results with Non-Heart-Beating Donors Lung Transplantation; D. Gómez de Antonio,<sup>1</sup> R. Laporta,<sup>2</sup> G. Mora,<sup>2</sup> C. López García-Gallo,<sup>2</sup> J. Moradiellos,<sup>1</sup> P. Gamez,<sup>1</sup> M. Córdoba,<sup>1</sup> A. de Pablo,<sup>2</sup> P. Ussetti,<sup>2</sup> M.C. Carreño,<sup>3</sup> A. Varela,<sup>1</sup> <sup>1</sup>Thoracic Surgery, Clínica Puerta de Hierro, Madrid, Spain; <sup>2</sup>Pneumology, Clínica Puerta de Hierro, Madrid, Spain; <sup>3</sup>Internal Medicine, Clínica Puerta de Hierro, Madrid, Spain**

**9:15 AM Invited Lecture: Update on the Eurotransplant High Urgency Allocation System, Axel Rahmel, MD, University of Leipzig, Leipzig, Germany**

**9:35 AM Invited Lecture: Lung Allocation Score Update, Stuart C. Sweet, MD, PhD, Washington University, St. Louis, MO**

**9:55 AM Invited Lecture: Organ Breakthrough Collaborative, Virginia McBride, RN, MPH, U.S. Department of Health and Human Services, Rockville, Maryland**

**10:15 AM - 10:30 AM**

Coffee Break in Auditorio Foyer

**10:30 AM - 12:30 PM**

**CONCURRENT SESSION 17**

**Clinical Heart Transplantation: The Cells Versus the Humors (Auditorio)**

**Chairs: Maryl R. Johnson, MD and Miguel A. Gomez-Sanchez, MD**

**10:30 AM (187) Flow-Cytometry Positive, Cytotoxicity-Negative Donor-Specific Crossmatch: To Transplant or Not To Transplant, That Is the Question; J.K. Patel,<sup>1</sup> E. Reed,<sup>1</sup> D. Gjertson,<sup>1</sup> G.W. Wu,<sup>1</sup> H. Laks,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA**

**10:45 AM (188) The Impact of a Positive Donor-Specific Crossmatch on Survival after Cardiac Transplantation; S. Likki,<sup>1</sup> J. Stehlik,<sup>1</sup> T.C. Fuller,<sup>1</sup> B.G. Kfoury,<sup>1</sup> F. Bader,<sup>1</sup> D. Eckels,<sup>1</sup> E.M. Gilbert,<sup>1</sup> J.C. Stringham,<sup>1</sup> M.E. Hammond,<sup>1</sup> D.G. Renlund,<sup>1</sup> U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT**

**11:00 AM (189)** *The Changing Pattern of Humoral Rejection in Cardiac Transplant Recipients*; J. Haythe, T. Dwyer, E. Burke, P. Green, K. Almuti, S. Itescu, C. Marboe, D. Mancini, Medicine, Columbia University, New York, NY

**11:15 AM (190)** *Asymptomatic Humoral Rejection after Heart Transplantation: Does It Require Therapy?*; J.K. Patel,<sup>1</sup> C. Lai,<sup>1</sup> M.C. Fishbein,<sup>1</sup> S.E. Go,<sup>1</sup> G.W. Wu,<sup>1</sup> H. Laks,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**11:30 AM (191)** *The Clinical Role of Gene Expression Testing in Anticipating the Future Development of Acute Cardiac Allograft Rejection*; M.R. Mehra,<sup>1</sup> J.A. Kobashigawa,<sup>2</sup> M.C. Deng,<sup>3</sup> F.L. Johnson,<sup>1</sup> H.M. Baron,<sup>4</sup> P.A. Uber,<sup>1</sup> P. Lal,<sup>4</sup> T. Klingler,<sup>4</sup> S. Rosenberg,<sup>4</sup> H.J. Eisen,<sup>5</sup> <sup>1</sup>Department of Medicine, University of Maryland, Baltimore, MD; <sup>2</sup>University of California at Los Angeles, Los Angeles, CA; <sup>3</sup>Columbia University College of Physicians and Surgeons, New York, NY; <sup>4</sup>Research and Development, XDx, Inc., South San Francisco, CA; <sup>5</sup>Drexel University College of Medicine, Philadelphia, PA

**11:45 AM (192)** *The Impact of a Repetitive Cellular or Antibody-Mediated Rejection Pattern on Cardiovascular Death in Heart Transplant Recipients*; A.G. Kfoury, M.E. Hammond, J. Stehlik, G.L. Snow, J.T. Seaman, J.W. Long, E.M. Gilbert, J.C. Stringham, D.G. Renlund, U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT

**NOON (193)** *Calcineurin Inhibitor "Holiday" with Anti-CD25 Monoclonal Antibody Coverage Results in an Improvement of Acute Renal Dysfunction in Heart Transplant Patients without Increasing the Risk of Acute Rejection*; M. Cantarovich, N. Giannetti, G. Fontaine, R. Chartier, E. Cyr, R. Cecere, Medicine, Nursing and Cardiovascular and Thoracic Surgery, McGill University Health Center, Montreal, QC, Canada

**12:15 PM (194)** *Adequate Cyclosporine (CsA) Microemulsion (NEORAL®) C2-Level Critical within the First 30 Days To Prevent Rejection after Cardiac Transplant*; J. Kobashigawa,<sup>1</sup> D.G. Renlund,<sup>2</sup> H.B. Lehmkuhl,<sup>2</sup> J. Segovia,<sup>2</sup> <sup>1</sup>UCLA Heart Transplant Program, David Geffen School of Medicine at UCLA, Los Angeles, CA; <sup>2</sup>for the International CERL080A2401 Study Group, Salt Lake City, UT

**10:30 AM - 12:30 PM**

**CONCURRENT SESSION 18**

**Lung/Heart-Lung Transplantation: The Frontier Advances in Lung Transplant (Venezia/Milan)**

**Chairs: Andrew J. Fisher, MRCP, PhD and Cecelia Chaparro, MD**

**10:30 AM (195)** *The Impact of a Natural Disaster on Lung Transplantation: Lessons Learned*; V.G. Valentine, L. Seoane, G.A. Lombard, S.G. LaPlace, P.M. McFadden, C.H. Van Meter, D.E. Taylor, Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA

**10:45 AM (196)** *Pre-Transplant Panel-Reactive Antibody and the Influence on Survival in Lung Transplant Recipients – Analysis of the UNOS Database*; L.U. Nwakanma,<sup>1</sup> C.E. Simpkins,<sup>2</sup> J.A. Williams,<sup>1</sup> D.C. Chang,<sup>2</sup> M.C. Borja,<sup>1</sup> A.S. Shah,<sup>1</sup> J.V. Conte,<sup>1</sup> <sup>1</sup>Division of Cardiac Surgery, Johns Hopkins Medical Institutions, Baltimore, MD; <sup>2</sup>Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD

**11:00 AM (197)** *Impact of HLA Class I and Class II Mismatching on Lung Transplant Recipient Mortality, Rejection and Bronchiolitis Obliterans*; M. Peltz,<sup>1</sup> L. Bennett Edwards,<sup>2</sup> M.E. Jessen,<sup>1</sup> F. Torres,<sup>3</sup> D.M. Meyer,<sup>1</sup> <sup>1</sup>Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, TX; <sup>2</sup>United Network for Organ Sharing, Richmond, VA; <sup>3</sup>Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas - St. Paul University Hospital, Dallas, TX

**11:15 AM (198)** *Improving Outcomes in Lung Transplantation*; R.D. Davis,<sup>1</sup> S.M. Palmer,<sup>1</sup> C.M. Lawrence,<sup>1</sup> <sup>1</sup>D. Duke Lung Transplant Team, <sup>1</sup>Lung Transplant, Duke University Medical Center, Durham, NC



**11:30 AM (199)** *Influenza Vaccination and Rejection in Lung Transplant Patients*; K.L. Radford,<sup>1</sup> M.S. Hayney,<sup>1</sup> A.M. Reynolds,<sup>1</sup> M.L. Francois,<sup>1</sup> R.B. Love,<sup>1</sup> <sup>1</sup>Cardiopulmonary Transplant, University of Wisconsin Hospital and Clinics, Madison, WI

**11:45 AM (200)** *C4d in Bronchoalveolar Lavage Is Associated with Anti-HLA Antibodies in Lung Transplanted Patients*; A.L. Girnita,<sup>1</sup> M.T. Lee,<sup>2</sup> W.M. Baldwin,<sup>2</sup> B. Detrick,<sup>2</sup> J.R. Pilewski,<sup>1</sup> S.A. Yousem,<sup>1</sup> K.J. Spichty,<sup>1</sup> K.R. McCurry,<sup>1</sup> A. Zeevi,<sup>1</sup> <sup>1</sup>University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>2</sup>Johns Hopkins University, SOM, Baltimore, MA

**NOON (201)** *Seven-Year Experience in Living-Donor Lobar Lung Transplantation*; H. Date,<sup>1</sup> M. Aoe,<sup>1</sup> M. Okazaki,<sup>1</sup> R. Sugimoto,<sup>1</sup> S. Sugimoto,<sup>1</sup> K. Goto,<sup>2</sup> Y. Sano,<sup>1</sup> <sup>1</sup>Cancer and Thoracic Surgery, Okayama University, Okayama, Japan; <sup>2</sup>Anesthesiology, Okayama University, Okayama, Japan

**12:15 PM (202)** *A Double-Blind Randomized Trial Comparing Basiliximab to Placebo in Lung Transplantation*; T.K. Waddell,<sup>1</sup> J.M. Borro,<sup>2</sup> A. Roman,<sup>3</sup> M.V. Carreño,<sup>4</sup> F. Zurbano,<sup>5</sup> F. Santos,<sup>6</sup> P. Morales,<sup>7</sup> A. Pacheco,<sup>8</sup> C. Chaparro,<sup>1</sup> C. Gutierrez,<sup>1</sup> S. Keshavjee,<sup>1</sup> <sup>1</sup>Toronto Lung Transplant Program, Toronto, ON, Canada; <sup>2</sup>Hospital Juan Canalejo, La Coruña, Spain; <sup>3</sup>Hospital Vall d'Hebron, Barcelona, Spain; <sup>4</sup>Hospital Puerta de Hierro, Madrid, Spain; <sup>5</sup>Hospital Marques de Valdecilla, Santander, Spain; <sup>6</sup>Hospital Reine Sofia, Cordova, Spain; <sup>7</sup>Hospital La Fe, Valencia, Spain; <sup>8</sup>Hospital Ramon y Cajal, Madrid, Spain

**10:30 AM - 12:30 PM**

**CONCURRENT SESSION 19**

**Donor Management and Organ Distribution/Preservation: How Do You Mend a Broken Heart? (Roma)**

**Chairs: Robert S. Poston, MD and Andreas Zuckermann, MD**

**10:30 AM (203)** *Hepatitis C Donor Hearts in Non-Induction Immunosuppressive Regimens Portend Poor Outcome after Heart Transplantation*; J.K. Patel,<sup>1</sup> A. Parikh,<sup>1</sup> B. Kubak,<sup>1</sup> O.M. Thompson,<sup>1</sup> J.P. Patel,<sup>1</sup> H. Laks,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**10:45 AM (204)** *Impact of Positive Hepatitis B Core Antibody Donors on Thoracic Transplantation*; W.D. Babcock,<sup>1</sup> L.B. Edwards,<sup>2</sup> C.W. Hoopes,<sup>3</sup> <sup>1</sup>Clinical Procurement, California Transplant Donor Network, Modesto, CA; <sup>2</sup>Research Department, United Network of Organ Sharing, Richmond, VA; <sup>3</sup>Department of Surgery; Cardiothoracic Transplantation, University of California, San Francisco, San Francisco, CA

**11:00 AM (205)** *The Risk of Primary Allograft Failure Using Hearts from Older Donors*; K. Lietz,<sup>1</sup> R. John,<sup>2</sup> K. Liao,<sup>2</sup> L. Joyce,<sup>2</sup> L.W. Miller,<sup>1</sup> <sup>1</sup>Cardiovascular Division, University of Minnesota, Minneapolis, MN; <sup>2</sup>Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

**11:15 AM (206)** *Ischaemia Time in Cardiac Transplantation: A UK National Study*; J.C. Hussey,<sup>1</sup> R.S. Bonser,<sup>1</sup> C.J. Rudge,<sup>1</sup> N.R. Banner,<sup>1</sup> <sup>1</sup>On behalf of the UK Transplant Cardiothoracic Advisory Group (CTAG), UK Transplant, Bristol, United Kingdom

**11:30 AM (207)** *Heart Preservation Using Continuous Ex Vivo Perfusion Improves Viability and Functional Recovery in Comparison to Cold Storage*; T. Ozeki,<sup>1</sup> M.H. Kwon,<sup>1</sup> M.J. Collins,<sup>1</sup> J.M. Brassil,<sup>2</sup> R.N. Pierson,<sup>1</sup> B.P. Griffith,<sup>1</sup> R.S. Poston,<sup>1</sup> <sup>1</sup>Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD; <sup>2</sup>Organ Recovery Systems, Inc., Chicago, IL

**11:45 AM (208)** *Effects of High-Potassium Heart Transplant Preservation Solutions on the Development of Cardiac Allograft Vasculopathy: A Multi-Institutional Investigation*; N. Moazami,<sup>1</sup> R.N. Brown,<sup>2</sup> J.K. Kirklin,<sup>2</sup> K. Aaronson,<sup>3</sup> A.B. VanBakel,<sup>4</sup> N. Lewis,<sup>5</sup> D.S. Feldman,<sup>6</sup> R.N. Oren,<sup>7</sup> J. Krull,<sup>1</sup> <sup>1</sup>Washington University in St. Louis, St. Louis, MO; <sup>2</sup>The University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>University of Michigan Medical Center, Ann Arbor, MI; <sup>4</sup>Medical University of South Carolina, Charleston, SC; <sup>5</sup>Veterans Affairs Medical Center, Richmond, VA; <sup>6</sup>Ohio State University, Columbus, OH; <sup>7</sup>University of Iowa Hospitals and Clinics, Iowa City, IA

**NOON (209)** *Donor Heart Selection: The Outcome of “Unacceptable” Donors*; N.H. Khasati,<sup>1</sup> A. Machaal,<sup>1</sup> N. Yonan,<sup>1</sup> <sup>1</sup>Transplant Unit/ Cardiothoracic Surgery, Wythenshawe Hospital, Manchester, United Kingdom

**12:15 PM (210)** *Coronary Atherosclerosis of the Donor Heart*; O. Grauhan,<sup>1</sup> J. Pazurek,<sup>1</sup> H. Siniawski,<sup>1</sup> M. Dandel,<sup>1</sup> H. Lehmkuhl,<sup>1</sup> C. Knosalla,<sup>1</sup> M. Pasic,<sup>1</sup> M. Huebler,<sup>1</sup> Y. Weng,<sup>1</sup> R. Hetzer,<sup>1</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, German Heart Institute, Berlin, Germany

**10:30 AM - 12:30 PM**

**CONCURRENT SESSION 20**

**Nursing and Social Sciences: Thoracic Transplant and Then What? Social, Psychological and Rehabilitative Outcomes (Germany SDBP)**

**Chairs: Jane MacIver, RN and Wayne Paris, LICSW**

**10:30 AM (211)** *Correlates of Fatigue in Advanced Heart Failure Patients*; L.S. Evangelista,<sup>1</sup> N. Pike,<sup>1</sup> A. Ter-Galstanyan,<sup>1</sup> M.A. Hamilton,<sup>2</sup> G.C. Fonarow,<sup>2</sup> <sup>1</sup>School of Nursing, University of California, Los Angeles, Los Angeles, CA; <sup>2</sup>School of Medicine, University of California, Los Angeles, Los Angeles, CA

**10:45 AM (212)** *Anxiety and Quality of Life in CHF Patients and Their Caregivers*; D.M. Weisshaar,<sup>1</sup> E.L. Heiges,<sup>1</sup> <sup>1</sup>CHF/Transplant Service, Kaiser Permanente Santa Teresa, San Jose, CA

**11:00 AM (213)** *Outcomes of Patients Removed from a Heart Transplant Waiting List*; K.J. Hoercher,<sup>1</sup> G. Singh,<sup>1</sup> J.M. Alster,<sup>1</sup> E.H. Blackstone,<sup>1</sup> N.G. Smedira,<sup>1</sup> <sup>1</sup>Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Cleveland, OH

**11:15 AM (214)** *Pretransplant Predictors of Posttransplant Medication Nonadherence in Lung Transplant Patients*; F. Dobbels,<sup>1,2</sup> L. Dupont,<sup>3</sup> G. Verleden,<sup>3</sup> J. Vanhaecke,<sup>2</sup> S. De Geest,<sup>1,4</sup> <sup>1</sup>Center for Health Services and Nursing Research, Katholieke Universiteit Leuven, Leuven, Belgium; <sup>2</sup>Heart Transplantation Program, University Hospitals and Katholieke Universiteit Leuven, Leuven, Belgium; <sup>3</sup>Lung Transplantation Program, University Hospitals and Katholieke Universiteit Leuven, Leuven, Belgium; <sup>4</sup>Institute of Nursing Science, University of Basel, Basel, Switzerland

**11:30 AM (215)** *The Process of Transition from Pediatric to Adult Transplant Care*; C.J. McCurdy, Heart Transplant, Toronto General Hospital, Toronto, ON, Canada

**11:45 AM (216)** *A Prospective Randomised Study on Home Based Exercise Training after Lung Transplantation*; U. Tegtbur,<sup>2</sup> J. Gottlieb,<sup>3</sup> C. Kugler,<sup>1</sup> E. Guetzlaff,<sup>2</sup> L. Stein,<sup>2</sup> A. Simon,<sup>1</sup> T. Welte,<sup>3</sup> A. Haverich,<sup>1</sup> M. Strueber,<sup>1</sup> <sup>1</sup>Hannover Thoracic Transplant Program. Thoracic and Cardiovascular Surgery, Medical School Hannover, Hannover, Germany; <sup>2</sup>Sportsphysiology/-Medicine, Medical School Hannover, Hannover, Germany; <sup>3</sup>Pulmonology, Medical School Hannover, Hannover, Germany

**NOON (217)** *Employment and Activity after Thoracic Organ Transplant*; K.N. White,<sup>1</sup> J.M. Morgan,<sup>1</sup> J.H. Dark,<sup>1</sup> G. Parry,<sup>1</sup> <sup>1</sup>Cardiopulmonary Transplant Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**12:15 PM (218)** *If There Is Smoke Is There Fire? Smoking Recidivism after Lung Transplant*; J.B. Rea,<sup>1</sup> M.F. Reidy,<sup>2</sup> <sup>1</sup>Advanced Practice Nursing, Duke University Hospital, Durham, NC; <sup>2</sup>Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center, Durham, NC

**12:30 PM - 2:00 PM**

**ISHLT Board of Directors Meeting (Alcudia)**

**12:30 PM - 2:00 PM**

**ROCHE LUNCHEON SYMPOSIUM: The Threat of Viral Disease in Heart and Lung Transplantation (Auditorio)**

**Supported by an Educational Grant from Roche**  
**Chairs: Shahid Husain, MD and Antonio B. Roman, PhD**

**12:45 PM** *Long Term Sequelae of Viral Infections in Thoracic Transplantation*, Glen Westall, FRACP, Alfred Hospital, Melbourne, Australia

**1:05 PM** *Prophylactic Strategies for CMV and EBV*, Hannah A. Valantine, MD, Stanford University, Palo Alto, CA

**1:25 PM** *Emerging Viral Threats*, Atul Humar, MD, Toronto General Hospital, Toronto, Ontario, Canada

**1:45 PM** *Discussion*

**12:30 PM - 2:00 PM**

**TRANSMEDICS LUNCHEON SYMPOSIUM: Toward Zero Ischemia in Heart Transplantation (Venezia/Milan)**

**Supported by an Educational Grant from TransMedics**

**Chairs: Bartley P. Griffith, MD and Axel Haverich, MD**

*Panel: Bartley P Griffith, MD; Axel Haverich, MD; Bruce Rosengard, MD; Asghar Khaghani, MD; Gero Tenderich, MD; Roland Hetzer, MD*

**12:45 PM** *Cardiac Preservation: Devices and Solutions*, Bartley P. Griffith, MD, University of Maryland, Baltimore, MD

**1:00 PM** *Potential Contribution of Warm Blood Perfusion Technology – a Multivariate Analysis of the Effects of Reduced Cold Ischemic Time and Prospective HLA Matching*, Ed Zavala, MD, Vanderbilt Transplant Center, Nashville, TN

**1:15 PM** *Put it in Quick and Put it in Warm*, John Wallwork, MBChB, FRCS, Papworth Hospital, Cambridge, United Kingdom

**1:25 PM** *Pre-Clinical Development of a Novel Beating Heart Preservation System: Enabling Isolated Organ Function and Assessment*, Valluvan Jeevanandam, MD, University of Chicago, Chicago, IL

**1:40 PM** *Initial Clinical Experience with Continuous Warm Blood Perfusion*, Bruce Rosengard, MD, Papworth Hospital, Cambridge, United Kingdom

**1:50 PM** *Concluding Panel Discussion*

**12:45 PM - 1:45 PM**

Lunch Buffet (Madrid Café)

**2:00 PM - 4:00 PM**

**CONCURRENT SESSION 21**

**Clinical Heart Transplantation: Complications after Heart Transplantation: Dealing with the Problems We Create (Auditorio)**

**Chairs: Stephan Schueler, MD and Allen S. Anderson, MD**

**2:00 PM (219)** *TGF- $\beta$  1 Polymorphisms, End Stage Renal Failure and Mortality after Heart Transplantation*; C.H.E. Weimar,<sup>1</sup> C.T.J. Holweg,<sup>1</sup> C.C. Baan,<sup>1</sup> A.P.W.M. Maat,<sup>2</sup> A.H.M.M Balk,<sup>3</sup> W. Weimar,<sup>1</sup> <sup>1</sup>Internal Medicine, Erasmus MC, Rotterdam, Netherlands; <sup>2</sup>Thoracic Surgery, Erasmus MC, Rotterdam, Netherlands; <sup>3</sup>Cardiology, Erasmus MC, Rotterdam, Netherlands

**2:15 PM (220)** *Statin Therapy Is Associated with a Reduced Risk of Chronic Renal Failure after Cardiac Transplantation*; S.A. Lubitz,<sup>1</sup> D.A. Baran,<sup>2</sup> M. Chan,<sup>1</sup> M. Courtney,<sup>1</sup> S. Pinney,<sup>1</sup> A. Gass,<sup>1</sup> <sup>1</sup>Mount Sinai Medical Center, New York, NY; <sup>2</sup>Newark Beth Israel Medical Center, Newark, NJ

**2:30 PM (221)** *Conversion from Calcineurin Inhibitors to Sirolimus Improves Renal Function in Heart Transplant Recipients with De Novo Renal Dysfunction*; I. El-Hamamsy,<sup>1</sup> L.M. Stevens,<sup>1</sup> M. White,<sup>2</sup> L.P. Perrault,<sup>1</sup> M. Pellerin,<sup>1</sup> M. Carrier,<sup>1</sup> <sup>1</sup>Cardiac Surgery, Montreal Heart Institute, Montreal, QC, Canada; <sup>2</sup>Cardiology, Montreal Heart Institute, Montreal, QC, Canada

**2:45 PM (222)** *Calcineurin Inhibitor Substitution (“Retirement”) with Anti-CD25 Monoclonal Antibodies: A Novel Strategy in Long-Term Heart Transplant Patients with Progressive Renal Dysfunction*; M.

Cantarovich, N. Giannetti, J.-P. Routy, G. Fontaine, R. Chartier, E. Cyr, R. Cecere, Medicine, Nursing and Cardiovascular and Thoracic Surgery, McGill University Health Center, Montreal, QC, Canada

**3:00 PM (223)** *CNI-Free Immunosuppressive Protocol Improves Renal Function in Heart Transplant Patients Previously on Reduced-Dose Cyclosporine Therapy*; T.J. Dengler,<sup>1</sup> C.G. Gleissner,<sup>1</sup> A. Doesch,<sup>1</sup> P. Ehlermann,<sup>1</sup> A. Koch,<sup>2</sup> P.A. Schnabel,<sup>3</sup> F.U. Sack,<sup>2</sup> <sup>1</sup>Cardiology, University of Heidelberg, Heidelberg, BW, Germany; <sup>2</sup>Cardiac Surgery, University of Heidelberg, Heidelberg, BW, Germany; <sup>3</sup>Pathology, University of Heidelberg, Heidelberg, BW, Germany

**3:15 PM (224)** *Incidence, Type and Prognosis of Malignancy after Heart Transplantation. Data from the Spanish Post-(Heart Transplant) Tumors Registry*; M.G. Crespo-Leiro,<sup>1</sup> L.A. Pulpon,<sup>2</sup> J.M. Arizon,<sup>3</sup> L. Almenar,<sup>4</sup> J. Delgado,<sup>5</sup> J. Palomo,<sup>6</sup> N. Manito,<sup>7</sup> G. Rabago,<sup>8</sup> E. Lage,<sup>9</sup> B. Diaz,<sup>10</sup> E. Roig,<sup>11</sup> D. Pascual,<sup>12</sup> T. Blasco,<sup>13</sup> L. Fuente,<sup>14</sup> M. Vals,<sup>15</sup> M. Camprecios,<sup>16</sup> J. Muniz,<sup>1</sup> <sup>1</sup>CHU Juan Canalejo, La Coruna, Spain; <sup>2</sup>Cardiology, Hospital Puerta de Hierro, Madrid, Spain; <sup>3</sup>Hospital Reina Sofia, Cordoba, Spain; <sup>4</sup>Hospital La Fe, Valencia, Spain; <sup>5</sup>Hospital 12 de Octubre, Madrid, Spain; <sup>6</sup>Hospital G. Maranon, Madrid, Spain; <sup>7</sup>Hospital Bellvitche, Barcelona, Spain; <sup>8</sup>Clinica U. Navarra, Pamplona, Spain; <sup>9</sup>Hospital Virgen Rocio, Sevilla, Sri Lanka; <sup>10</sup>Hospital Central Asturias, Oviedo, Spain; <sup>11</sup>Hospital Clinic, Barcelona, Spain; <sup>12</sup>Hospital V. Arrixaca, Murcia, Spain; <sup>13</sup>Hospital M. Servet, Zaragoza, Spain; <sup>14</sup>Hospital Clinico, Valladolid, Spain; <sup>15</sup>Hospital M. Valdecilla, Santander, Spain; <sup>16</sup>Hospital S. Cruz y S. Pablo, Barcelona, Spain

**3:30 PM (225)** *Sirolimus Associated Interstitial Pneumonitis in Heart Transplant Recipients*; J.F. Delgado,<sup>1</sup> J. Torres,<sup>1</sup> M.J. Ruiz-Cano,<sup>1</sup> V. Sanchez,<sup>1</sup> P. Escribano,<sup>1</sup> R. Matia,<sup>1</sup> J. Cortina,<sup>1</sup> C. Saenz de la Calzada,<sup>1</sup> <sup>1</sup>Cardiology, Doce de Octubre Hospital, Madrid, Spain

**3:45 PM (226)** *Permanent Pacing Requirements in the Bicaval Era of Cardiac Transplant*; S. Zieroth,<sup>1</sup> H. Ross,<sup>1</sup> V. Rao,<sup>1</sup> R. Cusimano,<sup>1</sup> D. Delgado,<sup>1</sup> M. Thevarajah,<sup>1</sup> D. Cameron,<sup>1</sup> K. Nanthakumar,<sup>1</sup> <sup>1</sup>Toronto General Hospital, University Health Network, Toronto, ON, Canada

**2:00 PM - 4:00 PM**

### **CONCURRENT SESSION 22**

#### **Mechanical Circulatory Support: What's New on the Block? (Venezia/Milan)**

**Chairs: Branislav Radovancevic, MD and Stephen R. Large, FRCS**

**2:00 PM (227)** *Dual Continuous Flow Pumps for Total Heart Replacement*; O.H. Frazier,<sup>1</sup> E. Tuzun,<sup>1</sup> C. Gemmato,<sup>1</sup> W.E. Cohn,<sup>1</sup> K. Kadipasaoglu,<sup>1</sup> B. Radovancevic,<sup>1</sup> <sup>1</sup>Center for Cardiac Support, Texas Heart Institute, Houston, TX

**2:15 PM (228)** *Effects of Left Ventricular Assist Devices with Different Flow Characteristics on Vasopressin Levels*; R.M. Delgado,<sup>1</sup> B. Radovancevic,<sup>1</sup> R. Radovancevic,<sup>1</sup> G. Rodriguez,<sup>1</sup> O.H. Frazier,<sup>1</sup> <sup>1</sup>Center for Cardiac Support, Texas Heart Institute, Houston, TX

**2:30 PM (229)** *Bridge to Recovery by Mechanical Ventricular Assist (VAD) – A Successful Therapy for Cardiac Failure Due to Acute Myocarditis (AM)*; F.M. Wagner, V. Hraska, V. Doering, P. Marcsek, C. Haun, M. Kubik, H. Reichensperner, Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

**2:45 PM (230)** *Partial Support for Chronic Heart Failure with a Subcutaneous Pump*; B. Meyns,<sup>1</sup> E. Verbeke,<sup>2</sup> W. Kerkhoffs,<sup>3</sup> N. Bethuyn,<sup>1</sup> I. Bakir,<sup>1</sup> O. Marseille,<sup>3</sup> O. Schumacher,<sup>3</sup> <sup>1</sup>Department of Cardiac Surgery, KU Leuven, Leuven, Belgium; <sup>2</sup>Department of Pathology, KU Leuven, Leuven, Belgium; <sup>3</sup>Circulite Inc, Aachen, Germany

**3:00 PM (231)** *Extracorporeal Membrane Oxygenation (ECMO) for Primary Graft Dysfunction (PGD) after Lung Transplantation: Analysis of the Extracorporeal Life Support Organisation (ELSO) Registry*; S. Fischer,<sup>1</sup> D. Bohn,<sup>2</sup> P. Rycus,<sup>3</sup> A.F. Pierre,<sup>1</sup> M. de Perrot,<sup>1</sup> T.K. Waddell,<sup>1</sup> S. Keshavjee,<sup>1</sup> <sup>1</sup>Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada; <sup>2</sup>Hospital for Sick Children,

University of Toronto, Toronto, ON, Canada; <sup>3</sup>Extracorporeal Life Support Organization (ELSO),  
University of Michigan, Ann Arbor, MI

**3:15 PM (232)** *Right Ventricular Assist Device Is Better Than Extracorporeal Membrane Oxygenation for Isolated Right Ventricular Failure Following Heart Transplantation*; Y. Toyoda,<sup>1</sup> K.R. McCurry,<sup>1</sup> B.G. Hattler,<sup>1</sup> M.A. Zenati,<sup>1</sup> H. Tsukui,<sup>1</sup> A.J. Boujoukos,<sup>2</sup> R.L. Kormos,<sup>1</sup> <sup>1</sup>Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>2</sup>Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

**3:30 PM (233)** *The Effects of Hyperperfusion on Postoperative Neurologic Dysfunction in Recipients of Left-Ventricular Assist Device*; K. Lietz,<sup>1</sup> K. Brown,<sup>2</sup> R. John,<sup>3</sup> D. Anderson,<sup>2</sup> L. Joyce,<sup>3</sup> L.W. Miller,<sup>1</sup> <sup>1</sup>Cardiovascular Division, University of Minnesota, Minneapolis, MN; <sup>2</sup>Division of Neurology, University of Minnesota, Minneapolis, MN; <sup>3</sup>Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

**3:45 PM (234)** *Effect of Clenbuterol on Cardiac and Skeletal Muscle Function during LVAD Support*; I. George,<sup>1</sup> S. Xydas,<sup>1</sup> J. Lamanca,<sup>2</sup> P. Colley,<sup>1</sup> C. Petrilli,<sup>2</sup> D. Mancini,<sup>2</sup> M. DiTullio,<sup>2</sup> C. Marboe,<sup>3</sup> E. Shane,<sup>4</sup> Y. Naka,<sup>1</sup> M.C. Oz,<sup>1</sup> S. Maybaum,<sup>2</sup> <sup>1</sup>Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY; <sup>2</sup>Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY; <sup>3</sup>Department of Pathology, Columbia University College of Physicians and Surgeons, New York, NY; <sup>4</sup>Department of Endocrinology, Columbia University College of Physicians and Surgeons, New York, NY

**200 PM - 4:00 PM**

**CONCURRENT SESSION 23**

**Clinical Immunosuppression: Better Living with Drugs (Roma)**

**Chairs: David O. Taylor, MD and Paul A. Corris, MB, FRCP**

**2:00 PM (235)** *Tacrolimus in Combination, Tacrolimus Alone Compared (TICTAC Trial): A Prospective Randomized Trial of Minimized Immunosuppression in Adult Heart Transplant Recipients*; D.A. Baran,<sup>1</sup> M.J. Zucker,<sup>1</sup> L.H. Arroyo,<sup>1</sup> M.M. Alwarshetty,<sup>1</sup> M.R. Ramirez,<sup>1</sup> S. Pinney,<sup>2</sup> S. Lubitz,<sup>2</sup> A.L. Gass,<sup>2</sup> J. McCahill,<sup>1</sup> S. Pardi,<sup>1</sup> J. Prevost-Fernandez,<sup>1</sup> T.W. Prendergast,<sup>1</sup> D.J. Goldstein,<sup>1</sup> M. Camacho,<sup>1</sup> S. Shah,<sup>1</sup> M. Cohen,<sup>1</sup> <sup>1</sup>Heart Transplant Center, Newark Beth Israel Medical Center, Newark, NJ; <sup>2</sup>Cardiovascular Institute, Mt. Sinai Medical Center, New York, NY

**2:15 PM (236)** *Campath-1H in Clinical Heart Transplantation*; S.M. Pham,<sup>1</sup> J. Jimenez,<sup>2</sup> B.M. Bednar,<sup>1</sup> A. Panos,<sup>1</sup> L. Futterman,<sup>1</sup> E.J. Bauerlein,<sup>2</sup> M. Ricci,<sup>1</sup> S.M. Mallon,<sup>2</sup> E.E. Rosenkranz,<sup>1</sup> P. Rusconi,<sup>3</sup> <sup>1</sup>Surgery, University of Miami, Miami, FL; <sup>2</sup>Medicine, University of Miami, Miami, FL; <sup>3</sup>Pediatric, University of Miami School of Medicine, Miami, FL

**2:30 PM (237)** *The Impact of Induction on Survival after Lung Transplantation: An Analysis of the ISHLT Registry*; R.R. Hachem,<sup>1</sup> L.B. Edwards,<sup>2</sup> R.D. Yusen,<sup>1</sup> M.M. Chakinala,<sup>1</sup> G.A. Patterson,<sup>3</sup> E.P. Trulock,<sup>1</sup> <sup>1</sup>Pulmonary & Critical Care, Washington University School of Medicine, St. Louis, MO; <sup>2</sup>UNOS, Richmond, VA; <sup>3</sup>Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO

**2:45 PM (238)** *Campath-1H Induction and Maintenance Drug Minimization in Lung Transplantation: One-Year Outcomes and Comparison with Triple Drug Immunosuppression with or without Dacluzimab Induction*; K.R. McCurry,<sup>1</sup> D.B. Zaldonis,<sup>1</sup> S. Husain,<sup>1</sup> A. Zeevi,<sup>1</sup> T. Starzl,<sup>1</sup> J. Pilewski,<sup>1</sup> <sup>1</sup>University of Pittsburgh, Pittsburgh, PA

**3:00 PM (239)** *A Prospective Randomized Study of Tacrolimus vs. Cyclosporine after Lung Transplantation*; R.R. Hachem,<sup>1</sup> M.M. Chakinala,<sup>1</sup> R.D. Yusen,<sup>1</sup> A.A. Aloush,<sup>2</sup> G.A. Patterson,<sup>2</sup> E.P. Trulock,<sup>1</sup> <sup>1</sup>Pulmonary & Critical Care, Washington University School of Medicine, St. Louis, MO; <sup>2</sup>Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO

**3:15 PM (240)** *Matrix Metalloprotease (MMP)-1 Serum Levels Correlate with Incidence of Acute Graft Rejection Episodes in Patients Undergoing Cardiac Transplantation*; S. Aharinejad,<sup>1,2</sup> K. Krenn,<sup>2</sup> A. Zuckermann,<sup>1</sup> P. Paulus,<sup>2</sup> D. Abraham,<sup>2</sup> M. Grimm,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Laboratory for Cardiovascular Research, Center for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria

**3:30 PM (241)** *De Novo C2 Monitoring Immediately after Cardiac Transplantation Is Not Associated with Improved Renal Function*; M.M. Kittleson,<sup>1</sup> A. Skye,<sup>2</sup> G.M. Felker,<sup>2</sup> P.B. Rosenberg,<sup>2</sup> J. Warren,<sup>2</sup> C.A. Milano,<sup>3</sup> S.D. Russell,<sup>1</sup> <sup>1</sup>Department of Medicine, Johns Hopkins Hospital, Baltimore, MD; <sup>2</sup>Department of Medicine, Duke University Medical Center, Durham, NC; <sup>3</sup>Department of Surgery, Duke University Medical Center, Durham, NC

**3:45 PM (242)** *Development of Proteinuria after Switch to Sirolimus Based Immunosuppression in Long-Term Cardiac Transplant Patients*; A. Aliabadi,<sup>1</sup> D. Kammerstätter,<sup>1</sup> G. Seebacher,<sup>1</sup> S. Rödler,<sup>1</sup> E. Wolner,<sup>1</sup> M. Grimm,<sup>1</sup> E. Pohanka,<sup>2</sup> A. Zuckermann,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria; <sup>2</sup>Department of Nephrology, Medical University of Vienna, Vienna, Austria

**200 PM - 4:00 PM**

**CONCURRENT SESSION 24**

**Basic Science and Immunobiology: Novel Concepts in Lung Rejection (Germany SDBP)**

**Chairs: Thomas K. Waddell, MD and Annette Boehler, MD**

**2:00 PM (243)** *Antimicrobial Peptides and Airway Innate Immunity in the Pathophysiology of Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation*; R.L. Anderson,<sup>1</sup> P.S. Hiemstra,<sup>1</sup> I.A. Forrest,<sup>2</sup> J. Lordan,<sup>2</sup> P.A. Corris,<sup>2</sup> A.J. Fisher,<sup>2</sup> <sup>1</sup>Pulmonology Department, Leiden University Medical Centre, Leiden, Netherlands; <sup>2</sup>Applied Immunobiology and Transplant Research Group, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom

**2:15 PM (244)** *Identification of a Unique Airway Epithelial Cell Antigen Defined by Post-Transplant Sera from Human Lung Transplant Recipients with Bronchiolitis Obliterans Syndrome Capable of Protein Kinase C Activation and Fibrotic Growth Factor Production*; T.A. Goers,<sup>1</sup> S. Ramachandran,<sup>1</sup> E. Trulock,<sup>2</sup> G.A. Patterson,<sup>1</sup> T. Mohanakumar,<sup>1,3</sup> <sup>1</sup>Surgery, Washington University School of Medicine, Saint Louis, MO; <sup>2</sup>Pulmonary Medicine, Washington University School of Medicine, Saint Louis, MO; <sup>3</sup>Immunology and Pathology, Washington University School of Medicine, Saint Louis, MO

**2:30 PM (245)** *Pro-Inflammatory Th1-Cytokines and HLA Class-II Alloimmunity May Predispose to Chronic Human Lung Allograft Rejection*; A. Bharat,<sup>1</sup> T. Street,<sup>1</sup> K. Narayanan,<sup>1</sup> R.C. Fields,<sup>1</sup> N. Steward,<sup>1</sup> A. Aloush,<sup>2</sup> E.P. Trulock,<sup>2</sup> G.A. Patterson,<sup>3</sup> T. Mohanakumar,<sup>1,4</sup> <sup>1</sup>Surgery/ Transplant, Washington University School of Medicine, St. Louis, MO; <sup>2</sup>Internal Medicine/ Pulmonary, Washington University School of Medicine, St. Louis, MO; <sup>3</sup>Surgery/ Cardiothoracic, Washington University School of Medicine, St. Louis, MO; <sup>4</sup>Pathology and Immunology, Washington University School of Medicine, St. Louis, MO

**2:45 PM (246)** *Dendritic Cell and Regulatory T-Cell Responses in a Murine Model of Obliterative Bronchiolitis*; R.C. Fields,<sup>1</sup> A. Bharat,<sup>1</sup> W. Liu,<sup>1</sup> G.A. Patterson,<sup>1</sup> T. Mohanakumar,<sup>1</sup> <sup>1</sup>Department of Surgery, Washington University School of Medicine, St. Louis, MO

**3:00 PM (247)** *Chronic Gastric Fluid Aspiration Causes Bronchiolitis Obliterans in Rat Pulmonary Allografts*; S.S. Lin,<sup>1,2</sup> B. Li,<sup>1</sup> M.G. Hartwig,<sup>1</sup> J.Z. Appel,<sup>1</sup> E.L. Bush,<sup>1</sup> C.-C. Hsieh,<sup>1,3</sup> W. Parker,<sup>1</sup> R.D. Davis,<sup>1</sup> <sup>1</sup>Department of Surgery, Duke University Medical Center, Durham, NC; <sup>2</sup>Department of Immunology, Duke University Medical Center, Durham, NC; <sup>3</sup>Department of Surgery, Kaohsiung Medical University, Kaohsiung, Taiwan

**3:15 PM (248)** *Pulmonary Allograft Tolerance Can Be Incuced across a Class I MHC Barrier in Swine Sensitized to MHC Class I Allopeptides Prior to Transplantation*; T. Shoji,<sup>1</sup> H. Sahara,<sup>1</sup> A. Muniappan,<sup>1</sup> D.A. Guenther,<sup>1</sup> J.C. Wain,<sup>1,2</sup> S.L. Houser,<sup>1</sup> M.A. Bravard,<sup>1</sup> A.C. Pujara,<sup>1</sup> D.H. Sachs,<sup>1</sup> J.C. Madsen,<sup>1,3</sup>

J.S. Allan,<sup>1,2</sup> <sup>1</sup>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA; <sup>2</sup>Division of Thoracic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA; <sup>3</sup>Division of Cardiac Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA

**3:30 PM (249)** *Prolonged Amelioration of Acute Lung Allograft Rejection by Overexpression of Human Interleukin-10 under Control of a Long Acting Ubiquitin C Promoter in Rats*; U. Stammberger,<sup>1</sup> M. Bilici,<sup>1</sup> A. Gazdhar,<sup>1</sup> R.A. Schmid,<sup>1</sup> <sup>1</sup>Division of General Thoracic Surgery, University Hospital, Bern, Switzerland

**3:45 PM (250)** *C3435T Polymorphism of the MDR1 Gene and Outcome in Lung Transplantation*; J.B. Barnard,<sup>1</sup> J. Fildes,<sup>1</sup> S. Richardson,<sup>1</sup> V. Pravica,<sup>2</sup> I.V. Hutchinson,<sup>2</sup> N. Yonan,<sup>1</sup> C. Leonard,<sup>1</sup> <sup>1</sup>The Transplant Centre, South Manchester Univeristy Hospitals NHS Trust, Manchester, United Kingdom; <sup>2</sup>Department of Immunology, Manchester Univeristy, Manchester, United Kingdom

**4:00 PM - 4:10 PM**

Coffee Break in Auditorio Foyer

**4:10 PM - 5:15 PM**

**CLOSING PLENARY SESSION (Auditorio)**

**Chairs: Robert C. Robbins, MD and R. Duane Davis, MD**

**4:10 PM (252)** *Featured Abstract: Patterns and Predictors of Quality of Life at 5 - 10 Years after Heart Transplantation*; K.L. Grady,<sup>1</sup> D.C. Naftel,<sup>2</sup> J. Kobashigawa,<sup>3</sup> J. Chait,<sup>3</sup> J.B. Young,<sup>4</sup> D. Pelegri,<sup>4</sup> J. Czerr,<sup>4</sup> M. McLeod,<sup>5</sup> A. Heroux,<sup>6</sup> R. Higgins,<sup>7</sup> C. White-Williams,<sup>8</sup> J.K. Kirklin,<sup>2</sup> <sup>1</sup>Cardiothoracic Surgery, Northwestern Memorial Hospital, Chicago, IL; <sup>2</sup>Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>UCLA Heart and Lung Transplantation, UCLA Medical Center, Los Angeles, CA; <sup>4</sup>Kaufman Center for Heart Failure, The Cleveland Clinic Foundation, Cleveland, OH; <sup>5</sup>Utilization Management, Rush University Medical Center, Chicago, IL; <sup>6</sup>Cardiology, Loyola University Medical Center, Maywood, IL; <sup>7</sup>Cardiovascular and Thoracic Surgery, Rush University Medical Center, Chicago, IL; <sup>8</sup>Nursing, University of Alabama at Birmingham, Birmingham, AL

**4:25 PM (251)** *Featured Abstract: The Impact of Patient Selection on Long-Term Outcomes of Left-Ventricular Assist Device Implantation as Destination Therapy for End-Stage Heart Failure*; K. Lietz,<sup>1</sup> J. Long,<sup>2</sup> A.G. Kfoury,<sup>2</sup> M.S. Slaughter,<sup>3</sup> M.A. Silver,<sup>3</sup> C.A. Milano,<sup>4</sup> J. Rogers,<sup>4</sup> L.W. Miller,<sup>1</sup> <sup>1</sup>Cardiovascular Division, University of Minnesota, Minneapolis, MN; <sup>2</sup>Divisions of Cardiology and Cardiothoracic Surgery, LDS Hospital, Salt Lake City, UT; <sup>3</sup>Divisions of Cardiology and Cardiothoracic Surgery, Advocate Christ Medical Center, Oak Lawn, IL; <sup>4</sup>Divisions of Cardiology and Cardiothoracic Surgery, Duke University Medical Center, Durham, NC

**4:40 PM**

**Nursing Excellence Award Presentation**

**4:45 PM** *Invited Lecture: Save A Life or Shave A Second: When Millions (\$) Make a Difference Technological Excellence Versus Economic Reality*, Roger W. Evans, PhD, Consultant in Health Care, Rochester, MN, and Lewis Butler, Senior Structures Analyst, Red Bull Racing, United Kingdom

**5:15 PM ADJOURN**

**5:30 PM - 7:30 PM**

**ISHLT Board of Directors Meeting (Alcudia)**

## **GENERAL POSTERS ON DISPLAY IN GERMANY FMDC**

**Thursday, April 6, 2006**

**(253) Sirolimus in Cardiac Transplantation: Role as a Primary Immunosuppressant in Calcineurin-Inhibitor Induced Nephrotoxicity;** S.S. Kushwaha,<sup>1</sup> Z. Khalpey,<sup>1</sup> R.P. Frantz,<sup>1</sup> R.J. Rodeheffer,<sup>1</sup> A.L. Clavell,<sup>1</sup> B.S. Edwards,<sup>1</sup> <sup>1</sup>Cardiovascular Diseases, Mayo Clinic, Rochester, MN

**(254) Clinical Implementation of Molecular Testing for the Non-Invasive Detection of Cardiac Allograft Rejection;** K. Albright,<sup>1</sup> J. Lee,<sup>2</sup> T. Rowe,<sup>1</sup> B. Garrett,<sup>1</sup> S. Hankins,<sup>2</sup> H. Eisen,<sup>2</sup> <sup>1</sup>Center for Advanced Heart Failure Care, Hahnemann University Hospital, Philadelphia, PA; <sup>2</sup>Division of Cardiology, Drexel University College of Medicine, Philadelphia, PA

**(255) Average First-Year BNP Predicts Poor Outcome after Heart Transplantation;** D. Cruz,<sup>1</sup> G.W. Wu,<sup>1</sup> J.K. Patel,<sup>1</sup> J. Kawano,<sup>1</sup> S. Sarkissian,<sup>1</sup> O.M. Thompson,<sup>1</sup> V. Vaidya,<sup>1</sup> H. Laks,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**(256) Antibody-Mediated Rejection of the Cardiac Allograft – Outcomes in the Post-OKT3 Era;** J. Stehlik,<sup>1</sup> A.G. Kfoury,<sup>1</sup> D.G. Renlund,<sup>1</sup> E.M. Gilbert,<sup>1</sup> J.C. Stringham,<sup>1</sup> J.T. Seaman,<sup>1</sup> G.L. Snow, M.E. Hammond,<sup>1</sup> <sup>1</sup>U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT

**(257) Evaluation of Blood Levels of Macrophage Inflammatory Protein 1 beta (MIP-1 $\beta$ ) in Acute Rejection after Human Heart Transplantation;** A.L.S. Roussoulières,<sup>1,2</sup> Y. Mekki,<sup>3</sup> P. Boissonnat,<sup>1</sup> L. Sebbag,<sup>1,4</sup> C. Cerutti,<sup>2</sup> J.L. McGregor,<sup>2,5,6</sup> O. Bastien,<sup>1</sup> <sup>1</sup>Department of Cardiac Transplantation, Hôpital Cardiologique Louis Pradel, Lyon, France; <sup>2</sup>INSERM U331/EA1582, INSERM, Lyon, France; <sup>3</sup>Department of Virology, Faculté de Médecine Claude Bernard, Lyon, France; <sup>4</sup>EMIU 0226, INSERM, Lyon, France; <sup>5</sup>Cardiovascular Division, King's College, London, United Kingdom; <sup>6</sup>Genomics and Atherothrombosis, Thrombosis Research Institute, London, United Kingdom

**(258) Over the Counter Medications – The New Risk Factor for Cardiac Transplant Cellular Rejection?;** A.S. Boguszewski,<sup>1</sup> M. Abu-mafouz,<sup>1</sup> B. Czerska,<sup>1</sup> C. Grant,<sup>1</sup> D. Lanfear,<sup>1</sup> R. Brewer, C. Somers, G. Franklin, B. Kiesweter, L. Bogdon, <sup>1</sup>Advanced Heart Failure and Transplant, Henry Ford Hospital Heart and Vascular Institute, Detroit, MI

**(259) Twenty-Four Year Experience with Cardiac Retransplantation;** J.G. Copeland, A. Herbst, R. Bose, G. Sethi, F. Arabia, P. Tsau, Surgery, University of Arizona, Tucson, AZ

**(260) What Is the Outcome of ISHLT Grade 1A/1B Rejections under Various Immunosuppressive Regimens?;** T. Ro,<sup>1</sup> J.K. Patel,<sup>1</sup> S. Sarkissian,<sup>1</sup> G.W. Wu,<sup>1</sup> H. Laks,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA

**(261) Percutaneous Transluminal Intervention in Coronary Allograft Vasculopathy;** G. Bruschi,<sup>1</sup> P. Colombo,<sup>1</sup> M. Frigerio,<sup>1</sup> A. Garascia,<sup>1</sup> P. Silva,<sup>1</sup> I. Bossi,<sup>1</sup> S. Klugmann,<sup>1</sup> E. Vitali,<sup>1</sup> <sup>1</sup>Cardiology and Cardiac Surgery “A. De Gasperis”, Niguarda Ca' Granda Hospital, Milan, Italy

**(262) Failure of Short-Term Reversed Remodelling in Patients with Chronic Heart Failure Indicates Benefit from Heart Transplantation on Long-Term;** B. Meyer, D. Moertl, M. Huelsmann, V. Kulemann, A. Zuckermann, M. Grimm, R. Pacher, R. Berger, Cardiology, Medical University of Vienna, Vienna, Austria; Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria

**(263) Sustained Oxidative Stress-Related Tissue Damage and Apoptosis in Human Cardiac Allografts;** U.M. Fischer,<sup>1</sup> A. Antonyan,<sup>2</sup> F. Kuhn-Regnier,<sup>1</sup> H.J. Geissler,<sup>1</sup> J.W.U. Fries,<sup>3</sup> W. Bloch,<sup>4</sup> U. Mehlhorn,<sup>1</sup> <sup>1</sup>Clinic for Cardiothoracic Surgery, University of Cologne, Cologne, Germany; <sup>2</sup>Institute I for Anatomy, University of Cologne, Cologne, Germany; <sup>3</sup>Institute for Pathology, University of Cologne, Cologne, Germany; <sup>4</sup>Molecular and Sports Medicine, German Sports Medicine, Cologne, Germany



**(264)** *The Change in B-Type Natriuretic Peptide Levels over Time Predicts Significant Rejection in Cardiac Transplant Recipients*; M.M. Kittleson,<sup>1</sup> D.V. Skojec,<sup>1</sup> H.C. Champion,<sup>1</sup> I.S. Wittstein,<sup>1</sup> J.M. Hare,<sup>1</sup> E.K. Kasper,<sup>1</sup> S.D. Russell,<sup>1</sup> <sup>1</sup>Medicine, Johns Hopkins Hospital, Baltimore, MD

**(265)** *The Incidence of Obesity after Heart Transplantation and Its Correlation with the Development of New Onset Diabetes in a Cohort of 327 Patients over a Study Period of 10 Years*; I.P. Garrido,<sup>1</sup> M.G. Crespo-Leiro,<sup>1</sup> M.J. Paniagua,<sup>1</sup> J. Garcia-Lara,<sup>1</sup> A. Castro-Beiras,<sup>1</sup> <sup>1</sup>Cardiac Transplantation Unit, Juan Canalejo Hospital, A Coruña, A Coruña, Spain

**(266)** *Incidence and Possible Determinants of Survival beyond Twenty Years after Orthotopic Heart Transplantation*; S.M. Haj-Yahia,<sup>1,2,3</sup> A.G. Mitchell,<sup>1</sup> E.J. Birks,<sup>1,2</sup> J. Mirhossaini,<sup>1</sup> J. Smith,<sup>2</sup> G. Santisi,<sup>1</sup> R. Radley-Smith,<sup>1</sup> M.H. Yacoub,<sup>2,3</sup> N.R. Banner,<sup>1,3</sup> A. Khaghani,<sup>1,2,3</sup> <sup>1</sup>Cardiothoracic Transplantation & Mechanical Circulatory Support, Royal Brompton & Harefield Hospital, London, United Kingdom; <sup>2</sup>The Magdi Yacoub Institute, Harefield Heart Science Centre, London, United Kingdom; <sup>3</sup>National Heart & Lung Institute, Imperial College of Science, Technology and Medicine, London, United Kingdom

**(267)** *Impact of Cyclosporine C2 Monitoring on Renal Function in De Novo Heart Transplant Patients: 10-Year Experience*; M. Cantarovich, N. Giannetti, M. deB. Edwardes, G. Fontaine, R. Chartier, E. Cyr, R. Cecere, Medicine, Cardiovascular and Thoracic Surgery, Epidemiology and Nursing, McGill University Health Center, Montreal, QC, Canada

**(268)** *Cardiotropic Viruses and Microvasculopathy after Heart Transplantation: Preliminary Insights from a Prospective Study*; N.E. Hiemann,<sup>1</sup> K. Klingel,<sup>2</sup> E. Wellnhofer,<sup>3</sup> J. Hug,<sup>3</sup> S. Dreyse,<sup>3</sup> M. Chevallier,<sup>1</sup> H.B. Lehmkuhl,<sup>1</sup> C. Knosalla,<sup>1</sup> R. Hetzer,<sup>1</sup> R. Kandolf,<sup>2</sup> R. Meyer,<sup>1</sup> <sup>1</sup>Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Molecular Pathology, University Hospital of Tuebingen, Tuebingen, Germany; <sup>3</sup>Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

**(269)** *Influence of Pretransplant Amiodarone on Posttransplant Cyclosporine Pharmacokinetics and Heart Rate*; J.A. Crompton,<sup>1</sup> M.B. Hagan,<sup>2</sup> J. Stehlik,<sup>2</sup> F. Bader,<sup>1</sup> E.M. Gilbert,<sup>1</sup> <sup>1</sup>Cardiac Transplant, University of Utah Hospital, Salt Lake City, UT; <sup>2</sup>Veterans Affairs Medical Center, Salt Lake City, UT

**(270)** *Diminished Pre-Operative Creatinine Clearance Is Not a Marker for Post-Operative Renal Failure or Mortality in Heart Transplant Recipients*; V.S. Reddy,<sup>1</sup> J. Mykytenko,<sup>1</sup> A. Smith,<sup>2</sup> B. Hott,<sup>2</sup> W. Book,<sup>2</sup> S.R. Laskar,<sup>2</sup> C. D'Amico,<sup>2</sup> J.D. Vega,<sup>1</sup> <sup>1</sup>Cardiac Surgery, Emory University, Atlanta, GA; <sup>2</sup>Heart Failure Cardiology, Emory University, Atlanta, GA

**(271)** *Pre-Transplant Glucose Intolerance and Not Diabetes Predicts Non-Fatal Major Adverse Cardiac Events after Cardiac Transplantation*; S. Smooke,<sup>1</sup> S. Dev,<sup>2</sup> J.K. Patel,<sup>1</sup> J. Kawano,<sup>1</sup> N.P. Almeda,<sup>1</sup> O.M. Thompson,<sup>1</sup> G.W. Wu,<sup>1</sup> H. Laks,<sup>1</sup> J.A. Kobashigawa,<sup>1</sup> <sup>1</sup>Medicine, University of California at Los Angeles, Los Angeles, CA; <sup>2</sup>Medicine, Northwestern University, Chicago, IL

**(272)** *Modified Inferior Vena Cava Anastomosis To Reduce Tricuspid Valve Regurgitation after Orthotopic Heart Transplantation*; D. Marelli,<sup>1</sup> S. Silvestry,<sup>1</sup> D. Zwas,<sup>1</sup> P. Mather,<sup>1</sup> S. Rubin,<sup>1</sup> R. Choudry,<sup>1</sup> A. Dempsey,<sup>1</sup> L. Stein,<sup>1</sup> J. Diehl,<sup>1</sup> A. Feldman,<sup>1</sup> <sup>1</sup>Heart Transplant Program, Thomas Jefferson University Hospital, Philadelphia, PA

**(273)** *Prevention of Subclinical CMV Infection Reduces Cardiac Allograft Disease Progression by Positively Affecting Coronary Remodeling*; L. Potena,<sup>1,2</sup> W. Fearon,<sup>2</sup> C. Holweg,<sup>2</sup> H. Luikart,<sup>2</sup> C. Chin,<sup>2</sup> J. Cooke,<sup>2</sup> D. Lewis,<sup>2</sup> E. Mocarski,<sup>2</sup> H. Valantine,<sup>2</sup> <sup>1</sup>Cardiovascular Diseases, University of Bologna, Bologna, Italy; <sup>2</sup>Cardiovascular Medicine, Stanford University, Stanford, CA

**(274)** *Thymoglobuline Induction Therapy Creates Excellent Long-Term Outcome of Patients with Positive Lymphocyte Crossmatch after Cardiac Transplantation*; A. Zuckermann,<sup>1</sup> A. Aliabadi,<sup>1</sup> D. Kammerstätter,<sup>1</sup> D. Dunkler,<sup>1</sup> B. Heidbauer,<sup>2</sup> G. Seebacher,<sup>1</sup> S. Aharinejad,<sup>1</sup> E. Wolner,<sup>1</sup> M. Grimm,<sup>1</sup> <sup>1</sup>Department of

Cardiothoracic Surgery, MedicalUniversity.of Vienna, Vienna, Austria; <sup>2</sup>Department of Transfusion Medicine, MedicalUniversity.of Vienna, Vienna, Austria

**(275)** *Does Renal Function Deteriorate More Rapidly in Diabetic Transplant Recipients Than in Normal Recipients?*; K. Almuti,<sup>1</sup> P. Green,<sup>2</sup> J. Haythe,<sup>1</sup> D. Mancini,<sup>1</sup> <sup>1</sup>Medicine, Columbia University, New York, NY; <sup>2</sup>Medicine, Albert Einstein College of Medicine, New York, NY

**(276)** *Effectiveness of Post-Transplant Prophylaxis with Anti-Hepatitis B Virus (HBV) Immunoglobulin in Heart Transplant Patients with Anti-HBV Core Antibodies and in Recipients of Organs from HBV Core Antibody Positive Donors*; M. Cantarovich, N. Giannetti, J. Tchevenkov, E. Cyr, D. Cencic, G. Fontaine, R. Cecere, Medicine, Surgery, Cardiovascular and Thoracic Surgery and Nursing, McGill University Health Center, Montreal, QC, Canada

**(277)** *Image Quality of 64-Slice Multi-Detector Computed Tomography Coronary Angiography in Heart Transplant Recipients*; M. Ferencik,<sup>1</sup> S.A. Gregory,<sup>2</sup> S. Achenbach,<sup>3</sup> R.W. Yeh,<sup>2</sup> U. Hoffmann,<sup>1</sup> I. Inglessis,<sup>2</sup> R.C. Cury,<sup>1</sup> K. Nieman,<sup>1</sup> O.C. Raffel,<sup>2</sup> I.A. McNulty,<sup>2</sup> T.J. Brady,<sup>1</sup> M.J. Semigran,<sup>2</sup> I.K. Jang,<sup>2</sup> <sup>1</sup>Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA; <sup>2</sup>Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA; <sup>3</sup>Department of Medicine II, University of Erlangen, Erlangen, Germany

**(278)** *“Virtual Crossmatching” Allows the Expansion of Effective Donor Pool for HLA-Sensitized Patients*; S. Gupta,<sup>1</sup> D.J. Cook,<sup>1</sup> M. Sharma,<sup>1</sup> G. Stawinski,<sup>1</sup> D. Taylor,<sup>1</sup> M.H. Yamani,<sup>1</sup> J.B. Young,<sup>1</sup> L. Coleman,<sup>1</sup> D. Hartman,<sup>1</sup> J. Campbell,<sup>1</sup> K. Ludrosky,<sup>1</sup> R. Starling,<sup>1</sup> N. Smedira,<sup>1</sup> <sup>1</sup>Transplant Center, Cleveland Clinic Foundation, Cleveland, OH

**(279)** *Gene Expression Profiles of Peripheral Blood Cells in Acute Cellular Cardiac Rejection Reflect Multiple Molecular Pathways*; A. Zeevi,<sup>1</sup> R.L. Dedrick,<sup>3</sup> S. Rosenberg,<sup>3</sup> R.C. Starling,<sup>4</sup> M. Cadeiras,<sup>2</sup> M.C. Deng,<sup>2</sup> <sup>1</sup>Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA; <sup>2</sup>Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY; <sup>3</sup>Research and Development, XDx, South San Francisco, CA; <sup>4</sup>Department of Cardiology, Cleveland Clinic Foundation, Cleveland, OH

**(280)** *From Symptoms of Depression to Diagnosis of Depression: The GAP among African American Females with Heart Failure*; G. Spezziani,<sup>1</sup> C. Arrieta,<sup>1</sup> J. Chirinos,<sup>1</sup> S. Mallon,<sup>1</sup> J. Jimenez,<sup>1</sup> <sup>1</sup>Cardiology, University of Miami, Jackson Memorial Medical Center, Miami, FL

**(281)** *What Is the Fate of Temporary Inactive Patients Listed for Heart Transplantation?*; J. Jimenez,<sup>1</sup> L.B. Edwards,<sup>2</sup> S. Mallon,<sup>1</sup> A. Pannos,<sup>3</sup> S. Pham,<sup>3</sup> <sup>1</sup>Medicine/Cardiology, University of Miami, Jackson Memorial Medical Center, Miami, FL; <sup>2</sup>Research Department, United Network for Organ Sharing, Miami, FL; <sup>3</sup>Surgery/CV Surgery, University of Miami, Jackson Memorial Medical Ctr, Miami, FL

**(282)** *Do Peak VO<sub>2</sub> and the Heart Failure Survival Score Predict Prognosis in Women?*; P. Green,<sup>1</sup> L. Lund,<sup>2</sup> K. Almuti,<sup>3</sup> J. Haythe,<sup>3</sup> D. Mancini,<sup>3</sup> <sup>1</sup>Medicine, Albert Einstein College of Medicine, Bronx, NY; <sup>2</sup>Medicine, Karolinska Institute, Stockholm, Sweden; <sup>3</sup>Medicine, Columbia University, New York, NY

**(283)** *Precent-Predicted Peak Oxygen Consumption Predicts Survival in Ambulatory Heart Failure Patients, but Does Not Negate Gender Effects on Survival*; S. Elmariah,<sup>1</sup> L.R. Goldberg,<sup>2</sup> M.T. Allen,<sup>2</sup> A. Kao,<sup>3</sup> <sup>1</sup>Department of Medicine, Lankenau Hospital, Wynnewood, PA; <sup>2</sup>Department of Medicine, Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA; <sup>3</sup>Department of Medicine, Division of Cardiology, Mid-America Heart Institute, Kansas City, MO

**(284)** *Factors Associated with Non-Completion of Cardiac Rehabilitation in Heart Failure Patients*; S.V. Pamboukian,<sup>1</sup> B. Sanderson,<sup>1</sup> A. Lazaryan,<sup>1</sup> V. Bitnner,<sup>1</sup> <sup>1</sup>Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, AL

**(285)** *Economic Evaluation of Everolimus and Mycophenolate Mofetil (MMF) vs Azathioprine (Aza) in De Novo Heart Transplantation*; J.M. Arizón,<sup>1</sup> D. Aumente,<sup>1</sup> L. Annemans,<sup>2,3</sup> <sup>1</sup>Cardiology, Hospital Reina Sofía, Córdoba, Spain; <sup>2</sup>University of Ghent, Ghent, Belgium; <sup>3</sup>IMS Health, Brussels, Belgium

**(286)** *Are Patients Informed? A Single Center's Solution*; B.A. Pisani,<sup>1</sup> J.C. Mendez,<sup>1</sup> A.J. Tector,<sup>1</sup> <sup>1</sup>Heart Transplant Program, St. Luke's Medical Center, Milwaukee, WI

**(287)** *Pulsatile Versus Non-Pulsatile LVAD Technology – Are We Doing Better Now?*; S. Klotz,<sup>1</sup> C. Schmid,<sup>1</sup> H. Welp,<sup>1</sup> J. Stypmann,<sup>2</sup> T.D.T. Tjan,<sup>1</sup> H.H. Scheld,<sup>1</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, University Hospital Muenster, Muenster, Germany; <sup>2</sup>Cardiology and Angiology, University Hospital Muenster, Muenster, Germany

**(288)** *Chronic Administration of Clenbuterol To Mechanically Unloaded, Failing Hearts Affects Calcium Handling and Myocyte Function – Relevance to LVAD Recovery*; G.K. Soppa,<sup>1</sup> J. Lee,<sup>1</sup> M.A. Stagg,<sup>1</sup> S. Youssef,<sup>1</sup> C.M. Terracciano,<sup>1</sup> M.H. Yacoub,<sup>1</sup> <sup>1</sup>Heart Science Centre, NHLI, Imperial College London, London, Middlesex, United Kingdom

**(289)** *Identification of Device Malfunction in the HeartMate XVE LVAD*; J.W. Haft,<sup>1</sup> K.D. Aaronson,<sup>2</sup> D.B. Dyke,<sup>2</sup> S.M. Wright,<sup>1</sup> Y. Suzuki,<sup>1</sup> F.D. Pagani,<sup>1</sup> <sup>1</sup>Section of Cardiac Surgery, University of Michigan, Ann Arbor, MI; <sup>2</sup>Division of Cardiology, University of Michigan, Ann Arbor, MI

**(290)** *Does Preoperative Mechanical Circulatory Support Identify Patients at Risk for Postoperative RV Failure Following LVAD Implantation?*; Y. Suzuki,<sup>1</sup> J.W. Haft,<sup>1</sup> K.D. Aaronson,<sup>2</sup> D.B. Dyke,<sup>2</sup> S. Wright,<sup>1</sup> M. Moscucci,<sup>2</sup> F.D. Pagani,<sup>1</sup> <sup>1</sup>Section of Cardiac Surgery, University of Michigan, Ann Arbor, MI; <sup>2</sup>Division of Cardiology, University of Michigan, Ann Arbor, MI

**(291)** *Influence of Patients Characteristics during LVAD on Pre- and Post-Transplant Mortality*; S. Klotz,<sup>1</sup> C. Reitz,<sup>2</sup> H. Welp,<sup>1</sup> C. Schmid,<sup>1</sup> T.D.T. Tjan,<sup>1</sup> A. Rukosujew,<sup>1</sup> H.H. Scheld,<sup>1</sup> <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, University Hospital Muenster, Muenster, Germany; <sup>2</sup>Department of Epidemiology and Social Medicine, University Hospital Muenster, Muenster, Germany

**(292)** *Partial Loading of the Left Ventricle during Mechanical Assist Device Support Is Associated with Improved Metabolism of Neuroendocrine Hormones and Increased Exercise Capacity*; H. Welp,<sup>1</sup> C. Etz,<sup>1</sup> S. Klotz,<sup>1</sup> T.T.D. Tjan,<sup>1</sup> M. Rothenburger,<sup>1</sup> A. Hoffmeier,<sup>1</sup> H.H. Scheld,<sup>1</sup> C. Schmid,<sup>1</sup> <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, University Hospital Muenster, Muenster, Germany

**(293)** *Initial Results of a European Multicenter Clinical Trial with the DuraHeart® Mag-Lev Centrifugal Left Ventricular Assist Device*; A. El-Banayosy,<sup>1</sup> R. Koerfer,<sup>1</sup> R. Hetzer,<sup>2</sup> G. Wieselthaler,<sup>3</sup> A. Pavie,<sup>4</sup> <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany; <sup>2</sup>German Heart Center Berlin, Berlin, Germany; <sup>3</sup>University of Vienna, Vienna, Austria; <sup>4</sup>Pitie Salpetriere Hospital, Paris, France

**(294)** *Incidence and Clinical Significance of Driveline Infections in Patients with the Jarvik 2000 Axial Flow Pump*; M. Hipkin,<sup>1</sup> P. Rogers,<sup>1</sup> C.T. Bowles,<sup>1</sup> P. Vuddamalay,<sup>2</sup> A. Hall,<sup>2</sup> A. Khaghani,<sup>1</sup> E.J. Birks,<sup>1</sup> <sup>1</sup>Transplant Unit, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; <sup>2</sup>Microbiology, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

**(295)** *End-Organ Function in Patients on Long-Term Circulatory Support with Continuous or Pulsatile Blood Flow Assist Devices*; B. Radovancevic,<sup>1</sup> E. de Kort,<sup>1</sup> R. Radovancevic,<sup>1</sup> I.D. Gregoric,<sup>1</sup> O.H. Frazier,<sup>1</sup> <sup>1</sup>Center for Cardiac Support, Texas Heart Institute, Houston, TX

**(296)** *Providing Long-Term Care to Destination Therapy LVAD Recipients in Distant Communities: Partnering with Local Teams*; K.D. Rasmusson,<sup>1</sup> J.W. Long,<sup>1</sup> K. Nelson,<sup>1</sup> A. Healy,<sup>1</sup> D.U. Blank,<sup>2</sup> D.G. Renlund, B.Y. Rasmusson, H. Smith,<sup>1</sup> S. Clayson,<sup>1</sup> A.G. Kfoury,<sup>1</sup> <sup>1</sup>Utah Artificial Heart Program, Salt Lake City, UT; <sup>2</sup>Idaho Heart Institute, Idaho Falls, ID

**(297)** *Sensitization in Axial Flow Devices Versus Pulsatile Left Ventricular Assist Devices*; I. George,<sup>1</sup> P. Colley,<sup>1</sup> E. Burke,<sup>1</sup> T. Martens,<sup>1</sup> B. Morrow,<sup>1</sup> M. Russo,<sup>1</sup> C. Soneru,<sup>1</sup> M. Tabaksblat,<sup>1</sup> C. Spadaccio,<sup>1</sup> Z. Lill,<sup>1</sup> F. Cheema,<sup>1</sup> S. Itescu,<sup>1</sup> M. Deng,<sup>2</sup> D. Mancini,<sup>2</sup> M.C. Oz,<sup>1</sup> Y. Naka,<sup>1</sup> <sup>1</sup>Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY; <sup>2</sup>Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY

**(298)** *Late Drive-Line Infections: The Achilles' Heel of Prolonged LVAD Support*; A. Zierer,<sup>1</sup> E. Milner,<sup>1</sup> M.K. Pasque,<sup>1</sup> G.A. Ewald,<sup>2</sup> A.S. Al-Dadah,<sup>1</sup> S.J. Melby,<sup>1</sup> K. Skelton,<sup>1</sup> N. Moazami,<sup>1</sup> <sup>1</sup>Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO; <sup>2</sup>Division of Cardiology, Washington University School of Medicine, St. Louis, MO

**(299)** *Outcomes of Non-Cardiac Surgery in Patients with Mechanical Circulatory Support*; D.M. Nelson,<sup>1</sup> J. Stehlik,<sup>2</sup> B.J. Christensen,<sup>3</sup> A.G. Kfoury,<sup>1</sup> M.A. Movsesian,<sup>2</sup> D.G. Renlund,<sup>1</sup> C.G. Cowley,<sup>1</sup> H.K. Smith,<sup>1</sup> B.Y. Rasumusson,<sup>1</sup> J.W. Long,<sup>1</sup> K. Nelson,<sup>1</sup> <sup>1</sup>Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT; <sup>2</sup>Cardiology, Salt Lake City VAMC, University of Utah, Salt Lake City, UT; <sup>3</sup>Surgery, LDS Hospital, Salt Lake City, UT

**(300)** *Thrombin-Mediated Rebound Hypercoagulability after Heparin Withdrawal in VAD Patients: A Possible Target for Serine Protease Inhibition*; M.H. Kwon,<sup>1</sup> S. Kallam,<sup>1</sup> R.S. Poston,<sup>1</sup> R.C. Carroll,<sup>2</sup> <sup>1</sup>Division of Cardiac Surgery, University of Maryland, Baltimore, MD; <sup>2</sup>Department of Anesthesiology, University of Tennessee Medical Center, Graduate School of Medicine, Knoxville, TN

**(301)** *Performance of the CorAide™, a Novel Magnetically Levitated Centrifugal Pump in Potential Destination Therapy Patients a Multi-Center European Clinical Trial*; A. El-Banayosy,<sup>1</sup> L. Arusoglu,<sup>1</sup> M. Morshuis,<sup>1</sup> L. Kizner,<sup>1</sup> P. Sarnowski,<sup>1</sup> D. Cobaugh,<sup>1</sup> R. Koerfer,<sup>1</sup> M. Vigano,<sup>2</sup> F. Gazzoli,<sup>2</sup> M. Rinaldi,<sup>2</sup> <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany; <sup>2</sup>Policlinico S. Matteo di Pavia, Pavia, Italy

**(302)** *Time to Allosensitization Following HeartMate Left Ventricular Assist Device Implantation*; R. Krishnamani,<sup>1</sup> D.A. Baran,<sup>1</sup> M.M. Alwarshetty,<sup>1</sup> M.J. Zucker,<sup>1</sup> L.H. Arroyo,<sup>1</sup> A. Martin,<sup>1</sup> T.W. Prendergast,<sup>1</sup> M. Camacho,<sup>1</sup> S. Shah,<sup>1</sup> N. McAllister,<sup>1</sup> D.J. Goldstein,<sup>1</sup> <sup>1</sup>Heart Failure and Transplant, Newark Beth Israel Medical Center, Newark, NJ

**(303)** *Initial Clinical Experience with the HeartMate II Left Ventricular Assist System*; O.H. Frazier,<sup>1</sup> T.J. Myers,<sup>1</sup> N. Palanichamy,<sup>1</sup> C. Gemmato,<sup>1</sup> I.D. Gregoric,<sup>1</sup> R.M. Delgado,<sup>1</sup> B. Radovancevic,<sup>1</sup> <sup>1</sup>Center for Cardiac Support, Texas Heart Institute, Houston, TX

**(304)** *Use of the Levitronix CentriMag Ventricular Assist Device (VAD) for the Treatment of Refractory Cardiogenic Shock in Patients with End-Stage Heart Failure*; R. John,<sup>1</sup> K. Liao,<sup>1</sup> K. Lietz,<sup>1</sup> M.M. Colvin-Adams,<sup>1</sup> A.J. Boyle,<sup>1</sup> L.W. Miller,<sup>1</sup> L.D. Joyce,<sup>1</sup> <sup>1</sup>Cardiothoracic and Cardiovascular Division, University of Minnesota, Minneapolis, MN

**(305)** *Improvement of Renal and Hepatic Function in Advanced Heart Failure Patients Implanted with the HeartMate II Continuous Flow LVAD*; S.D. Russell,<sup>1</sup> L. Chen,<sup>2</sup> J.G. Rogers,<sup>3</sup> C.A. Milano,<sup>3</sup> H.T. Massey,<sup>2</sup> D.J. Farrar,<sup>4</sup> J. Conte,<sup>1</sup> <sup>1</sup>Medicine and Surgery, Johns Hopkins Hospital, Baltimore, MD; <sup>2</sup>Medicine and Surgery, University of Rochester, Rochester, NY; <sup>3</sup>Medicine and Surgery, Duke University Medical Center, Durham, NC; <sup>4</sup>Thoratec Corporation, Burlington, MA

**(306)** *Effect of LVAD on Renal Function and Other Outcomes in Patients with Impaired Renal Function*; R. Howser,<sup>1</sup> J. Butler,<sup>2</sup> J.K. Freehling,<sup>1</sup> R.N. Pierson III,<sup>3</sup> <sup>1</sup>WorldHeart Inc, Oakland, CA; <sup>2</sup>Medicine/Cardiology, Vanderbilt University Medical Center, Nashville, TN; <sup>3</sup>Cardiac Surgery, University of Maryland Medical Center, Baltimore, MD

**(307)** *Peritransplant Anticoagulation Management in Patients with Left Ventricular Assist Devices*; H. Welp,<sup>1</sup> C. Etz,<sup>1</sup> S. Klotz,<sup>1</sup> A. Rukosujew,<sup>1</sup> M. Rothenburger,<sup>1</sup> T.T.D. Tjan,<sup>1</sup> H.H. Scheld,<sup>1</sup> C. Schmid,<sup>1</sup> <sup>1</sup>Department of Cardiovascular and Thoracic Surgery, University Hospital Muenster, Muenster, Germany

**(308)** *Treatment of Hypertension in Destination LVAD Recipients: A Single Center Analysis*; K.D. Rasmussen, J.W. Long, J.R. Child, B.Y. Rasmussen, D.G. Renlund, A. Healy, S.J. Brush, B. Kerwin, A.G. Kfoury, Utah Artificial Heart Program, Salt Lake City, UT

**(309)** *Structural, Hemodynamic and Clinical Improvements among Patients with Advanced Heart Failure Treated with Alagebrium (A Novel Oral Advanced Glycation End-Product Crosslink Breaker)*; V. Thohan,<sup>1</sup> M.M. Koerner,<sup>2</sup> C.M. Pratt,<sup>1</sup> G. Torre,<sup>1</sup> <sup>1</sup>Cardiology, Methodist DeBakey Heart Center, Houston, TX; <sup>2</sup>Cardiology, Baylor College of Medicine, Houston, TX

**(310)** *Production Needs for Clinical Xenotransplantation*; C.G.A. McGregor,<sup>1</sup> J.M. Risdahl,<sup>1</sup> S.L. Edgerton,<sup>1</sup> G.W. Byrne,<sup>1</sup> M.J. Timmons,<sup>1</sup> R.C. Walker,<sup>1</sup> J.S. Logan,<sup>1</sup> <sup>1</sup>William J von Liebig Transplant Center; Department of Surgery, Mayo Clinic, Rochester, MN

**(311)** WITHDRAWN

**(312)** *Paracrine Effects of Transplanted Bone Marrow Cells and Skeletal Myoblasts on Recipient Cardiomyocyte Function in a Rat Model of Heart Failure*; J. Lee,<sup>1</sup> S. Fukushima,<sup>1</sup> M.A. Stagg,<sup>1</sup> G.K. Soppa,<sup>1</sup> S.J. Youssef,<sup>1</sup> M.H. Yacoub,<sup>1</sup> K. Suzuki,<sup>1</sup> C.M. Terracciano,<sup>1</sup> <sup>1</sup>National Heart & Lung Institute, Imperial College London, Harefield, Middlesex, United Kingdom

**(313)** *Quantification of Left Ventricular Mechanical Dyssynchrony by Conductance Catheter in the Failing Heart: Effect of Biventricular Pacing*; G. Szabó,<sup>1</sup> P. Soós,<sup>2</sup> B. Merkely,<sup>2</sup> S. Hagl,<sup>1</sup> <sup>1</sup>Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; <sup>2</sup>Cardiovascular Surgery, Semmelweis University, Budapest, Hungary

**(314)** *Post-Transplant Employment and Its Relationship to Physical Status*; W. Paris,<sup>1</sup> I. Nizami,<sup>2</sup> C. Hille,<sup>2</sup> R. Cross,<sup>2</sup> D. Nelson,<sup>2</sup> C. Elkins,<sup>2</sup> P. Kanaly,<sup>2</sup> J. Chaffin,<sup>2</sup> <sup>1</sup>School of Social Work, Southern Illinois University, Carbondale, IL; <sup>2</sup>Nazih Zuhdi Transplantation Institute, Integris Baptist Medical Center, Oklahoma City, OK

**(315)** *Pretransplant Psychological Risk Evaluation Strongly Predicts Mortality after Cardiac Transplantation*; S.E. Moscoloni,<sup>1</sup> M.F. Marquez,<sup>1</sup> M. Diez,<sup>1</sup> A.M. Bertolotti,<sup>1</sup> R.R. Favaloro,<sup>1</sup> <sup>1</sup>Intrathoracic Transplant, Favaloro Foundation, Buenos Aires, Argentina

**(316)** *Anxiety, Depression and Social Competence in Children and Adolescents Undergoing Transplantation*; J. Wray,<sup>1</sup> R. Radley-Smith,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Transplantation, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

**(317)** *Neurocognitive Dysfunction and End Stage Heart Disease: Differences among Etiologies*; A. Madan,<sup>1,2</sup> C. White-Williams,<sup>3</sup> A.H. Thurstin,<sup>4</sup> B.A. Bush,<sup>4</sup> B.K. Rayburn,<sup>3</sup> <sup>1</sup>Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC; <sup>2</sup>Department of Psychology, University of Alabama at Birmingham, Birmingham, AL; <sup>3</sup>Department of Cardiovascular Services, University of Alabama at Birmingham, Birmingham, AL; <sup>4</sup>Department of Psychiatry and Neurobiology, University of Alabama at Birmingham, Birmingham, AL

**(318)** *Anti-HLA Antibodies in Heart Transplantation*; N. Suci-Foca,<sup>1</sup> E.R. Vasilescu,<sup>1</sup> A.I. Colovai,<sup>1</sup> E. Ho,<sup>1</sup> L. Medinger,<sup>1</sup> M. Deng,<sup>2</sup> M. Cadeiras,<sup>2</sup> R. Cortesini,<sup>1</sup> C. Marboe,<sup>1</sup> S. Itescu,<sup>2</sup> D. Mancini,<sup>2</sup> <sup>1</sup>Pathology, Columbia University, New York, NY; <sup>2</sup>Medicine, Columbia University, New York, NY

**(319)** *Identification of Non-HLA Target Antigens Recognized after Lung Transplantation*; H.G. Otten,<sup>1</sup> J.M.M. van den Bosch,<sup>2</sup> W.G.J. van Ginkel,<sup>1</sup> M. van Loon,<sup>1</sup> E.A. van de Graaf,<sup>2</sup> <sup>1</sup>Department of Immunology, University Medical Center, Utrecht, Netherlands; <sup>2</sup>Heart-Lung Center, University Medical Center, Utrecht, Netherlands

**(320)** *The Phosphodiesterase Type IV (PDE IV) Inhibitor Cilomilast Decreases Pro-Inflammatory Cytokine Production from Primary Bronchial Epithelial Cells Derived from Lung Transplant Recipients*; C. Ward,<sup>1</sup> D. Murphy,<sup>1</sup> I. Forrest,<sup>1</sup> D. Jones,<sup>2</sup> G. Pritchard,<sup>1</sup> R. Stovold,<sup>1</sup> A. Fisher,<sup>1</sup> T. Cawston,<sup>2</sup> J. Lordan,<sup>1</sup> P. Corris,<sup>1</sup> <sup>1</sup>The Applied Immunobiology and Transplantation Group, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; <sup>2</sup>Musculoskeletal Research Group, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom

**(321)** *Discordant Function of CD8<sup>+</sup>CD28<sup>-</sup> T Cells in the Blood and BAL of Lung Transplant Recipients: The Impact of CMV and Acute Rejection*; G.P. Westall,<sup>1</sup> A.G. Brooks,<sup>2</sup> T.C. Kotsimbos,<sup>1</sup> <sup>1</sup>Heart and Lung Transplant Unit, Department of Allergy Immunology and Respiratory Medicine, Alfred Hospital, and Monash University Medical School, Melbourne, Victoria, Australia; <sup>2</sup>Department of Microbiology and Immunology, Melbourne University, Melbourne, Victoria, Australia

**(322)** *P- Glycoprotein Expression on Peripheral Blood Mononuclear Cells and Biopsy Proven Acute Rejection in Heart Transplantation*; J.B. Barnard,<sup>1</sup> J. Fildes,<sup>1</sup> S. Richardson,<sup>1</sup> N. Khasati,<sup>1</sup> V. Pravica,<sup>2</sup> I.V. Hutchinson,<sup>2</sup> C.T. Leonard,<sup>1</sup> N. Yonan,<sup>1</sup> <sup>1</sup>The Transplant Centre, South Manchester University Hospitals NHS Trust, Manchester, United Kingdom; <sup>2</sup>Department of Immunology, Manchester University, Manchester, United Kingdom

**(323)** *The Antimicrobial Peptide, Human Beta Defensin-2, in Acute Rejection after Human Lung Transplantation*; R.L. Anderson,<sup>1</sup> P.S. Hiemstra,<sup>1</sup> I.A. Forrest,<sup>3</sup> D. Proud,<sup>2</sup> C. Ward,<sup>3</sup> J. Lordan,<sup>3</sup> P.A. Corris,<sup>3</sup> A.J. Fisher,<sup>3</sup> <sup>1</sup>Pulmonology Department, Leiden University Medical Centre, Leiden, Netherlands; <sup>2</sup>University of Calgary, Calgary, Canada; <sup>3</sup>Applied Immunobiology and Transplantation Research Group, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom

**(324)** *Resistance to Depletion and Enhanced Homeostatic Proliferation by Memory Cells in the Setting of Induced Lymphopenia*; D.C. Neujahr,<sup>1</sup> C. Chen,<sup>1</sup> L. Turka,<sup>1</sup> <sup>1</sup>Medicine, University of Pennsylvania, Philadelphia, PA

**(325)** *Impact of Campath-1H Conditioning on DC Subsets in Peripheral Blood of Lung Transplant Recipients*; D. Metes,<sup>1</sup> N. Murase,<sup>1</sup> P. McGregor,<sup>1</sup> A. Farran,<sup>1</sup> C. Macedo,<sup>1</sup> S. Yousem,<sup>1</sup> J. Pilewski,<sup>1</sup> D. Zaldonis,<sup>1</sup> K. McCurry,<sup>1</sup> A. Zeevi,<sup>1</sup> <sup>1</sup>Surgery, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA

**(326)** *Donor Bone Marrow Modulates the Host Immune Responses to Lung Allografts*; M. Pang,<sup>1</sup> S. Li,<sup>2</sup> S. Salgar,<sup>2</sup> C. Liotta,<sup>2</sup> R. Vazquez-Padron,<sup>2</sup> J. Matthew,<sup>2</sup> S.M. Pham,<sup>2</sup> <sup>1</sup>Medicine, University of Miami School of Medicine, Miami, FL; <sup>2</sup>Surgery, University of Miami School of Medicine, Miami, FL

**(327)** *Effect of MHC Class II Expression on Chimerism in Allogeneic Fetal Liver Treated Mice*; K. Tao,<sup>1</sup> L. Mai\*,<sup>1</sup> L.J. West,<sup>2</sup> <sup>1</sup>Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada; <sup>2</sup>Department of Pediatrics, Stollery Children's Hospital, Edmonton, AB, Canada

**(328)** *Macrophage Depletion Suppresses Cardiac Allograft Vasculopathy in Mice*; W.H. Kitchens,<sup>1</sup> C.M. Chase,<sup>1</sup> S. Uehara,<sup>1</sup> R.B. Colvin,<sup>2</sup> P.S. Russell,<sup>1</sup> J.C. Madsen,<sup>3</sup> <sup>1</sup>Department of Transplant Surgery, Massachusetts General Hospital, Boston, MA; <sup>2</sup>Department of Pathology, Massachusetts General Hospital, Boston, MA; <sup>3</sup>Department of Cardiac Surgery, Massachusetts General Hospital, Boston, MA

**(329)** *TLR2 Signaling Blocks Regulatory T Cell Suppression Leading to Immune Activation Following Cardiac Allograft Transplantation*; S. Ramachandran,<sup>1</sup> T.A. Goers,<sup>1</sup> W. Liu,<sup>1</sup> G.A. Patterson,<sup>1</sup> T. Mohanakumar,<sup>1,2</sup> <sup>1</sup>Surgery, Washington University School of Medicine, St. Louis, MO; <sup>2</sup>Pathology & Immunology, Washington University School of Medicine, St. Louis, MO

**(330)** *siRNA-Mediated Silencing of the IL-1 and Its Impact on the Pathogenesis of Obliterative Airway Disease Following Tracheal Transplantation*; T.A. Goers,<sup>1</sup> S. Ramachandran,<sup>1</sup> N. Benshoff,<sup>1</sup> T. Mohanakumar,<sup>1,2</sup> <sup>1</sup>Surgery, Washington University School of Medicine, Saint Louis, MO; <sup>2</sup>Immunology and Pathology, Washington University School of Medicine, Saint Louis, MO



## **GENERAL POSTERS ON DISPLAY IN GERMANY FMDC**

**Friday, April 7, 2006**

**(331)** *Anti-TNF- (Infliximab®) Significantly Reduced the Development of Transplant Arteriosclerosis in Murine Aortic Allografts*; M. Wollin,<sup>1</sup> S. Abele,<sup>2</sup> M. Ramsperger-Gleixner,<sup>2</sup> B. Spriewald,<sup>1</sup> T. Fischlein,<sup>2</sup> M. Weyand,<sup>2</sup> S.M. Ensminger,<sup>2</sup> <sup>1</sup>Department of Medicine III, University of Erlangen Nuernberg, Erlangen, Bavaria, Germany; <sup>2</sup>Department of Cardiac Surgery, University of Erlangen Nuernberg, Erlangen, Bavaria, Germany

**(332)** *Increases in Activated Platelet Microparticles Expressing Surface PAI-1 Vitronectin- and Vimentin-Ternary Complexes in Mice Allograft Recipients*; H.S. Leong,<sup>1</sup> N. Rezai,<sup>1</sup> B. McManus,<sup>1</sup> T.J. Podor,<sup>1</sup> <sup>1</sup>Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

**(333)** *Clopidogrel (Plavix®) Significantly Reduced the Development of Transplant Arteriosclerosis in Murine Aortic Allografts*; S. Abele,<sup>1</sup> M. Wollin,<sup>2</sup> N.E. Hiemann,<sup>3</sup> F. Harig,<sup>1</sup> T. Fischlein,<sup>1</sup> M. Weyand,<sup>1</sup> S.M. Ensminger,<sup>1</sup> <sup>1</sup>Department of Cardiac Surgery, University of Erlangen Nuernberg, Erlangen, Bavaria, Germany; <sup>2</sup>Department of Medicine III, University of Erlangen Nuernberg, Erlangen, Bavaria, Germany; <sup>3</sup>Department of Cardiothoracic Surgery, German Heart Center Berlin, Berlin, Germany

**(334)** *VEGFR-3 Signalling Mediates Lymphangiogenesis and Alloimmune Reactions in Cardiac Allografts*; A.I. Nykanen, H. Sandelin, M.A.I. Keranen, R. Tuuminen, P.K. Koskinen, K. Alitalo, K.B. Lemstrom, Transplantation Laboratory, University of Helsinki, Helsinki, Finland

**(335)** *Vascular Endothelial Growth Factor (VEGF) Has a Dual Role in Experimental Obliterative Bronchiolitis (OB)*; R. Krebs,<sup>1</sup> M.E. Hollmén,<sup>1</sup> J.M. Tikkanen,<sup>1</sup> Y. Wu,<sup>2</sup> D.J. Hicklin,<sup>2</sup> P.K. Koskinen,<sup>1</sup> K.B. Lemström,<sup>1</sup> <sup>1</sup>Transplantation Laboratory, University of Helsinki, Helsinki, Finland; <sup>2</sup>ImClone Systems Incorporated, New York, NY

**(336)** *Ischemic Time, Minor and Major Antigen Mismatches All Contribute Independently to Endothelial Cell Repopulation after Aorta Transplantation in Mice*; G. Warnecke,<sup>1</sup> K.J. Wood,<sup>1</sup> <sup>1</sup>Nuffield Department. of Surgery, University of Oxford, Oxford, United Kingdom

**(337)** *Rag2(-/-)/gc(-/-) Mice as Hosts for Human Vessel Transplantation and Allogeneic Human Leukocyte Reconstitution: A Marked Improvement over the SCIDhu Model*; G. Warnecke,<sup>1</sup> D.P. Taggart,<sup>1</sup> K.J. Wood,<sup>1</sup> <sup>1</sup>Nuffield Department. of Surgery, University of Oxford, Oxford, United Kingdom

**(338)** *Acetylation of Sp3 Converts It from a Repressor to an Activator during Pathologic Cardiac Hypertrophy: A Potential Mechanism of Action for Prevention of Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors*; A. Azakie, J.R. Fineman, Y. He, Surgery, UCSF, San Francisco, CA; Pediatrics, UCSF, San Francisco, CA

**(339)** *Optimising Long-Term Preservation of the Transplanted Heart Using Glyceryl Trinitrate and Cariporide*; A. Hing,<sup>1</sup> M. Hicks,<sup>1,2</sup> L. Gao,<sup>1</sup> S.C. Faddy,<sup>3</sup> A.C. McMahon,<sup>4</sup> S.H. Kesteven,<sup>4</sup> M.P. Feneley,<sup>3,4</sup> M.K. Wilson,<sup>5</sup> P.S. Macdonald,<sup>1,3</sup> <sup>1</sup>Transplant Program, The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; <sup>2</sup>Department of Clinical Pharmacology, St. Vincent's Hospital, Sydney, NSW, Australia; <sup>3</sup>Department of Cardiology, St. Vincent's Hospital, Sydney, NSW, Australia; <sup>4</sup>Cardiovascular Mechanics Program, The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; <sup>5</sup>Department of Cardiothoracic Surgery, St. Vincent's Hospital, Sydney, NSW, Australia

**(340)** *A Neutrophil Elastase Inhibitor ONO-5046 Reduced Reperfusion Injury of the Lung Harvested from Endotoxin-Primed Rat*; S. Suzuki,<sup>1</sup> T. Sugawara,<sup>1</sup> T. Tabata,<sup>1</sup> Y. Hoshikawa,<sup>1</sup> H. Oishi,<sup>1</sup> Y. Okada,<sup>1</sup> Y. Matsumura,<sup>1</sup> T. Kondo,<sup>1</sup> <sup>1</sup>Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan



**(341)** *Effect of Lung Allocation Score on Lung Transplant Waiting List*; R.M. Lingaraju,<sup>1</sup> N.P. Blumenthal,<sup>1</sup> J. Wei,<sup>1</sup> V.N. Ahya,<sup>1</sup> J.S. Sager,<sup>1</sup> J.D. Christie,<sup>1</sup> R.M. Kotloff,<sup>1</sup> A. Pocchettino,<sup>1</sup> D. Hadjiiladis,<sup>1</sup> <sup>1</sup>Lung Transplant Program, University of Pennsylvania, Philadelphia, PA

**(342)** *Evaluation of Combined Lung and Multi-Organ Non Heart Beating Donor(NHBD) Retrieval Techniques*; B. Levvey,<sup>1</sup> T. Oto,<sup>1</sup> R. McEgan,<sup>1</sup> M. Mennen,<sup>1</sup> T. Higuchi,<sup>1</sup> T. Williams,<sup>1</sup> L. Eriksson,<sup>1</sup> F. Rosenfeldt,<sup>1</sup> G. Snell,<sup>1</sup> <sup>1</sup>Lung Transplant Service, The Alfred Hospital, Melbourne, Victoria, Australia

**(343)** *Allocation to Zone A Status 1A/1B Heart Candidates before Local Status 2 Is Associated with Reduced Deaths in All Geographic Regions in the U.S.*; R.T. Bustami,<sup>1</sup> T.E. Hulbert-Shearon,<sup>2</sup> A.M. Rodgers,<sup>1</sup> S. Murray,<sup>2</sup> K.P. McCullough,<sup>1</sup> E.R. Garrity,<sup>3</sup> R.M. Merion,<sup>2</sup> <sup>1</sup>SRTR, URREA, Ann Arbor, MI; <sup>2</sup>SRTR, University of Michigan, Ann Arbor, MI; <sup>3</sup>Loyola Cardiovascular Institute, Loyola University Medical Center, Maywood, IL

**(344)** *Novel Use of Inhaled Perfluorocarbon To Enhance Donor Lung Preservation and Minimize Acute Lung Injury in a Syngeneic Rat Transplant Model*; A.K. Singhal,<sup>1</sup> M. Christofidou-Solomidou,<sup>2</sup> C. Solomides,<sup>3</sup> B.I. Goldman,<sup>3</sup> S. Furukawa,<sup>1</sup> <sup>1</sup>Department of Surgery, Temple University School of Medicine, Philadelphia, PA; <sup>2</sup>Department of Medicine, University of Pennsylvania, Philadelphia, PA; <sup>3</sup>Department of Pathology, Temple University School of Medicine, Philadelphia, PA

**(345)** *Exogenic Surfactant Therapy as an Adjuvant Therapy for Lung Preservation – Evaluation of the Optimal Time Point for Instillation*; T. Wittwer,<sup>1</sup> R. Nagib,<sup>1</sup> M. Ochs,<sup>2</sup> M. Vollroth,<sup>1</sup> C. Muehlfeld,<sup>3</sup> N. Madershahian,<sup>1</sup> J. Groetzner,<sup>1</sup> D. Vehre,<sup>1</sup> T. Wahlers,<sup>1</sup> <sup>1</sup>Department. of Cardiothoracic and Vascular Surgery, Friedrich Schiller University, Jena, Germany; <sup>2</sup>Institute of Anatomy, University of Bern, Bern, Switzerland; <sup>3</sup>Department. of Electron Microscopy, University of Goettingen, Goettingen, Germany

**(346)** *Poly (ADP-Ribose) Polymerase Inhibition Prolongs Safe Cardiac Preservation Times and Improves Cardiac Function after Heart Transplantation*; G. Szabó,<sup>1</sup> N. Stumpf,<sup>1</sup> C. Szabó,<sup>2</sup> S. Hagl,<sup>1</sup> <sup>1</sup>Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; <sup>2</sup>Institut of Physiology, Semmelweis University, Budapest, Hungary

**(347)** *N-Acetyl Cysteine Reduces Inflammatory Triggers in BAL from Mice Lungs Following Warm Ischemia and Reperfusion*; N. Geudens,<sup>1</sup> B. Vanaudenaerde,<sup>2</sup> A. Neyrinck,<sup>1</sup> F. Rega,<sup>1</sup> C. Van De Wauwer,<sup>1</sup> G. Verleden,<sup>2</sup> E. Verbeken,<sup>3</sup> D. Van Raemdonck,<sup>1</sup> <sup>1</sup>Center for Experimental Surgery and Anaesthesiology, Catholic University, Leuven, Belgium; <sup>2</sup>Pneumology, Catholic University, Leuven, Belgium; <sup>3</sup>Pathology, Catholic University, Leuven, Belgium

**(348)** *The Technique of Bilateral Native Lung Sparing Lobar Transplantation in a Canine Model*; S. Sugimoto,<sup>1</sup> H. Date,<sup>1</sup> R. Sugimoto,<sup>1</sup> M. Aoe,<sup>1</sup> Y. Sano,<sup>1</sup> <sup>1</sup>Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

**(349)** *A CMV QPCR Threshold of  $1 \times 10^4$  Copies/ml for Preemptive Therapy in CMV Mismatched Recipients Does Prevent CMV Disease*; G. Parry,<sup>1</sup> A. Krause,<sup>2</sup> J. Forty,<sup>1</sup> F.K. Gould,<sup>2</sup> <sup>1</sup>Cardiopulmonary Transplant Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom; <sup>2</sup>Department of Medical Microbiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**(350)** *Varicella Infection in Adult Heart or Lung Transplantation*; A.L. Jones,<sup>1</sup> M.M. Burke,<sup>2</sup> A. Hall,<sup>2</sup> M. Carby,<sup>2</sup> N.R. Banner,<sup>2</sup> <sup>1</sup>Thoracic Medicine, Royal Free Hospital, Hampstead, London, United Kingdom; <sup>2</sup>Transplant Medicine, Harefield Hospital, Harefield, Middlesex, United Kingdom

**(351)** *Role of Cylex® Assay in Monitoring Cytomegalovirus (CMV) Infection or Disease in Lung Transplant Recipients*; S. Husain,<sup>1</sup> K. Raza,<sup>1</sup> K.R. McCurry,<sup>2</sup> J. Pilewski,<sup>3</sup> K.J. Spichty,<sup>4</sup> J. Woodcock,<sup>5</sup> R. Kowalski,<sup>5</sup> J. Britz,<sup>5</sup> A. Zeevi,<sup>4</sup> <sup>1</sup>Division of Infect Dis, University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>Division of Surgery, University of Pittsburgh, Pittsburgh, PA; <sup>3</sup>Division of Pulm & Crit Care, University of Pittsburgh, Pittsburgh, PA; <sup>4</sup>Pathology, University of Pittsburgh, Pittsburgh, PA; <sup>5</sup>Cylex Inc, Baltimore, MD

**(352)** *Simkania negevensis* Infection and Acute Rejection in Lung Transplant Recipients; S. Husain,<sup>1</sup> S. Kahane,<sup>2</sup> G. Friedman,<sup>2</sup> K.R. McCurry,<sup>3</sup> J. Pilewski,<sup>4</sup> D.L. Paterson,<sup>1</sup> D. Greenberg,<sup>2</sup> <sup>1</sup>Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA; <sup>2</sup>Division of Infectious Diseases, Ben-Gurion University, Beer-Sheva, Israel; <sup>3</sup>Division of Surgery, University of Pittsburgh, Pittsburgh, PA; <sup>4</sup>Div of Pulm & Critical Care, University of Pittsburgh, Pittsburgh, PA

**(353)** *Decrease in Incident Fungal Infections Following Discontinuation of Aerosolized Amphotericin B Lipid Complex as Primary Prophylaxis in Lung Transplant Recipients*; P.V. Chin-Hong,<sup>1</sup> C. Hoopes,<sup>2</sup> J. Golden,<sup>1</sup> S. Hays,<sup>1</sup> <sup>1</sup>Department of Medicine, University of California at San Francisco, San Francisco, CA; <sup>2</sup>Department of Surgery, University of California at San Francisco, San Francisco, CA

**(354)** *Mycophenolate Mofetil Compared to Azathioprine Allows Cyclosporine Sparing after De Novo Heart Transplantation with Better Renal Function and Increased Steroid Weaning*; I.M. Hamour,<sup>1</sup> H. Lyster,<sup>1</sup> M.M. Burke,<sup>2</sup> M.L. Rose,<sup>3</sup> N.R. Banner,<sup>1</sup> <sup>1</sup>Cardiothoracic Transplantation Department, Harefield Hospital, Hill End Road, Harefield, Middlesex, United Kingdom; <sup>2</sup>Histopathology Department, Harefield Hospital, Hill End Road, Harefield, Middlesex, United Kingdom; <sup>3</sup>Department of Transplant Immunology, Imperial College, Harefield Hospital, Hill End Road, Harefield, Middlesex, United Kingdom

**(355)** *Canadian Pilot Study To Determine Safe and Effective Dosing of Cyclosporine and Everolimus in Stable Cardiac Transplant Recipients: Twelve-Week Interim Analysis*; H. Ross,<sup>1</sup> J. Burton,<sup>2</sup> P. Pflugfelder,<sup>3</sup> R. Loertscher,<sup>4</sup> R. Dorent,<sup>5</sup> <sup>1</sup>Medicine, University of Toronto, Toronto, ON, Canada; <sup>2</sup>Medicine, University of Alberta, Edmonton, AB, Canada; <sup>3</sup>Medicine, University of Western Ontario, London, ON, Canada; <sup>4</sup>Novartis Pharma, Dorval, QC, Canada; <sup>5</sup>Novartis Pharma, Basel, Switzerland

**(356)** *Calcineurin Inhibitor-Free Immunosuppression Using Everolimus in Long Term Heart Transplant Recipients – Procedures of Switching Protocols and Side Effects*; M. Rothenburger,<sup>1</sup> J. Stypmann,<sup>2</sup> H. Welp,<sup>1</sup> O. Sezer,<sup>1</sup> T. Wichter,<sup>2</sup> H.H. Scheld,<sup>1</sup> C. Schmid,<sup>1</sup> <sup>1</sup>Thoracic and Cardiovascular Surgery, University Hospital Muenster, Muenster, Germany; <sup>2</sup>Cardiology and Angiology, University Hospital Muenster, Muenster, Germany

**(357)** *Does Basiliximab Decrease Acute Rejection and Improve Renal Function in Cardiac Transplant Recipients at Mid-Term Follow-Up*; D. Rosenbaum,<sup>1</sup> J. Mitchell,<sup>1</sup> B. Adams,<sup>1</sup> M. Paul,<sup>1</sup> P. Kaiser,<sup>1</sup> D. Meyer,<sup>1</sup> M. Jessen,<sup>1</sup> M. Wait,<sup>1</sup> P. Rosenberg,<sup>3</sup> M. Drazner,<sup>2</sup> C. Yancy,<sup>2</sup> W.S. Ring,<sup>1</sup> J.M. DiMaio,<sup>1</sup> <sup>1</sup>Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX; <sup>2</sup>Internal Medicine, UT Southwestern Medical Center, Dallas, TX; <sup>3</sup>Internal Medicine, Duke University, Durham, NC

**(358)** *Comparison of Basiliximab and OKT3 as Induction Agents after Heart Transplantation*; D. Vaqueriza,<sup>1</sup> J.F. Delgado,<sup>1</sup> V. Sanchez,<sup>1</sup> E. Renes,<sup>1</sup> P. Escribano,<sup>1</sup> J. Cortina,<sup>1</sup> C. Saenz de la Calzada,<sup>1</sup> <sup>1</sup>Cardiology, Doce de Octubre Hospital, Madrid, Spain

**(359)** *Sirolimus or Mycophenolate Mofetil (MMF): Which Is the Better Partner for Tacrolimus in Heart Transplant Recipients?*; J. Groetzner,<sup>1</sup> T. Wittwer,<sup>1</sup> J. Strauch,<sup>1</sup> N. Madershahian,<sup>1</sup> R. Nagib,<sup>1</sup> U. Franke,<sup>1</sup> Th. Wahlers,<sup>1</sup> <sup>1</sup>Cardio-Thoracic & Vascular Surgery, Friedrich Schiller University Hospital, Jena, Germany

**(360)** *Elective Conversion from Cellcept to Myfortic under Control of Mycophenolic Acid (MPA) Concentration in Stable Heart Transplant Recipients – 1 Year Follow-Up*; M.W. Zakliczynski,<sup>1</sup> M. Zembala,<sup>1</sup> <sup>1</sup>Department of Cardiac Surgery & Transplantation, Silesian Center for Heart Disease, Zabrze, Poland

**(361)** *The Effect of Sirolimus on Renal Function When Used in Heart Transplantation Patients with Calcineurin Inhibitor Related Renal Impairment*; A. Al Riyami,<sup>1</sup> M. Chandavimol,<sup>1</sup> C. Imai,<sup>1</sup> L. Straatman,<sup>1</sup> A. Kaan,<sup>1</sup> A. Ignaszewski,<sup>1</sup> <sup>1</sup>Cardiology, St. Paul's Hospital, Vancouver, BC, Canada

**(362)** *Remodeling of Established Transplant Airway Obliterative Fibrosis: The Role of Matrix Metalloproteinases*; M. Sato,<sup>1</sup> T. Ogura,<sup>1</sup> G. D'Cruz,<sup>1</sup> M. Anraku,<sup>1</sup> P. Chartrand,<sup>1</sup> T.K. Waddell,<sup>1</sup> B.

Alman,<sup>2</sup> M. Liu,<sup>1</sup> S. Keshavjee,<sup>1</sup> <sup>1</sup>Thoracic Surgery, Toronto General Hospital, Research Institute, Toronto, ON, Canada; <sup>2</sup>Developmental Biology, The Hospital for Sick Children, Toronto, ON, Canada

**(363)** *Preconditioning with Cyclosporine Alters Survival after Murine Myocardial Ischemia-Reperfusion-Injury*; S. Laudi,<sup>1</sup> V. Schmitz,<sup>1</sup> S. Trump,<sup>1</sup> U. Christians,<sup>1</sup> W. Steudel,<sup>1</sup> <sup>1</sup>Department of Anesthesiology, University of Colorado Health Sciences Center, Denver, CO

**(364)** *Limited Role for Primary Immunosuppression with Everolimus after Pulmonary Transplantation*; G. Warnecke,<sup>1</sup> M. Avsar,<sup>1</sup> S. Thissen,<sup>1</sup> B. Kruse,<sup>1</sup> R. Reinhard,<sup>1</sup> C. Peters,<sup>1</sup> A.R. Simon,<sup>1</sup> A. Haverich,<sup>1</sup> M. Struber,<sup>1</sup> <sup>1</sup>Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany

**(365)** *Impact of Extended Donors on Long Term Outcome after Lung Transplantation*; Y. Shargall,<sup>1</sup> S. Keshavjee,<sup>1</sup> A. Pierre,<sup>1</sup> T.K. Waddell,<sup>1</sup> C. Chaparro,<sup>1</sup> M. Hutcheon,<sup>1</sup> L. Singer,<sup>1</sup> M. de Perrot,<sup>1</sup> <sup>1</sup>Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

**(366)** *Determining Antibody Status during Desensitization Therapies in Lung Transplantation*; N.L. Reinsmoen,<sup>1</sup> J.Z. Appel,<sup>2</sup> W.F. Herczyk,<sup>1</sup> B.O. Burgess,<sup>1</sup> S.M. Palmer,<sup>2</sup> K. Savik,<sup>3</sup> Y. Carter,<sup>2</sup> R.D. Savik,<sup>2</sup> <sup>1</sup>Pathology, Duke University Medical Center, Durham, NC; <sup>2</sup>Surgery, Duke University Medical Center, Durham, NC; <sup>3</sup>Surgery, University of Minnesota, Minneapolis, MN

**(367)** *Impact of Perioperative Inhaled Nitric Oxide on Long-Term Outcome after Lung Transplantation*; Y. Shargall,<sup>1</sup> M. de Perrot,<sup>1</sup> K. McRae,<sup>1</sup> D. Hadjiliadis,<sup>1</sup> J. Granton,<sup>1</sup> A. Matte-Martyn,<sup>1</sup> M. Hutcheon,<sup>1</sup> L.G. Singer,<sup>1</sup> S. Keshavjee,<sup>1</sup> T.K. Waddell,<sup>1</sup> <sup>1</sup>Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

**(368)** *Sleep Disordered Breathing before and after Lung Transplantation: More Common Than You Think*; M.A. Malouf,<sup>1</sup> M. Milross,<sup>2</sup> R. Grunstein,<sup>2</sup> C. Aboyou,<sup>1</sup> D. Jankelson,<sup>1</sup> M. Plit,<sup>1</sup> A.R. Glanville,<sup>1</sup> <sup>1</sup>The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; <sup>2</sup>Woolcock Institute, Sydney, NSW, Australia

**(369)** *Sirolimus-Associated Pneumonitis in Lung Transplant Recipients*; M.R. Antunez,<sup>1,2</sup> J. Parmar,<sup>1</sup> M.A. Hutcheon,<sup>1</sup> C. Chaparro,<sup>1</sup> T.K. Waddell,<sup>1</sup> S. Keshavjee,<sup>1</sup> L.G. Singer,<sup>1</sup> <sup>1</sup>Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada; <sup>2</sup>Intensive Care Unit, Clinica Alemana, Santiago, Chile

**(370)** *Lung Transplant from Uncontrolled NHB. An Excellent Alternative for Organs Shortage. Results after 36 Months of a Successful Program*; F. Del Rio,<sup>1</sup> J.R. Nunez,<sup>1</sup> F. Hernado,<sup>2</sup> A. Gomez,<sup>2</sup> J. Calatayud,<sup>2</sup> O. Rodriguez,<sup>2</sup> A. Varela,<sup>3</sup> J.L. Balibrea,<sup>2</sup> <sup>1</sup>Transplant Coordination Unit, University Hospital San Carlos, Madrid, Spain; <sup>2</sup>Thoracic Surgery Unit, University Hospital San Carlos, Madrid, Spain; <sup>3</sup>Thoracic Surgery Unit, Clinica Puerta de Hierro, Madrid, Spain

**(371)** *Risk Factors for Early Mortality in Patients with Primary Graft Dysfunction after Lung Transplantation*; C.L. Kuntz,<sup>1,2</sup> J.S. Sager,<sup>2</sup> D. Hadjiliadia,<sup>2</sup> V.N. Ahya,<sup>2</sup> A. Pochettino,<sup>3</sup> R.M. Kotloff,<sup>2</sup> J.D. Christie,<sup>1,2</sup> <sup>1</sup>Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA; <sup>2</sup>Department of Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; <sup>3</sup>Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA

**(372)** *Short and Long Term Outcome Following Laparoscopic Nissen Fundoplication for Gastro-Oesophageal Reflux Disease Post Lung Transplantation*; P.M. Hopkins,<sup>1</sup> L. Fletcher,<sup>2</sup> F. Kermeen,<sup>1</sup> J. Dunning,<sup>1</sup> K. McNeil,<sup>1</sup> D. Gotley,<sup>2</sup> <sup>1</sup>Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia; <sup>2</sup>Department of Gastroenterology, The Princess Alexandra Hospital, Brisbane, Queensland, Australia

**(373)** *Use of a Real Time TaqMan PCR Assay To Measure EBV DNA Load in Bronchoalveolar Lavage Fluid*; P.H. Michelson,<sup>1</sup> R.M. Wadowsky,<sup>2</sup> G. Kurland,<sup>1</sup> S.A. Webber,<sup>1</sup> M.G. Michaels,<sup>1</sup> <sup>1</sup>Pediatrics,

Children's Hospital of Pittsburgh, Pittsburgh, PA; <sup>2</sup>Pathology, Children's Hospital of Pittsburgh, Pittsburgh, PA

**(374) Pharmacogenetics Variation of Mycophenolate Mofetil in Lung Transplant Recipients: A Preliminary Study;** N. Partovi,<sup>1</sup> L.S.L. Ting,<sup>2</sup> M.H.H. Ensom,<sup>3</sup> C. Guillemette,<sup>5</sup> K.W. Riggs,<sup>2</sup> R.D. Levy,<sup>4</sup> <sup>1</sup>University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada; <sup>2</sup>Faculty of Pharmacy, University of British Columbia, Vancouver, BC, Canada; <sup>3</sup>University of British Columbia, Children's and Women's Health Centre of British Columbia, Vancouver, BC, Canada; <sup>4</sup>University of British Columbia, St. Paul's Hospital and BC Transplant Society, Vancouver, BC, Canada; <sup>5</sup>Laval University Medical Center (CHUL), Faculty of Pharmacy, Laval University, Quebec, QC, Canada

**(375) Lung Transplantation Following Bone Marrow Transplantation for Malignancy – A Single Center Experience;** J.T. Gottlieb,<sup>1</sup> A.R. Simon,<sup>3</sup> M. Ballmann,<sup>2</sup> B. Hertenstein,<sup>4</sup> A. Goerler,<sup>3</sup> T. Welte,<sup>1</sup> M. Strueber,<sup>3</sup> <sup>1</sup>Respiratory Medicine, Hannover Thoracic Transplant Program, Hannover, Germany; <sup>2</sup>Pediatrics, Hannover Thoracic Transplant Program, Hannover, Germany; <sup>3</sup>Cardio-Thoracic Surgery, Hannover Thoracic Transplant Program, Hannover, Germany; <sup>4</sup>Hemato-Oncology, Hannover Medical School, Hannover, Germany

**(376) Incidence of Renal Failure in Lung Transplant Recipients Receiving Tacrolimus and Sirolimus Immunosuppressive Regimen;** S.M. Bhorade,<sup>1</sup> V. Ahya,<sup>2</sup> R. Kotloff,<sup>2</sup> M. Baz,<sup>3</sup> V. Valentine,<sup>4</sup> S. Arcasoy,<sup>5</sup> R. Love,<sup>6</sup> R. Durazo,<sup>7</sup> W.T. Vigneswaran,<sup>1</sup> E.R. Garrity,<sup>1</sup> <sup>1</sup>Medicine, Loyola University Medical Center, Maywood, IL; <sup>2</sup>Medicine, University of Pennsylvania, Philadelphia, PA; <sup>3</sup>Medicine, University of Florida, Gainesville, FL; <sup>4</sup>Medicine, Ochsner Transplant Center, New Orleans, LA; <sup>5</sup>Medicine, Columbia University, New York, NY; <sup>6</sup>Epidemiology, Loyola University Medical Center, Maywood, IL

**(377) Single-Breath Washout in Lateral Decubitus Reflects Function of Single Lungs Grafted for Emphysema: A Computerized Tomography (CT) Study;** A. Van Muylem,<sup>1</sup> P. Scillia,<sup>2</sup> C. Knoop,<sup>1</sup> M. Paiva,<sup>3</sup> M. Estenne,<sup>1</sup> <sup>1</sup>Chest Service, Erasme University Hospital, Brussels, Belgium; <sup>2</sup>Department of Radiology, Erasme University Hospital, Brussels, Belgium; <sup>3</sup>Biomedical Physics Laboratory, Université Libre de Bruxelles, Brussels, Belgium

**(378) Early Results of Lung Transplantation after Implementation of the New Lung Allocation Score;** D. Hadjiliadis,<sup>1</sup> V.N. Ahya,<sup>1</sup> J.D. Christie,<sup>1</sup> J.S. Sager,<sup>1</sup> A. Pocchettino,<sup>1</sup> R.M. Kotloff,<sup>1</sup> <sup>1</sup>Lung Transplant Program, University of Pennsylvania, Philadelphia, PA; <sup>2</sup>Research Department, United Network of Organ Sharing, Richmond, VA

**(379) Abolition of Cytomegalovirus Disease with Aggressive Prophylaxis and Preemptive Therapy in Mismatched Lung Transplant Recipients;** P.M. Hopkins,<sup>1</sup> F. Kermeen,<sup>1</sup> J. Dunning,<sup>1</sup> K. McNeil,<sup>1</sup> <sup>1</sup>Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Queensland, Australia

**(380) Levels of Specific Anti-Pseudomonas Aeruginosa IgG Antibodies in Cystic Fibrosis Patients before and after Lung Transplantation;** L.J. Dupont,<sup>1,3</sup> K. Lagrou,<sup>2</sup> K. Colpaert,<sup>3</sup> X. Bossuyt,<sup>1</sup> D.E. Van Raemdonck,<sup>1</sup> G.M. Verleden,<sup>1</sup> <sup>1</sup>Lung Transplant Unit, University Hospital Gasthuisberg, KULeuven, Leuven, Belgium; <sup>2</sup>Laboratory of Immunology, University Hospital Gasthuisberg, KULeuven, Leuven, Belgium; <sup>3</sup>Adult CF Center, University Hospital Gasthuisberg, KULeuven, Leuven, Belgium

**(381) Histological Appearances in Patients with Radiologically Defined Primary Graft Dysfunction (PGD);** C.M. Burton,<sup>1</sup> M. Zemtsovski,<sup>2</sup> M. Iversen,<sup>1</sup> N. Milman,<sup>1</sup> J. Carlsen,<sup>1</sup> C.B. Andersen,<sup>3</sup> <sup>1</sup>Division of Lung Transplantation, The Heart Centre, Rigshospitalet, Copenhagen, Denmark; <sup>2</sup>Department of Thoracic Anaesthesiology, Rigshospitalet, Copenhagen, Denmark; <sup>3</sup>Diagnostic Centre, Rigshospitalet, Copenhagen, Denmark

**(382) The Role of Primary Graft Dysfunction or Recurrent Acute Rejection Episodes in the Development of Pseudomonas Colonisation after Lung Transplantation;** P. Botha,<sup>1</sup> L. Archer,<sup>1</sup> R.L. Anderson,<sup>1</sup> J. Lordan,<sup>2</sup> J.H. Dark,<sup>1</sup> P.A. Corris,<sup>2</sup> F.K. Gould,<sup>1</sup> A. Fisher,<sup>2</sup> <sup>1</sup>Department of Cardio-pulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom;

<sup>2</sup>Immunobiology and Transplantation Research Group, University of Newcastle upon Tyne, Newcastle upon Tyne, Tyne and Wear, United Kingdom

**(383)** *Non-Invasive Monitoring of Pulmonary Vascular Resistance Changes in Patients with Pulmonary Hypertension*; M. Dandel,<sup>1</sup> H.B. Lehmkuhl,<sup>1</sup> M. Bettmann,<sup>1</sup> C. Knosalla,<sup>1</sup> O. Grauhan,<sup>1</sup> R. Hetzer,<sup>1</sup>  
<sup>1</sup>Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

**(384)** *Efficacy of Sildenafil as a Rescue Therapy in Patients with Pulmonary Arterial Hypertension Chronically Treated with Prostacyclin: Two-Year Experience*; M.J. Ruiz,<sup>1</sup> P. Escribano,<sup>1</sup> C. Jiménez,<sup>1</sup> R. Tello,<sup>1</sup> J. Delgado,<sup>1</sup> <sup>1</sup>Cardiology Department, Hospital "Doce de Octubre", Madrid, Spain

**(385)** *Successful Liver Transplantation Following Vasodilator Therapy for Portopulmonary Hypertension: Single Center Series*; V. Kaza,<sup>1</sup> N. Sussman,<sup>1</sup> C. O'Mahoney,<sup>2</sup> J. Goss,<sup>2</sup> R.J. Stribling,<sup>1</sup> A.E. Frost,<sup>1</sup>  
<sup>1</sup>Medicine, Baylor College of Medicine, Houston, TX; <sup>2</sup>Surgery, Baylor College of Medicine, Houston, TX

**(386)** *Impact of Iloprost and Bosentan Therapy on the Outcome of Patients with End-Stage Primary Pulmonary Hypertension*; M. Dandel,<sup>1</sup> H.B. Lehmkuhl,<sup>1</sup> Y. Weng,<sup>1</sup> S. Mulahasanovic,<sup>1</sup> O. Grauhan,<sup>1</sup> C. Knosalla,<sup>1</sup> R. Hetzer,<sup>1</sup> <sup>1</sup>Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

**(387)** *Long-Term Results of Bosentan in the Treatment of Patients with Eisenmenger's Syndrome*; J. Segovia,<sup>1</sup> V. Moñivas,<sup>1</sup> L. Alonso-Pulpón,<sup>1</sup> M. Gómez-Bueno,<sup>1</sup> P. Ortiz,<sup>1</sup> J.M. Escudier,<sup>1</sup> A. Blasco,<sup>1</sup> A. Hernández-Rivas,<sup>1</sup> J. Jurado,<sup>1</sup> <sup>1</sup>Unidad de Trasplante Cardíaco, Clínica Puerta de Hierro, Madrid, Spain

**(388)** *Insulin Resistance and Pulmonary Arterial Hypertension*; R.L. Doyle,<sup>1</sup> J.L. Faul,<sup>1</sup> J. Liu,<sup>1</sup> R.T. Zamanian,<sup>1</sup> M. Rabinovitch,<sup>1</sup> G.R. Reaven,<sup>2</sup> <sup>1</sup>Vera M. Wall Center for Pulmonary Vascular Disease, Stanford University, Stanford, CA; <sup>2</sup>Division of Endocrinology, Stanford University, Stanford, CA

**(389)** *Disease-Specific Differences in Health-Related Quality of Life in Patients Referred or Listed for Lung Transplantation*; L.G. Singer,<sup>1,3</sup> N. Chowdhury,<sup>1</sup> J.T. Granton,<sup>1,3</sup> D.E. Tullis,<sup>2,3</sup> T.K. Waddell,<sup>1,3</sup> M. Krahn,<sup>1,3</sup> <sup>1</sup>University Health Network, Toronto, ON, Canada; <sup>2</sup>St. Michael's Hospital, Toronto, ON, Canada; <sup>3</sup>University of Toronto, Toronto, ON, Canada

**(390)** *Factors Influencing Survival to Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis Placed on the Waiting List 1999-2004*; L.S. Mackay,<sup>1</sup> R.L. Anderson,<sup>1</sup> J. Lordan,<sup>1</sup> P.A. Corris,<sup>1</sup> A.J. Fisher,<sup>1</sup> <sup>1</sup>Cardiopulmonary Transplant Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**(391)** *Factors Influencing Medication Adherence after Lung Transplantation*; M.J. Wessels-Bakker,<sup>1</sup> G.D. Nossent,<sup>1</sup> E.A. van de Graaf,<sup>1</sup> <sup>1</sup>Heart Lung Centre Utrecht, University Medical Centre Utrecht, Utrecht, Netherlands

**(392)** *Self-Reported Symptom Distress and Symptom Frequency of Immunosuppressive Therapy in Lung Transplant Recipients*; C. Kugler,<sup>1</sup> S. Fischer,<sup>1</sup> J. Gottlieb,<sup>1</sup> H. Hecker,<sup>2</sup> B. Gohrbandt,<sup>1</sup> U. Tegtbur,<sup>1</sup> T. Welte,<sup>1</sup> A. Haverich,<sup>1</sup> M. Strueber,<sup>1</sup> <sup>1</sup>Thoracic Transplant Program, Hannover Medical School, Hannover, Germany; <sup>2</sup>Department of Biostatistics, Hannover Medical School, Hannover, Germany

**(393)** *Psychosocial and Biological Factors Influencing Perceptions of Health Status*; J. Salyer,<sup>1</sup> M.P. Flattery,<sup>2</sup> P.B. Sharp,<sup>1</sup> K.M. Baker,<sup>1</sup> A. Allen,<sup>1</sup> A. Best,<sup>3</sup> <sup>1</sup>Adult Health, Virginia Commonwealth University School of Nursing, Richmond, VA; <sup>2</sup>Heart Failure/Transplant Program, Virginia Commonwealth University Health System, Richmond, VA; <sup>3</sup>Biostatistics, Virginia Commonwealth University School of Medicine, Richmond, VA

**(394)** *The Impact of Education Classes on Patients Awaiting Lung Transplantation*; M.L. Francois,<sup>1</sup> M.S. Hayney,<sup>1</sup> K.L. Radford,<sup>1</sup> A. Reynolds,<sup>1</sup> R.B. Love,<sup>1</sup> <sup>1</sup>Cardiopulmonary Transplant, University Hospital and Clinics, Madison, WI

**(395) Psychological Adjustment and Quality of Life – A Nursing Challenge in All Different Phases after Heart Transplant;** I. Grov,<sup>1</sup> A. Relbo,<sup>1</sup> L. Gullestad,<sup>1</sup> M. Hellesvik,<sup>2</sup> B. Sivertsen,<sup>2</sup> S. Simonsen,<sup>1</sup> O.E. Havik,<sup>1</sup> <sup>1</sup>Department of Cardiology, Rikshospitalet University Hospital, Oslo, Norway; <sup>2</sup>Department of Psychology, University of Bergen, Bergen, Norway

**(396) Molecular Diagnostic Assay for the Non-Invasive Detection of Cardiac Allograft Rejection: Implication for Transplant Nursing Practice;** K.J. Albright,<sup>1</sup> T.M. Rowe,<sup>2</sup> H.J. Eisen,<sup>3</sup> <sup>1</sup>Heart Transplant, Hahnemann Hospital, Philadelphia, PA; <sup>2</sup>Heart Transplant, Hahnemann Hospital, Philadelphia, PA; <sup>3</sup>Heart Failure and Transplant, Hahnemann Hospital, Philadelphia, Pa

**(397) Abnormal Tissue Doppler Derived Diastolic Function in Pediatric Transplant Recipients;** S. Strigl,<sup>1</sup> R. Hardy,<sup>1</sup> J. Glickstein,<sup>1</sup> D.T. Hsu,<sup>1</sup> L.J. Addonizio,<sup>1</sup> A. Prakash,<sup>1</sup> <sup>1</sup>Division of Pediatric Cardiology, Columbia University College of Physicians and Surgeons, New York, NY

**(398) The United Kingdom's Experience of ABO-Incompatible Cardiac Transplantation;** S.L. Roche,<sup>1</sup> C.R. Kirk,<sup>1</sup> M. Burch,<sup>2</sup> M.J. Elliott,<sup>2</sup> J.R.L. Hamilton,<sup>1</sup> A. Hasan,<sup>1</sup> <sup>1</sup>Paediatric Cardiology and Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom; <sup>2</sup>Cardiothoracic Transplantation, Great Ormond Street Hospital for Children, London, United Kingdom

**(399) Feasibility and Safety of Intravascular Ultrasound for Measurement of Coronary Atheroma Burden in Children after Heart Transplantation;** M.J. Fenton,<sup>1</sup> M. Burch,<sup>1</sup> <sup>1</sup>Deptment of Cardiothoracic Transplantation, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

**(400) Utilizing the Child Health Questionnaire To Assess Quality of Life Following Pediatric Heart Transplantation;** S.J. Anthony,<sup>1,2</sup> S.M. Pollock-Barziv,<sup>3</sup> A.I. Dipchand,<sup>1,3</sup> L.J. West,<sup>1,3</sup> <sup>1</sup>Paediatric Academic Multi-Organ Transplant Program, The Hospital for Sick Children, Toronto, ON, Canada; <sup>2</sup>Department of Social Work, The Hospital for Sick Children, Toronto, ON, Canada; <sup>3</sup>Division of Cardiology, The Hospital for Sick Children, Toronto, ON, Canada

**(401) Poorer Outcome for Females Following Pediatric Heart Transplantation;** A.M. Berg,<sup>1</sup> R.N. Vincent,<sup>3</sup> K.R. Kanter,<sup>2</sup> B.E. Kogon,<sup>2</sup> W.T. Mahle,<sup>3</sup> <sup>1</sup>School of Nursing, Emory University School of Medicine, Atlanta, GA; <sup>2</sup>Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, GA; <sup>3</sup>Sibley Cardiology, Children's Healthcare of Atlanta, Atlanta, GA

**(402) School Attendance Following Cardiac Transplantation;** J. Flett,<sup>1</sup> A. Nicholson,<sup>1</sup> J. Duncan,<sup>1</sup> G. Parry,<sup>1</sup> C.R. Kirk,<sup>1</sup> <sup>1</sup>Paediatric Cardiology and Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**(403) WITHDRAWN**

**(404) Exercise Capacity in Paediatric Heart Transplant Recipients and the Diagnostic Utility of Exercise Testing;** A.I. Dipchand,<sup>1</sup> B.W. McCrindle,<sup>1</sup> I. Kehler-Reimer,<sup>1</sup> P.F. Kantor,<sup>1</sup> L.J. West,<sup>1</sup> J. Russell,<sup>1</sup> <sup>1</sup>Cardiology, Hospital for Sick Children, Toronto, ON, Canada

**(405) Long Term Outcomes of Pediatric Liver-Lung Transplant Recipients;** A. Faro,<sup>1</sup> P. Schuler,<sup>1</sup> C. Huddleston,<sup>2</sup> S. Gandhi,<sup>2</sup> R. Shepherd,<sup>1</sup> J. Lowell,<sup>3</sup> M. Nadler,<sup>3</sup> S.C. Sweet,<sup>1,4</sup> <sup>1</sup>Pediatrics, Washington University in St. Louis, St. Louis, MO; <sup>2</sup>Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, MO; <sup>3</sup>Surgery, Washington University in St. Louis, St. Louis, MO

**(406) Mechanical Bridge-to-Transplantation in a Pediatric Population: A Single Center Experience;** R.R. Davies,<sup>1</sup> J.M. Chen,<sup>1</sup> S.R. Mital,<sup>2</sup> L.J. Addonizio,<sup>2</sup> D.T. Hsu,<sup>2</sup> J.M. Lamour,<sup>2</sup> J.M. Quaegebeur,<sup>1</sup> R.S. Mosca,<sup>1</sup> <sup>1</sup>Section of Pediatric Cardiac Surgery, Children's Hospital of NewYork-Presbyterian, Columbia University College of Physicians and Surgeons, New York, NY; <sup>2</sup>Section of Pediatric Cardiology, Children's Hospital of NewYork-Presbyterian, Columbia University College of Physicians and Surgeons, New York, NY

**(407)** *Long Term Psychological Outcome of Paediatric Heart Transplant Recipients – Is Normality a Realistic Goal?*; T. Lunnon-Wood,<sup>1</sup> J. Wray,<sup>2</sup> <sup>1</sup>Department of Cardiothoracic Transplantation, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom; <sup>2</sup>Department of Cardiothoracic Transplant, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

**(408)** *Prevention of Pediatric Graft Coronary Artery Disease: Atorvastatin*; C. Chin,<sup>1</sup> D. Bernstein,<sup>1</sup> J. Shek,<sup>2</sup> P. Gamberg,<sup>2</sup> S. Perry,<sup>1</sup> <sup>1</sup>Pediatric Cardiology, Stanford University, Stanford, CA; <sup>2</sup>Cardiothoracic Surgery, Stanford University, Stanford, CA

**(409)** *Heart Transplantation in High-Risk Infant Patients: Evaluating Outcomes in Patients with HLA-Sensitization and ABO-Incompatibility*; S.M. Pollock-BarZiv,<sup>1</sup> A. Ang,<sup>1</sup> A.I. Dipchand,<sup>1</sup> P. Kantor,<sup>1</sup> L.J. West,<sup>1</sup> <sup>1</sup>Department. of Paediatrics, Hospital. for Sick Children/University. of Toronto, Toronto, ON, Canada

**(410)** *Post-Transplant Hypertension in Lung Recipients Is Not Associated with Generalized Vasoconstriction or Endothelial Dysfunction*; M. Silverborn,<sup>1</sup> A. Ambring,<sup>2</sup> F. Nilsson,<sup>1</sup> P. Friberg,<sup>2</sup> A. Jeppsson,<sup>1</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden; <sup>2</sup>Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden

**(411)** *Impact of Surgical Technique on Lung Transplant Bronchial Anastomotic Complications*; E. Granger, P. Spratt, P. Jansz, M. Horton, A. Glanville, The Lung Transplant Unit, St Vincent's Hospital, Sydney, New South Wales, Australia

**(412)** *Primary Graft Dysfunction (PGD) after Lung Transplantation: Acute Humoral Rejection May Play a Causative Role*; A. Haccuria,<sup>1</sup> C. Knoop,<sup>1</sup> C. Magro,<sup>2</sup> D. Knight,<sup>2</sup> J. Waldman,<sup>2</sup> A. Pope-Harman,<sup>3</sup> M. Dumonceaux,<sup>1</sup> M. Rimmelink,<sup>4</sup> B. Rondelet,<sup>5</sup> J.L. Vachiéry,<sup>6</sup> M. Estenne,<sup>1</sup> <sup>1</sup>Chest Medicine, Erasme University Hospital, Brussels, Belgium; <sup>2</sup>Pathology, Ohio State University, Columbus, OH; <sup>3</sup>Division of Pulmonary, Critical Care and Sleep Medicine, Ohio State University, Columbus, OH; <sup>4</sup>Pathology, Erasme University Hospital, Brussels, Belgium; <sup>5</sup>Thoracic Surgery, Erasme University Hospital, Brussels, Belgium; <sup>6</sup>Cardiology, Erasme University Hospital, Brussels, Belgium

**(413)** *Risk Factors for Airway Complications Early after Lung Transplantation*; C. Van De Wauwer,<sup>1</sup> L. Dupont,<sup>2</sup> P. De Leyn,<sup>1</sup> W. Coosemans,<sup>1</sup> P. Nafteux,<sup>1</sup> G. Decker,<sup>1</sup> T. Lerut,<sup>1</sup> G.M. Verleden,<sup>2</sup> D. Van Raemdonck,<sup>1</sup> <sup>1</sup>Department of Thoracic Surgery, UZ Leuven, Leuven, Belgium; <sup>2</sup>Department of Pulmonary Medicine, UZ Leuven, Leuven, Belgium

**(414)** *Lack of Stem Cells Fusion with Resident Cardiomyocytes in Sex Mismatched Heart Transplants*; A. Angelini,<sup>1</sup> C. Castellani,<sup>1</sup> M. Della Barbera,<sup>1</sup> M. Valente,<sup>1</sup> A.L.P. Caforio,<sup>2</sup> F. Tona,<sup>2</sup> A. Gambino,<sup>3</sup> G. Feltrin,<sup>3</sup> G. Gerosa,<sup>3</sup> G. Thiene,<sup>1</sup> <sup>1</sup>Department of Pathology, University of Padua, Padua, Italy; <sup>2</sup>Department of Cardiology, University of Padua, Padua, Italy; <sup>3</sup>Department of Cardiovascular Surgery, University of Padua, Padua, Italy

**(415)** *Over-Expression of Squamous Cell Carcinoma Antigen (SCCA) in Native Lung with Idiopathic Pulmonary Fibrosis*; F. Calabrese,<sup>1</sup> C. Giacometti,<sup>1</sup> G. Marulli,<sup>2</sup> M. Loy,<sup>2</sup> F. Rea,<sup>2</sup> C. Agostini,<sup>3</sup> M. Saetta,<sup>2</sup> M. Valente,<sup>1</sup> <sup>1</sup>Institute of Pathology, University of Padua, Padua, Italy; <sup>2</sup>Department of Cardiothoracic Sciences, University of Padua, Padua, Italy; <sup>3</sup>Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy

**(416)** WITHDRAWN

**(417)** *Probabilistic Modeling of Rejection in Cardiac Allograft Patients as Measured by Biopsy and Molecular Diagnostics*; P.J. Danaher,<sup>1</sup> T.M. Klingler,<sup>1</sup> G.J. Berry,<sup>2</sup> M.E. Billingham,<sup>2</sup> H.J. Eisen,<sup>3</sup> J.G. Wohlgenuth,<sup>1</sup> H.M. Baron,<sup>1</sup> M.C. Deng,<sup>4</sup> C.C. Marboe,<sup>5</sup> <sup>1</sup>Research and Development, XDx, South San Francisco, CA; <sup>2</sup>Department of Pathology, Stanford University School of Medicine, Stanford, CA; <sup>3</sup>Department of Cardiology, Drexel University College of Medicine, Philadelphia, PA; <sup>4</sup>Department of

Medicine, Columbia University College of Physicians and Surgeons, New York, NY; <sup>5</sup>Department of Pathology, Columbia University Medical Center, New York, NY

**(418)** *Getting Old with a New Heart (and at Least Ten Years of Immunosuppression on Your Back...)*; V. Martinelli,<sup>1</sup> P. Fusar Poli,<sup>1</sup> C. Klersy,<sup>2</sup> C. Campana,<sup>3</sup> M. Vigano,<sup>4</sup> P.L. Politi,<sup>1</sup> <sup>1</sup>Psychiatry, University of Pavia, Pavia, Italy; <sup>2</sup>Biometry & Clinical Epidemiology, IRCCS Policlinico San Matteo, Pavia, Italy; <sup>3</sup>Cardiology, IRCCS Policlinico San Matteo, Pavia, Italy; <sup>4</sup>Cardiac Surgery, IRCCS Policlinico San Matteo, Pavia, Italy

**(419)** WITHDRAWN

**(420)** *Perception of Everyday Life after Lung Transplantation in Denmark*; D. Thomsen,<sup>1</sup> B 3144, University Hospital, Blegdamsvej 9, Copenhagen, Denmark



## EXHIBIT FLOOR PLANS

<b>Booth Number</b>	<b>Company Name</b>
E100	SynCardia Systems
E101	Ventracor
E102	MicroMed Cardiovascular
E103	Genzyme Europe B.V.
E105	Elsevier
E200	Therakos, Inc.
E201	Arrow International
E202	Berlin Heart AG
E203	World Heart Corporation
E204	Abiomed
E300	Vitrolife, Inc.
E302	Levitronix
E304	Medical Insight Research
E400	Thoratec Corporation
E401	Scanlan International, Inc.
E403	Vascutek Deutschland GMBH/Terumo Heart Division
E405	Organ Recovery Systems
L100	Novartis Pharma AG
L200	TransMedics
L300	Astellas
L400	F. Hoffmann-La Roche Ltd.
L500	Encysive Pharmaceuticals
L600	XDx
???	ISHLT Registry

## EXHIBITORS

Abiomed  
22 Cherry Hill Dr.  
Danvers, MA 01923  
Email: [marketing@abiomed.com](mailto:marketing@abiomed.com)  
www.abiomed.com  
Booth#: E204

ABIOMED, Inc. develops, manufactures and markets medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently sells the BVS® 5000 Biventricular Support System and the AB5000™ Circulatory Support System for the temporary support of patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the Impella® Recover™ minimally invasive cardiovascular support systems. The Company's AbioCor® Implantable Replacement Heart is currently under FDA review.

Astellas Pharma Europe Limited  
Lovett House, Lovett Road,  
Staines, Middlesex, United Kingdom TW18 3AZ  
Email: [media@eu.astellas.com](mailto:media@eu.astellas.com)  
www.astellas.com  
Booth #: L300

On 1 April 2005, Fujisawa and Yamanouchi officially merged to form Astellas Pharma Inc. Astellas develops and markets pharmaceuticals, including Prograf (tacrolimus), which provide the promise of a healthier life to people across the world.

The merger of Fujisawa and Yamanouchi brings together two companies with renowned R&D capabilities and achievements. With a combined R&D budget of over \$1.3 billion, Astellas will have increased resources to develop innovative products in multiple franchise areas, most notably Transplantation. The fusion of the two companies' specialties will increase the flow of drug discovery targets, expand the chemical library, and boost capacity to produce life-enhancing compounds. Astellas endeavors to maintain its track record for developing high profile, market-leading products that become new standards of care.

Astellas is proud to be the Platinum sponsor of ISHLT 2006.

Arrow International  
Hill & George Ave  
Reading, PA 19610  
[www.arrowinternational.com](http://www.arrowinternational.com)  
Booth #: E201

Arrow International, Inc. develops, manufactures and markets a broad range of clinically advanced, disposable catheters and related products for critical and cardiac care. The Company's products are used primarily by anesthesiologists, critical care specialists, surgeons, emergency and trauma physicians, cardiologists, interventional radiologists, electrophysiologists, and other health care providers.

Berlin Heart AG  
Katrin Neiss / Linda Buerk  
Wiesenweg 10  
12247 Berlin

Germany

Email: [neiss@berlinheart.de](mailto:neiss@berlinheart.de) / [buerk@berlinheart.de](mailto:buerk@berlinheart.de)

[www.berlinheart.de](http://www.berlinheart.de)

Booth #: E202

INCOR<sup>®</sup> - implantable third generation axial flow LVAD system with unique contact free magnetically levitated impeller.

EXCOR<sup>®</sup> - extracorporeal pneumatically driven Uni/BiVAD system with a full range of pumps and cannulas for support of all patient sizes from newborn to adult.

Elsevier

1600 John F. Kennedy Blvd

Suite 1800

Philadelphia, PA 19103

Email: [N.Johnson@Elsevier.com](mailto:N.Johnson@Elsevier.com)

[www.elsevierhealth.com](http://www.elsevierhealth.com)

Booth #: E105

ELSEVIER, proud publisher of the **JOURNAL OF HEART & LUNG TRANSPLANTATION**, official journal of the ISHLT. ELSEVIER proudly publishes Mosby, Saunders, Churchill Livingstone, Butterworth-Heinemann, and Hanley & Belfus Titles.

ELSEVIER. Building Insights. Breaking Boundaries.

Encysive Pharmaceuticals

4848 Loop Central Drive, Suite 700

Houston, TX 77027

Email: [encyinfo@encysive.com](mailto:encyinfo@encysive.com)

[www.encysive.com](http://www.encysive.com)

Booth # L500

Encysive Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs.

Encysive is transforming from an R&D-focused organization to a fully integrated pharmaceutical company. Our long-term business strategy includes:

- A singular focus on the vascular system because of its central importance in the development of a number of serious diseases;
- The identification of disease targets that have significant unmet needs;
- The recruitment and retention of drug development professionals with the skills necessary to rapidly discover, formulate and optimize product candidates, and
- The addition of business and marketing teams capable of successfully launching our products.

Genzyme Europe B.V.

Gooimeer 10

Naarden, 1411 DD, The Netherlands

Email: [luz.ballart@genzyme.com](mailto:luz.ballart@genzyme.com)

[www.genzyme.com](http://www.genzyme.com)

Booth # E103

"One of the world's foremost biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences to address a range of unmet medical needs. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, **transplant** and immune disease, cancer, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial research and development program focused on genetic diseases, immune system disorders, heart disease, and cancer."

ISHLT Registry  
700 North 4<sup>th</sup> Street  
Richmond, VA 23219  
Email: [help@ishlt.org](mailto:help@ishlt.org)  
Booth #: TBD ?????

The International Registry for Heart and Lung Transplantation provides on-going, current information on the worldwide thoracic organ transplantation experience. Additionally, we maintain the Mechanical Circulatory Support Device Database to collect data on the implantation and outcomes of patients receiving cardiac assist devices. The data, utilized for scientific study, contributes to the body of knowledge regarding thoracic transplantation and cardiac device management. Our goal is to identify overall best practices for improving cardiothoracic patient care.

This year the exhibit will make your center-specific information available for your review. In addition, members can view data screens from both the ISHLT Registry and the MCSDB Database and receive guidance on enrollment, training on submission of data and instructions for submitting special data requests.

Levitronix  
Technoparkstrasse 1  
Zurich, CH8005, Switzerland  
Email : [kent@levitronix.com](mailto:kent@levitronix.com)  
[www.levitronix.com](http://www.levitronix.com)  
Booth #: E302

The Levitronix CentriMag Ventricular Assist System (VAS) is designed to provide temporary mechanical circulatory support to one or both sides of the heart for up to 14 days with a maximal flow capability of 10 l/min. In the United States, the device is undergoing trials to assess its safety for the treatment of cardiogenic shock following acute myocardial infarction or postcardiotomy cardiogenic shock, and also as an RVAS for temporary right ventricular support in patients who have had a commercial LVAS implanted. The system is approved (CE Marked) in Europe for commercial use.

Medical Insight Research  
25 Burlington Mall Road, 6<sup>th</sup> Floor  
Burlington, MA 07803  
Booth #: E304

Medical Insight Research is an economic research and strategy consulting firm specializing in the health care, pharmaceutical, and biotechnology industry.

MicroMed Cardiovascular, Inc.

Wholly owned company of MicroMed Technology, Inc.

**8965 Interchange Drive**

Houston, TX 77054

[www.micromedtech.com](http://www.micromedtech.com)

Booth #: E102

MicroMed presents the DeBakey VAD and *Child*, miniaturized axial-flow VADs that represent next generation implantable circulatory support. The DeBakey VAD is in multi-center trials; DeBakey VAD *Child* is commercially available through an HDE.

Novartis Pharma AG

Gerard Cooney

BASEL CH-4002

Switzerland

Email: [gerard.cooney@novartis.com](mailto:gerard.cooney@novartis.com)

<http://www.novartis.com/>

Booth #: L100

Novartis is a world leader in transplantation and immunology, pioneering and revolutionizing the field of transplantation with the discovery and introduction of cyclosporine more than 20 years ago. We have one of the broadest portfolios of immunosuppressant drugs due to our continued research and strong commitment to provide solutions to unmet medical needs for the transplant recipient. *Neoral*, *myfortic* and *Simulect* are established products used to protect transplanted organs from rejection. One of our new products, *Certican*, is the first immunosuppressant that demonstrated a significant impact on cardiac allograft vasculopathy in one of the largest trials in cardiac transplantation.

Organ Recovery Systems

Corporate Village Business Park

DaVincilaan 2, Box 6

Zaventem, 1935, Belgium

Email: [lrodgers@organ-recovery.com](mailto:lrodgers@organ-recovery.com)

[www.organ-recovery.com](http://www.organ-recovery.com)

Booth #: E405

About Organ Recovery Systems

Organ Recovery Systems develops technologies to improve the quality and quantity of organs for transplantation. The company markets LifePort<sup>®</sup>, a growing family of mobile perfusion devices that establishes a new continuum of care for ex vivo organs. LifePort<sup>®</sup> Kidney Transporter is now in routine use worldwide and has been recognized for excellence in design by Popular Science (Best of What's New 2003), the Industrial Designers Society of America (Silver Award IDEA2004), the Medical Design Excellence Awards (Gold Winner 2004), the Museum of Modern Art (SAFE: Design Takes on Risk 2005-2006), and the Smithsonian Cooper-Hewitt National Design Museum (National Design Triennial 2006-2007). We also operate the Request<sup>SM</sup> research program, in fulfillment of our vision: to make the very most of every donor's gift. For more information please visit [www.organ-recovery.com](http://www.organ-recovery.com).

Roche

Booth #L400

Scanlan International Inc.  
One Scanlan Plaza  
Saint Paul, MN 55107  
Email: [info@scanlangroup.com](mailto:info@scanlangroup.com)  
[www.scanlaninternational.com](http://www.scanlaninternational.com)  
Booth #: E401

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 designs in stainless steel and titanium instrumentation featuring Needle Holders, forceps, and clamps, including Scanlan SUPER CUT™ and ULTRA SHARP® scissors, Heifetz™ temporary occlusion clips, and DIAMOND DUST™ instrumentation. Offering a wide variety of custom modifications to accommodate surgeons' specific needs. Single-use products include Surg-I-Loop® PLUS, single-use Aorta/Vein Punch, A/C LOCATOR® and RADIOMARK® graft markers, Vasco-Stat® single-use bulldog clamps, as well as SURG-I-PAW® jaw covers and SOFT-GRIP™ fabric clamp covers. Exclusive worldwide distributor for Surgical Acuity HiRes™ class II Magnifying Loupes.

SynCardia Systems, Inc.  
1992 East Silverlake  
Tucson, AZ 85713  
Email: [msloan@syncardia.com](mailto:msloan@syncardia.com)  
[www.syncardia.com](http://www.syncardia.com)  
Booth #: E100

The CardioWest™ temporary Total Artificial Heart (TAH-t) is the only FDA approved device capable of providing circulatory restoration in morbidly ill patients with irreversible bi-ventricular failure, bridging them to transplantation when a donor human heart becomes available. The CardioWest™ TAH-t has also been approved by Health Canada for use in Canada and has the CE mark for use in Europe and in other countries. In 2004, the TAH-t was named the number one advancement in Cardiovascular Medicine by the American Heart Association.

Terumo Heart  
Albert-Einstein-Ring 19  
Hamburg, 22591, Germany  
Email: [Ingrid.craninckx@duraheart.de](mailto:Ingrid.craninckx@duraheart.de)  
Booth #: E403

Terumo Heart, Inc. is a global leader in the development and design of Ventricular Assist Devices (VADs). With the DuraHeart™ LVAS the company has successfully entered this market with the only actively magnetically levitated, third generation system centrifugal LVAD. This unique design allows for no contact points within the blood chamber, thereby further minimizing the risk of mechanical wear and thrombus formation.

The DuraHeart™ LVAS is expected to initiate commercial sales in Europe in the near future.

Therakos, Inc.  
437 Creamery Way  
Exton, PA 19341  
[www.therakos.com](http://www.therakos.com)  
Booth #: E200

THERAKOS, Inc., an immune cell therapy company, is a worldwide leader in extracorporeal disease management. THERAKOS<sub>SM</sub> Photopheresis, including the THERAKOS<sub>SM</sub> UVAR® XTS™ Photopheresis System and

THERAKOS<sub>SM</sub> UVADEX® Methoxsalen Sterile Solution, is approved for the palliative treatment of skin manifestations in Cutaneous T-Cell Lymphoma, and is currently being studied in other immune mediated diseases.

Thoratec Corporation  
Booth # E400

TransMedics  
200 Minuteman Road, Ste. 302  
Andover, MA 01810  
[www.transmedics.com](http://www.transmedics.com)  
Booth #: L200

The TransMedics Organ Care System is a novel medical device that maintains hearts in their beating, functioning state outside of the body to minimize ischemic injury and to allow ex-vivo visual, functional and metabolic assessment. The Organ Care System perfuses organs with warm, oxygenated, nutrient-rich blood from the time of removal until implantation. The system is designed with the goals of providing patients with the healthiest possible organs; increasing the number of organs available and improving post transplant outcomes. The Organ Care System is currently undergoing extensive clinical evaluations in heart transplantation and preclinical development for lungs and other solid organs. We invite you to visit our booth to learn more.

Ventracor  
126 Greville St  
Chatswood,  
2067, New South Wales, Australia  
Email: [info@ventracor.com](mailto:info@ventracor.com)  
[www.ventracor.com](http://www.ventracor.com)  
Booth #: E101

The VentrAssist™ is a third generation LVAS indicated for Bridge To Transplant and Destination Therapy. The VentrAssist™ is an outstanding advance over older heart assist devices. Its unique combination of features and benefits include:

- small size
- hydrodynamically suspended impeller
- no wearing parts
- inherent flow regulation that mimics normal physiology
- minimal anticoagulation required

The VentrAssist™ LVAS has been implanted in patients ranging from 10 to 76 years old. It is currently in clinical trials in Europe, Australasia and the United States. It is not available for commercial use. Please visit our Booth E101 for more information.

Vitrolife, Inc.  
3601 South Inca St.  
Englewood, CO, 80111  
[www.vitrolife.com](http://www.vitrolife.com)  
Booth # E300



Vitrolife develops specialized media and devices for preparation and cultivation of cells, tissues and organs. The products of Vitrolife Transplantation Systems are clinically proven solutions that supports thoracic and cardiovascular surgery. Vitrolife's Perfadex® is optimized for preservation of lungs for transplantation.

World Heart Corporation  
7799 Pardee Lne  
Oakland, CA 94621  
[www.worldheart.com](http://www.worldheart.com)  
Booth #: E203

World Heart Corporation is a global medical device company that is currently focused on the development and commercialization of pulsatile ventricular assist devices. World Heart's Novacor® LVAS is well established in the marketplace and is in development of next-generation and rotary devices.

XDx  
750 Gateway Blvd, Suite H  
South San Francisco, CA 94080  
Website: [www.allomap.com](http://www.allomap.com)  
Booth #: L600

AlloMap molecular expression testing uses quantitative real-time PCR to measure the expression of 20 genes that indicates the absence of acute cellular rejection. Based on circulating mononuclear cells found in the blood, AlloMap testing translates complex molecular signatures from multiple biological pathways into an objective, clinically actionable score. Results are reported as an integer ranging from 0 to 40. The AlloMap test was developed and its performance characteristics determined by the licensed XDx laboratory.

## **FUTURE ISHLT MEETINGS**

April 25-28, 2007

ISHLT 27th Annual Meeting and Scientific Sessions  
Hilton San Francisco  
San Francisco, CA

April 9-12, 2008

ISHLT 28th Annual Meeting and Scientific Sessions  
Boston Marriott and Hynes Convention Center  
Boston, MA